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Abstract
This thesis reports the investigation of the role of the insulin receptor 
substrate 2 (Irs2) and von Hippel-Lindau (Vhl) genes in B-cell function, using 
the cre-loxP system to delete these genes in the pancreas of mice. Pancreatic 
8-cells sense and respond to the metabolic status of the body via cellular 
signalling networks. The genes studied represent critical nodes in the insulin 
(Irs2) and hypoxia response (Vhl) cellular signalling pathways.
IRS2 mediated insulin and insulin like growth factor 1 receptor signalling 
(IIS) has previously been demonstrated to be critical in maintaining a functional 
8-cell mass in the presence of peripheral insulin resistance. However, in these 
previous studies, the study of irs2 null 8-cell function was complicated by the 
insulin resistance. Therefore, this thesis reports the generation and 
characterisation of the pancreatic lrs2 knock out (Plrs2KO) mouse, which has 
enabled the clarification of the role of lrs2 in the pancreas without the 
complication of increased body mass or insulin resistance. This has 
demonstrated the importance of IRS2 mediated IIS in maintaining correct 6-cell 
function, by positively regulating 8-cell mass and insulin secretion, thereby 
controlling whole body glucose homeostasis.
The transcription factor hypoxia inducible factor (HIF) initiates the 
transcription of hypoxia response genes. HIF is earmarked for destruction by 
the VHL protein in the presence of oxygen, but HIF is stabilised and active 
during hypoxia. To investigate the role of HIF in the B-cell, B-cell and pancreas 
specific Vhl knock out mice were generated (BVhlKO and PVhlKO) and 
characterised. These models exhibited 6-cell HIF1a activation and glucose 
intolerance due to altered gene transcription, defective glucose sensing and 
insulin secretion, despite having a normal 8-cell mass. This has established that 
HIF can regulate insulin secretion and 8-cell function. Importantly, these data 
have implications for human islet transplantation whereby HIF activation may 
impair glucose sensing and therefore insulin secretion in islet grafts.
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Chapter 1: Introduction
1.1 Control o f blood glucose levels
Blood glucose levels are tightly controlled by hormones secreted from the 
pancreatic islets of Langerhans (endocrine pancreas). Deviation from a 
physiologically normal blood glucose concentration can cause damage to cells, 
tissues and organs. Therefore correct glucose homeostasis is essential to sustain 
health. Islet B-cells sense glucose and secrete appropriate amounts of insulin to 
maintain blood glucose levels. Insulin acts to lower blood glucose 
concentrations by stimulating target tissues (cells containing the insulin 
receptor), principally skeletal muscle, liver and fat (white adipose tissue), to 
take up glucose from the blood stream and store it as glycogen or lipid and, in 
the case of the liver, to cease glycogenolysis and gluconeogenesis. Glucagon 
secreted from islet a-cells in response to low blood glucose levels, acts on the 
liver to stimulate glycogenolysis and gluconeogenesis to boost blood glucose 
levels. The net effect of the opposing actions of these hormones is to maintain 
a blood glucose concentration between 4 and 7 mmol/l in a normal non­
diabetic human.
1.2 Diabetes mellitus
Diabetes mellitus is a complex metabolic syndrome characterised by 
insufficient insulin secretion and/or insulin action, resulting in loss of 
homeostatic control of blood glucose concentrations and hyperglycaemia. 
Diabetes mellitus is classified as two main forms: type 1 (T1DM) or type 2 
(T2DM). T1DM involves autoimmune destruction of B-cells, resulting in an 
insufficient B-cell mass and therefore insulin deficiency and elevated blood 
glucose.
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The pathogenesis of T2DM is currently less well understood. The two critical 
components of T2DM are insulin resistance and B-cell dysfunction (DeFronzo, 
1997). Insulin resistance is the failure of insulin target tissues such as muscle, 
liver and fat to respond appropriately to insulin, resulting in hyperglycaemia 
due to reduced glucose uptake from the blood stream and reduced insulin 
inhibition of hepatic gluconeogenesis. A further complication of insulin 
resistance is impaired lipid metabolism, resulting in increased hepatic 
triglyceride levels, increased circulating non-esterified fatty acid (NEFA) levels, 
and increased white adipose tissue deposition (Kahn, 2003). Insulin resistance is 
caused in part by genetic mutation (George et al., 2004) but is commonly 
induced in modern society by environmental factors such as diet and lifestyle 
(Zimmet et al., 2001). Many insulin resistant individuals maintain euglycaemia, 
but in some individuals a subsequent failure of the B-cells to compensate for 
insulin resistance results in the progression to T2DM.
The aetiology of T2DM is still being debated, but it is clear that insulin 
resistance and B-cell failure are critical components in the progression of the 
disease (Kahn, 2003). The current increasing global trend of T2DM cases 
suggests that an underlying genetic susceptibility to the disease in some 
individuals is manifested as T2DM when combined with the diet and lifestyle of 
modern society. Increasing global obesity incidence and insulin resistance are 
drivers for T2DM in individuals genetically predisposed to the disease 
(Kopelman, 2000). Importantly, the trend for increased recorded cases of T2DM 
globally has reached epidemic proportions, and is present both in developing 
and developed countries (Zimmet et al., 2001). There are currently over 2 
million recorded cases of diabetes in the United Kingdom, and 85-95% of these 
are thought to be T2DM (Diabetes UK website: www.diabetes.org.uk).
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T2DM
Genetics Environment
Environment
Genetics
insulin resistance
Insulin resistance 
with
6-cell compensation
Figure 1.1: The proposed aetiology o f T2DM. Environmental and genetic 
factors define the insulin sensitivity o f peripheral insulin target tissues, and 
the ability of B-cells to compensate fo r this by increasing insulin output to 
maintain euglycaemia. Environmental factors that increase insulin resistance 
and B-cell stress combine with genetic factors to influence continued B-cell 
compensation or B-cell failure. Once control of blood glucose and lipid 
homeostasis is lost, elevated concentrations of these nutrients further erode 
B-cell function, leading to T2DM.
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1.3 B-cell dysfunction and insulin secretion defects
Correct B-cell function requires a sufficient quantity of B-cells with adequate 
insulin secretory capacity to match the insulin requirements of the organism. A 
loss of B-cell function may be caused by genetic mutation, as seen in maturity 
onset diabetes of the young (MODY). The definition MODY groups individuals in 
which monogenic mutations (autosomal dominantly inherited) cause diabetes 
not associated with obesity. The current MODY gene mutations lead to diabetic 
phenotypes caused in part by impaired B-cell function, as MODY genes encode 
either key B-cell transcription factors, or glucokinase (involved in glucose 
sensing). The MODY genes are: hepatic nuclear factors (Hnf 1a/1b/4a), 
glucokinase (Gcfc), pancreatic duodenal homeobox factor 1 (Pdx1) and NeuroD 
(Barroso, 2005). Although well characterised, MODY cases only account for 2.1 
% of non-insulin dependent diabetes cases in a German study cohort 
(Ledermann, 1995) and this rate is thought to reflect the incidence of MODY in 
European populations (Owen and Hattersley, 2001). Another rare documented 
monogenic mutation responsible for B-cell dysfunction is maternally inherited 
diabetes and deafness (MIDD), caused by a mitochondrial gene mutation, but as 
with MODY, only accounts for a minority of diabetes cases (Barroso, 2005).
Obesity causes increased insulin resistance, and requires increased B-cell 
insulin secretion to maintain euglycaemia. In two thirds of obese humans, B- 
cell insulin secretion compensates for this insulin resistance and blood glucose 
levels are maintained within a physiological range by hyperinsulinaemia. 
However, the remaining one third of obese patients show an inability to 
increase insulin secretion to meet the increased demand for insulin, and 
therefore progress to T2DM with hyperglycaemia and relative hypoinsulinaemia 
(Lingohr et al., 2002). This impaired compensatory insulin secretion may be 
due to reduced insulin secretion from each B-cell, and/or an insufficient mass 
of B-cells.
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1.4 Glucose stimulated insulin secretion from islet B-cells
Pancreatic islet 6-cells are responsible for sensing elevated glucose 
concentrations in the blood stream and secreting insulin appropriately, to 
lower blood glucose. Glucose stimulated insulin secretion (GSIS) is widely 
studied, as understanding the physiology and pathophysiology of the GSIS 
pathway may be critical to improve treatment of T2DM patients. The broadly 
accepted “triggering” pathway of GSIS is described below, followed by factors 
that sustain insulin secretion.
1.4.1 The triggering pathway of insulin secretion
1.4.1.1 Glucose metabolism
Glucose enters the B-cell via the 6-cell glucose transporter Giut2 (Thorens et 
al., 1988), which characteristically has a high Km for glucose (17 mmol/l) 
compared to 1.4 mmol/l for other transporters (Johnson et al., 1990). This 
allows the 6-cell the capacity to rapidly equilibrate its cytosol with the full 
range of physiological extracellular glucose concentrations. Once inside the 6- 
cell, glucose is phosphorylated to glucose-6-phosphate by the high affinity 
glucokinase (hexokinase IV); regarded as the rate limiting step in the priming of 
glycolysis (Schuit et al., 2001). Glucose-6-phosphate undergoes glycolysis to 
pyruvate via multiple intermediates including fructose-6-phosphate, 
glyceraldehyde-3-phosphate and phosphoglycerate, with ATP produced as a 
byproduct (Michal, 1999). Following glycolysis, pyruvate can either enter the 
mitochondrial tricarboxylic acid (TCA) cycle via the acetyl-CoA intermediate, 
or be converted to lactate: downregulation of lactate dehydrogenase-A (LDHA) 
in 6-cells ensures the mitochondria receive an optimal supply (Zhao et al., 
2001). Entry of acetyl-CoA to the TCA cycle drives the reduction of the pyridine 
nucleotide NAD* and flavoprotein FAD++ by addition of hydrogen ions (H*). 
These reducing equivalents are supplied to the electron transport chain at 
complexes I and II (NADH and FADH2 respectively) and H* transferred to the
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mitochondrial intermembrane space via complexes I, III and IV (Duchen et al., 
1993). Oxygen is consumed by complex IV to scavenge electrons and produce 
water, making the whole process oxygen dependent; hence aerobic respiration. 
The proton motive force from the dissipation of the H* gradient polarising the 
mitochondrial inner membrane is harnessed by ATP synthase to produce ATP 
(Michal, 1999). This ATP leaves the mitochondria by exchange for cytoplasmic 
ADP, therefore increasing the cytoplasmic ATP/ADP ratio which, in sufficient 
quantities, acts as the trigger for insulin secretion.
1.4.1.2 The importance of oxygen
For each molecule of glucose entering the 8-cell, glycolysis (anaerobic 
respiration) alone will produce 2 molecules of ATP (James et al., 1996). 
Complete mitochondrial oxidative respiration (aerobic) however, will produce 
36 molecules of ATP (James et al., 1996), although the net gain will be slightly 
lower due to ATP used for activities such as active transport. Therefore ATP 
produced by oxidative respiration contributes far more significantly to the 
triggering of insulin secretion. Following this logic it is essential that B-cells
receive an adequate supply of oxygen to sustain a high rate of mitochondrial
activity and normal GSIS. Measurement of the in vivo oxygen tension in 
pancreatic islets within their native tissue compartment, revealed that islets 
have a high oxygen tension relative to pancreatic exocrine tissue (-70% of islet 
O2 tension) and the renal cortex (-50% of islet O2 tension): this suggests a high 
demand for oxygen by islet cells (Carlsson et al., 1998).
1.4.1.3 Conversion of metabolic signals to insulin secretion
Glucose derived metabolic signals are turned into electrical activity of the 6- 
cell and insulin secretion via ATP sensitive potassium channels (KATP channels), 
principally KIR6.2. A glucose stimulated increase in the cytoplasmic ATP/ADP 
ratio closes KATP channels leading to membrane depolarisation and the opening 
of L-type voltage dependent calcium channels (VDCC), allowing calcium ion 
(Ca2*) influx to stimulate insulin vesicle exocytosis (Aguilar-Bryan and Bryan,
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1999). The KIR6.2 KATP channel forming subunit constitutively binds a 
regulatory subunit, SUR, which is the site of action of sulfonylurea drugs acting 
to close KATP channels and stimulate insulin secretion (Aguilar-Bryan and 
Bryan, 1999).
1.4.2 Sustained insulin secretion
Insulin secretion from rodent and human islets is biphasic, and the initial rapid 
rise in GSIS (first phase) is thought to be insulin secreted from the readily 
releasable pool of membrane docked and primed vesicles on the B-cell 
membrane. Second phase GSIS is thought to be due to sustained movement of 
insulin vesicles into the readily releasable pool from the intracellular reserve 
and membrane docked pools (Rorsman et al., 2000). Factors governing the 
movement of vesicles into the readily releasable pool can augment the quantity 
of insulin secreted during both phases, and although these still require a 
triggering signal from glucose, they act to amplify the secretory signal 
(Henquin, 2000).
Two key effectors promoting movement of insulin vesicles to the B-cell 
membrane for secretion are cyclic AMP (cAMP) and protein kinase C (PKC). 
Elevation of cAMP above a threshold concentration is required for normal GSIS 
activity (Pipeleers et al., 1985) and the ability of glucose-dependent 
insulinotropic peptide (GIP), glucagon-like peptide 1 (GLP1) and glucagon to 
potentiate insulin secretion relies on their stimulatory effect on cAMP 
production (Moens et al., 1996). There are many isoforms of PKC, separated 
into three discrete subfamilies based on their mode of activation. Conventional 
isoforms are activated by diacylglycerol (DAG), phosphatidylserine (PS) and 
Ca2+, novel isoforms by DAG and PS, and atypical isoforms by PS (Jones and 
Persaud, 1998b). PKC activation in the B-cell is required to potentiate the 
sustained secretion of insulin (second phase), rather than trigger secretion 
(Persaud et al., 1991). PKC kinase activation by DAG or increased intracellular
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calcium levels provides a mechanism whereby glucose may promote the 
membrane localisation and secretion priming of insulin vesicles (MacDonald et 
al., 2005).
In summary, glucose metabolism stimulated depolarisation of the B-cell is 
required to trigger insulin secretion, but PKC activation and cAMP are required 
for the sustained secretion of insulin.
1. Glucose uptake 
and phosphorylation
2. Glycolysis 
(anaerobic)
3. Mitochondrial 
respiration 
(aerobic)
4. ATP production
5. Depolarisation
6. Calcium influx
7. Insulin vesicle exocytosis
Figure 1.2: Triggering o f glucose stimulated insulin secretion (GSIS) in the 
B-cell. Glucose enters the B-cell via the high Km glucose transporter 2 (Glut2), 
is phophorylated by glucokinase and undergoes glycolysis to pyruvate, which 
enters the mitochondrial TCA cycle, via the intermediate acetyl-coA, and 
drives the reduction of NAD* and FAD**. The reducing equivalents NADH and 
FADH2 pass protons (H*), via the electron transport chain and facilita ted by the 
consumption of oxygen and production of water, to polarise the inner 
mitochondrial membrane. Dissipation of this proton gradient is harnessed to 
produce ATP. Increases in the intracellular ATP/ADP ratio close ATP sensitive 
potassium (KATP) channels, depolarise the B-cell membrane and open voltage 
dependent calcium channels (VDCC). The subsequent calcium (Ca2*) influx 
stimulates insulin vesicle exocytosis.
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1.4.3 Loss of B-cell insulin secretion
As well as impaired GSIS due to monogenic gene mutation in MODY patients 
(see above), impaired GSIS at the level of the individual B-cell has been 
reported in islets isolated from human T2DM patients (Marchetti et al., 2006). 
Multiple defects were observed including decreased glucose transport, 
phosphorylation and oxidation, along with increased cellular oxidative stress 
and apoptosis. Another study reported morphological and functional 
mitochondrial defects in human T2DM islets, with upregulation of mitochondrial 
complex I, ATP synthase and uncoupling protein 2 (Anello et al., 2005). The 
suggested explanation for these features is exposure of B-cells to high glucose 
results in increased mitochondrial substrate availability, increased 
mitochondrial metabolism (handled by increased mitochondrial enzyme 
expression) and subsequent oxidative stress. Uncoupling protein 2 allows 
dissipation of an excessive proton gradient generated across the mitochondrial 
inner membrane from glucose metabolism, bypassing ATP production and the 
trigger for insulin secretion. Interestingly, it has been reported independently 
that B-cells in a partial pancreatectomy rat model of impaired glucose 
tolerance and hyperglycaemia, show increased LDHA expression, potentially 
shuttling the glucose derivative pyruvate away from mitochondria and 
bypassing insulin secretion (Jonas et al., 1999).
The cause of these defects may be due to genetic mutation, B-cell 
hyperglycaemic stress due to loss of glucose homeostasis or hyperlipidaemic 
stress due to obesity and diabetes. For example, isolated human islets showed 
a loss of GSIS following culture for 4 days in the presence of high (33 mmol/l) 
glucose (Maedler et al., 2002) or the saturated fatty acid, palmitic acid 
(Maedler et al., 2003).
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1.5 Insulin and glucagon action
Insulin exerts its effects on target tissues/cells expressing the insulin receptor 
(INSR). Classically, insulin was thought to target liver, muscle and WAT (white 
adipose tissue) to control blood glucose and metabolism. In the liver, insulin 
secreted following elevation of blood glucose promotes storage of glucose as 
glycogen, glycolysis of glucose to acetyl-coA and subsequent lipogenesis, and 
inhibition of glycogenolysis (Pessin and Saltiel, 2000). In the liver, these actions 
of insulin are opposed by glucagon secreted from islet a-cells in response to 
low blood glucose levels (Jiang and Zhang, 2003). In skeletal muscle, insulin 
stimulates the uptake of glucose via translocation of glucose transporter 4 
(GLUT4) to the membrane, and storage of excess glucose as glycogen, whilst 
inhibiting glycogenolysis (Pessin and Saltiel, 2000). Muscle glycogenolysis is not 
stimulated by glucagon and glucose cannot be released into the blood stream, 
rather it is utilised as a local energy source during times of muscle activity or 
stimulation by adrenalin. In WAT, insulin stimulates glucose uptake via GLUT4, 
glycolysis and subsequent lipogenesis, whilst inhibiting lipolysis and the release 
of non-esterified fatty acids (NEFA) (Laviola et al., 2006). Insulin resistance 
decreases the sensitivity of these mechanisms in insulin target tissues to the 
anabolic effects of insulin (Pessin and Saltiel, 2000).
1.5.1 a-cell dysfunction in diabetes mellitus
A further endocrine complication of diabetic disease is a-cell dysfunction. 
Although much less well studied than B-cell failure, loss of glucose sensing in 
islet a-cells can cause hyperglucagonaemia in the presence of hyperglycaemia, 
and therefore sustained hepatic glucose output, further impairing homeostatic 
control of blood glucose levels (Dunning et al., 2005). In T1DM and severe 
T2DM, impaired glucose sensing can lead to an inability of a-cells to sense 
hypoglycaemia, resulting in a life threatening failure of the body to boost blood
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glucose levels, via glucagon secretion, back into a physiologically safe range 
(Dunning et al., 2005; Ravier and Rutter, 2005). Interestingly, a Korean T2DM 
study cohort was found to have reduced 8-cell mass, as predicted, but also an 
increased a-cell mass (Yoon et al., 2003), suggesting that this may also play a 
role in the pathogenesis of the disease.
form**0*
Figure 1.3: Insulin action and the control o f blood glucose levels. Insulin 
secreted from pancreatic islet B-cells in response to elevated blood glucose, 
acts on muscle/fat to stimulate glucose uptake and storage as glycogen or lipid 
respectively. In the liver insulin stimulates glucose storage as glycogen and 
lipid, and inhibits glycogenolysis and gluconeogenesis; actions opposed by the 
islet hormone glucagon, which is secreted from islet a-cells in response to 
hypoglycaemio to increase blood glucose levels.
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1.6 Generic insulin recep to r signalling
Understanding how insulin exerts its physiological effects in target tissues/cells 
is critical, as insulin resistance is a key component in the progression of T2DM. 
This is an ongoing and complicated field of research which has been greatly 
aided with the advent of mouse genetic knock out and transgenic technology, 
whereby putative insulin signalling (or related) genes can be disrupted, 
deleted, replaced or overexpressed globally, in specific tissues and at specific 
time points during development. The effect of these manipulations on other 
signalling proteins, whole body physiology, metabolism and gene transcription 
can then be analysed in vivo or in vitro.
The following is a general overview of the insulin intracellular signalling 
network as currently accepted (simplified as a diagram in Fig. 1.4). Examination 
of independent insulin signalling components and their relevance to 8-cell 
function are discussed further on, under insulin signalling in the 8-cell.
1.6.1 Insulin receptor signalling
Insulin target cells express the INSR, a tetramer composed of two a /8  sub unit 
dimers, linked by disulphide bonds. The two extracellular a-subunits, when 
bound to insulin, release their inhibition of the kinase activity of the 
intracellular 8-subunits, which subsequently undergo autophosphorylation 
(Goren et al., 1987). This triggers recruitment of insulin receptor substrate 
(IRS) docking proteins which are phosphorylated by the activated receptor. This 
coordinates binding of intracellular signalling proteins to the phosphorylated 
IRS carboxyl terminus tyrosine residues, initiating intracellular signalling 
cascades. This is an important stage in the pathway as the IRS protein allows 
the activation of diverse signalling pathways and therefore control over diverse 
cellular functions, coordinated to some extent by the type of IRS recruited, and
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modified by the regulation of this interaction (Taniguchi et al., 2006; Thirone 
et al., 2006).
The IRS proteins recruit two main pathways to the activated INSR/IRS complex: 
the phosphatidylinositol-3-kinase (PI3 kinase) pathway and mitogen activated 
protein kinase (MAP kinase)/extracellular signal related protein kinase (ERK) 
pathway. PI3 kinase is widely accepted to exert the metabolic effects of insulin 
within the cell along with cell survival, while PI3 kinase and MAP kinase 
together are associated with controlling growth and proliferation of the cell.
The IRS proteins are structured to facilitate their role as receptor docking 
proteins (Fig.1.5). At the amino terminus the pleckstrin homology (PH) domain 
facilitates membrane binding, and a phosphotyrosine binding (PTB) domain 
enables the IRS to bind to the activated INSR or insulin-like growth factor 1 
receptor (IGF1R). IRS2 contains an additional motif to facilitate receptor 
binding, which is not present on the other IRS proteins, and may alter its 
receptor binding kinetics (Thirone et al., 2006). The carboxyl terminus of each 
IRS protein contains a unique compliment of tyrosine residues that are 
phosphorylated by the activated receptor after IRS docking/binding. These 
recruit intracellular signalling proteins that contain SH2 domains such as p85 
(the PI3 kinase regulatory subunit), or GRB2/mSOS (mammalian son of 
sevenless) which initiates the MAP kinase/ERK signalling cascade. IRS1, IRS2 
and IRS4 share a similar pattern and number of tyrosine residues, whereas IRS3 
is truncated.
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Figure 1.4: Schematic overview o f the intracellular INSR/IGF1 receptor 
signalling network. The critical nodes of INSR/IRS, PI3 kinase and AKT have 
been highlighted. Activation of the INSR or IGF1 receptor (IGF1R) by ligand 
binding causes recruitment and phosphorylation of an IRS docking protein. This 
stimulates either recruitment of p85 and PI3 kinase pathway activation, or 
recruitment of Grb2-mS0S and activation of the MAP kinase/ERK pathway. AKT 
activation is a signalling node downstream of PI3 kinase, critical for 
coordinating some of the metabolic actions of insulin. Diagram taken from 
Taniguchi et.al., 2006.
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Figure 1.5: Diagram showing structure o f the insulin receptor substrate 
(IRS) proteins. Pleckstrin homology (PH) and phosphotyrosine binding (PTB) 
domains enable IRS to bind the plasma membrane and activated INSR/IGF1R 
respectively. IRS contains an additional domain thought to facilitate receptor 
binding. Subsequent tyrosine phosphorylation of the IRS by the receptor, 
allows binding of downstream effectors to the carboxyl terminus 
(phospho)tyrosine residues: principally, p85 (PI3 kinase pathway) and Grb2- 
mSOS (MAPkinase/ERK pathway). A: Generic structure of IRS proteins. B: 
Structure of IRS proteins 1-4. Diagram taken from Thirone et.al., 2006.
1.6.2 The PI3 kinase pathway
The PI3 kinase family contains signalling kinases (catalytic subunits) and 
associated adapter/regulatory subunits. The best metabolically studied are the 
class la PI3 kinases which consist of a PI3 kinase dimer made up of a regulatory
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subunit (p85/55/50a or 6) and catalytic subunit (p110 a, B or 6). The 
regulatory subunit contains a Src-homology 2 (SH2) domain which binds to the 
phosphorylated IRS tyrosine residue. After p85/IRS binding, the catalytic 
subunit becomes active and adds the 3-position phosphate group to 
phosphoinositide-4,5-biphosphate (PIP2), generating the signalling lipid 
phosphoinositide-3,4,5-triphosphate (PIP3). PIP3 activity is negatively regulated 
by removal of the inositol 3-position or 5-position phosphate group by 
phosphatase and tensin homologue (PTEN) or SH2 domain containing inositol 5’ 
phosphatase (SHIP2) respectively. PIP3 acts as a membrane recruitment signal 
for the 3-phosphoinositide dependent protein kinases 1 /2 (PDK1 and 2) and the 
serine/threonine kinase AKT (also known as protein kinase B; PKB). Once 
colocalised PDK1/2 activates AKT by phosphorylation (Alessi et al., 1997; 
Shepherd et al., 1998). Activated AKT represents a highly divergent node in the 
insulin signalling pathway. AKT directly alters the activity of transcription 
factors such as F0X01 (Tran et al., 2003), altering the expression of metabolic 
genes. AKT stimulates glycogen synthesis via glycogen synthase kinase 3 (Cross 
et al., 1995), and glucose uptake via phosphorylation of a Rab GTPase- 
activating protein (GAP) regulating GLUT4 membrane localisation (Sano et al., 
2003). AKT promotes protein synthesis via the mammalian target of rapamycin 
(mTOR) pathway and subsequent activation of p70S6 kinase (ribosomal protein 
S6 kinase 70kd) and inhibition of 4EBP1 (eukaryotic initiation factor 4E binding 
protein 1) (Harris and Lawrence, 2003), and promotes cell survival by the 
inhibition of the pro-apoptotic BAD (Datta et al., 1997). In adipocytes, 
activated AKT activates phosphodiesterase 3B (PDE3B) by phosphorylation 
(Kitamura et al., 1999), resulting in reduced cAMP levels and reduced protein 
kinase A activity, thus inhibiting lipolysis.
Class II PI3 kinases which are involved in inositol signalling are activated by 
insulin (Brown et al., 1999) and are therefore regarded as metabolically 
important, but require further study to elucidate their function. Also 
implicated in metabolism is the class lb PI3kinase, p110y catalytic and p101 
adapter subunits, although this subclass is activated by G-protein coupled
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receptor systems rather than insulin/growth factor receptors (Vanhaesebroeck 
et al., 2005).
1.6.3 The MAP kinase pathway
The MAP kinase pathway is activated by GRB2 recruitment to its respective 
phosphorylated IRS tyrosine residue. The subsequent recruitment and 
activation of mSOS stimulates guanine nucleotide exchange and activation of 
the small GTPase Ras, resulting in Mek phosphorylation which in turn activates 
MAP kinase/ERK1 and ERK2. Activated ERK1/2 stimulate cell growth and 
proliferation by directly phosphorylating p90 S6 kinase (ribosomal protein S6 
kinase 90 kd) thus controlling protein synthesis. Activated ERK1/2 also control 
gene transcription via the transcription factor ELK (Taniguchi et al., 2006).
1 .7  Factors contro lling  B-cell mass
There are many growth factors proposed to be involved in the regulation of 
adult B-cell mass. This section reviews the most pertinent factors, most of 
which have been validated using an in wVo, or primary B-cell model. The action 
of insulin and IGF1 will be more thoroughly discussed further on in the 
introduction with relevant knock out mouse data.
1.7.1 Insulin-like growth factors
Insulin-like growth factors 1 and 2 (IGF1, IGF2) have both been implicated in 
increasing B-cell mass by promoting survival and proliferation of B-cells in 
various contexts. Circulating IGF1 is produced by the liver, however IGF1 is 
expressed locally in the pancreas, in capillary endothelial cells (Smith et al., 
1991). Interestingly, induction of Igf1 mRNA expression in rat pancreatic ductal 
epithelial cells, following partial pancreatectomy, gave strong evidence for the 
role of IGF1 in promoting expansion of B-cell mass (Smith et al., 1991). IGF1
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has been shown to promote growth in a transformed 6-cell line, acting in 
concert with glucose (Hugl et al., 1998), and to prevent interleukin-16 induced 
6-cell dysfunction and apoptosis when transferred to isolated human islets by 
adenovirus (Giannoukakis et al., 2000). Global overexpression of /g/2 results in 
hyperplasia in many organs, and in the pancreas causes five times overgrowth 
of islets when compared to controls, despite normal circulating glucose and 
insulin levels (Petrik et al., 1999). IGF1R signalling acts via IRS2 in the 6-cell (as 
discussed below), and activates PI3 kinase and MAP kinase intracellular 
signalling cascades.
1.7.2 Growth hormone and prolactin
Growth hormone secreted from the pituitary is regarded as a 6-cell mitogen, 
and acts on 6-cells via the growth hormone receptor to activate Janus kinase-2 
(JAK2). JAK2 subsequently activates the signal transducer and activator of 
transcription (STAT) transcription factors 1, 3 and 5 (Nielsen et al., 2001). 
STAT5 activation by growth hormone has been implicated in promoting 
proliferation via expression of cyclins, suppression of inflammatory cytokines 
via expression of suppressor of cytokine signalling (SOCS) family proteins, and 
expression of the anti-apoptotic protein 6CL-XL (Nielsen et al., 2001). 
Prolactin, secreted during pregnancy, acts via the prolactin receptor in the 
pancreas, and utilises the JAK2/STAT pathway. This is thought to mediate its 6- 
cell mitogenic effects in a similar manner to growth hormone (Nielsen et al., 
2001). It has been shown that prolactin receptor signalling during pregnancy 
activates components of the insulin signalling pathway including IRS proteins 
(Amaral et al., 2004) demonstrating cross talk between the JAK/STAT and 
insulin signalling pathways.
1.7.3 Leptin
Leptin is a hormone secreted from adipocytes in white adipose tissue, which 
acts as a negative feedback signal on the 6-cell, inhibiting insulin secretion
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(Morton et al., 1999), there by limiting further insulin stimulated growth of 
adipocyte mass; creating an adipo-insular axis. Deletion of the leptin receptor 
in B-cells results in an enlarged islet cell mass, fasting hyperinsulinaemia, yet 
impaired glucose tolerance and GSIS (Covey et al., 2006). This suggests leptin 
negatively regulates growth of B-cell mass and fasting insulin secretion, and 
obesity induced hyperleptinaemia may impair adaptive B-cell hyperplasia. The 
leptin receptor in B-cells is similar to the growth hormone/cytokine receptor, 
and activates JAK2 and STAT3 pathways to exert its intracellular function 
(Morton et al., 1999).
Interestingly, leptin has been shown to stimulate IRS2 phosphorylation in 
myotubes (Kellerer et al., 1997). Activation of the JAK2/STAT3 pathway by 
leptin stimulates PI3 kinase activity via recruitment of SH2B and IRS1/2 to the 
activated JAK2 protein in a kidney cell line and mouse embryonic fibroblasts 
(Duan et al., 2004). Despite these findings in other tissues, the interaction 
between leptin and INSR signalling in the B-cell has not been reported.
1.7.4 Glucagon-like peptide 1 and growth factor signalling
Glucagon-like peptide 1 (GLP1) is a preproglucagon derived peptide expressed 
from the glucagon gene in gut enteroendocrine L-cells, and secreted in 
response to ingested nutrients within the gut. GLP1 has a mitogenic action on 
B-cells, and exerts this effect via its G-protein coupled receptor present on the 
B-cell membrane (Buteau et al., 2003). Interestingly, its mode of action 
appears to involve transactivation of the epidermal growth factor (EGF) 
receptor pathway. The proposed mechanism involves activation of c-Src 
downstream of the GLP1 receptor, and subsequent cleavage and release of EGF 
ligands, possibly the B-cell expressed betacellulin, from the B-cell extracellular 
membrane allowing activation of the EGF receptor in an autocrine manner 
(Buteau et al., 2003). GLP1 transactivation of the EGF receptor has been 
demonstrated to lead to PI3 kinase activation of AKT and nuclear exclusion of
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F0X01, relieving its inhibition of the Pdx1 and Foxa2 gene promoters (Buteau 
et al., 2006). This mechanism may mediate the PI3 kinase dependent GLP1 
stimulation of B-cell proliferation, although PKC£ is also thought to play a role.
GLP1 activation of its G-protein coupled receptor also acts to raise intracellular 
cyclic AMP (cAMP) levels, leading to activation of protein kinase A (PKA) and 
the transcription factor CREB (cAMP response element binding protein). 
Expression of dominant negative forms of CREB within B-cells leads to a loss of 
B-cell mass and diabetes (Jhala et al., 2003). Importantly, this study 
highlighted the ability of the GLP1/cAMP pathway to potentiate insulin and 
IGF1 survival signalling in the B-cell, as they demonstrated that CREB induces 
Irs2 expression, and suggest that loss of this mechanism may account for the 
loss of B-cell mass observed.
1.7.5 Vascular endothelial growth factor and Hepatocyte growth 
factor
Vascular endothelial growth factor (VEGF) A is constitutively expressed in 
pancreatic B-cells, and is thought to be involved in the induction of blood 
vessels and islet vascularisation during development (Christofori et al., 1995). 
The subsequent hormonal interplay between blood vessels and islet is regarded 
as critical for correct islet development (Lammert et al., 2001). One 
documented example of this interplay is the adaptation of the adult B-cell mass 
to increased demand for insulin during pregnancy. Circulating prolactin 
(gestational lactogenic hormone) from the pituitary gland stimulates B-cells to 
release VEGF-A, which in turn stimulates hepatocyte growth factor (HGF) 
secretion from vascular endothelial cells local to the B-cell (Johansson et al., 
2006). The subsequent HGF stimulation of the B-cell promotes proliferation and 
survival, therefore leading to expansion of the B-cell mass to compensate for 
the increased insulin resistant pregnant state. It has since been demonstrated 
that deletion of the HGF (c-met) receptor in B-cells using conditional gene 
targeting results in reduced B-cell pancreatic area, impaired insulin secretion
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and hyperglycaemia (Dai et al., 2005). This indicates that functional HGF/c- 
met signalling is required to maintain a sufficient 8-cell mass. It has also been 
shown that deletion of VEGF-A in mouse B-cells causes impaired islet 
vascularisation and therefore insufficient insulin delivery to the in vivo 
circulation to maintain normal glucose tolerance, despite normal islet function 
ex vivo (Brissova et al., 2006).
IRS proteins have been implicated in mediating both the expression and action 
of VEGF. IRS1 is recruited to the VEGF receptor (type 2) in kidney cells in vitro, 
and activates the PI3 kinase pathway in response to VEGF stimulation (Senthil 
et al., 2002). The expression of VEGF in transformed pancreatic cancer cells is 
dependent on IRS2 mediated IGF1R signalling, acting via the PI3 kinase but not 
MAP kinase pathway (Neid et al., 2004).
1.7.6 Nerve growth factor
B-cells, which posses functional nerve growth factor (NGF) receptors (TrkA and 
NTR), are exposed to circulating NGF from the pituitary, and also express and 
secrete functional NGF locally (Pierucci et al., 2001). These researchers 
showed that NGF withdrawal from the B-cell by treatment with an a-NGF 
monoclonal antibody increased the B-cell apoptotic rate. This was due to 
reduced signalling via the PI3 kinase survival pathway, and subsequent 
reduction in anti-apoptotic BAD phosphorylation and Bcl-xL expression. IRS1 
and IRS2 have been shown to bind to the TrkA receptor and recruit p85 in 
response to NGF treatment in transformed kidney cells (Miranda et al., 2001). 
Therefore this interaction may play a role in mediating the effect of NGF 
activation of PI3 kinase in B-cells.
1.7.7 Fibroblast growth factors
Adult mouse B-cells show expression of fibroblast growth factors (FGF) 1, 2, 4, 
5, 7 and 10 as well as FGF receptors (FGFR) 1 and 2. When FGFRIc signalling
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was blocked by expression of a dominant negative mutant FGFRIc, B-cell 
function was impaired and mass reduced in the adult mouse, despite normal 
development (Hart et al., 2000). This implicates FGFR1 signalling in 
maintaining a functional B-cell mass, likely sustained by a B-cell autocrine 
feedback loop.
1.7.8 Inflammatory cytokines
Pro-inflammatory cytokines have classically been associated with auto-immune 
destruction of B-cells during the progression of T1DM. However, 
hyperglycaemia induced production of pro-inflammatory cytokines has been 
proposed as a link between glucose toxicity and B-cell apoptosis in T2DM. For 
example, four day culture of human islets in high glucose induces upregulation 
of interleukin 1B (IL1B) production in the B-cell. This causes activation of the 
transcription factor nuclear factor-kB, increased FAS (transforming nuclear 
factor receptor super family member 6) signalling and apoptosis, leading to B- 
cell dysfunction (Maedler et al., 2002). It has also been suggested that this 
pathway may be programmed to be antiapoptotic in the B-cell when exposed to 
transient elevations in blood glucose, but switches to pro-apoptotic signalling 
in response to chronically elevated blood glucose levels, thus mediating glucose 
toxicity (Donath et al., 2005).
1.7.9 Glucose
Glucose has been reported to stimulate B-cell proliferation independently of 
other factors. This makes physiological sense as elevated blood glucose 
indicates a need for insulin, hence the trigger for secretion, but when elevated 
higher than a physiologically safe range (4-7 mmol/1) indicates inadequate 
insulin secretion, therefore requiring an expansion of B-cell mass to 
compensate. A well characterised in vivo model demonstrating hyperglycaemia 
and increased B-cell mass growth is the rat 90% partial pancreatectomy model 
(Jonas et al., 1999) where the remaining pancreas shows a rapid increase of B-
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cell mass in the presence of chronic hyperglycaemia and hypoinsulinaemia. 
Another study observed the effect of glucose on B-cell proliferation using a 
transformed B-cell line, which revealed that glucose independently induced B- 
cell proliferation, and potentiated IGF1 induced B-cell proliferation within 
physiological concentrations (Hugl et al., 1998). A subsequent study using the 
same approach suggested that glucose activates mTOR and p70S6 kinase 
independently of AKT, and also activates ERK1 and ERK2 (Dickson et al., 2001).
It has been demonstrated that glucose induced calcium ion (Ca2+) influx (part of 
the B-cell GSIS mechanism), possibly acting through a calcium/calmodulin 
dependent kinase (CaM kinase), stimulates the activation of the transcription 
factor CREB, promoting B-cell survival and sustained B-cell mass (Jhala et al.,
2003). This also suggests that as Irs2 expression is upregulated by CREB, glucose 
may act to potentiate IRS2 mediated survival signalling in the B-cell, as stated 
above. A study reporting loss of insulin secretion in rat islets due to 
desensitisation of CaM kinase II with sustained high Ca2+ (Jones and Persaud, 
1998a), suggests that desensitisation of CaM kinases in vivo by chronic B-cell 
depolarisation due to sustained hyperglycaemia, may result in reduced 
activation of CREB and reduced Irs2 expression, and contribute to the 
pathogenesis of T2DM.
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Figure 1.6: Factors promoting an increased B-cell mass. Factors positively 
regulating B-cell mass are shown, see text fo r modes o f action and 
abbreviations.
1.7.10 Loss of B-cell mass
Loss of B-cell mass is a critical component in the progression of T2DM. The 
mechanism underlying compensation for obesity induced insulin resistance is 
thought to involve expansion of the B-cell mass to increase the insulin 
secretory capacity of the endocrine pancreas, as most rodent and human 
models of T2DM show a loss of B-cell mass (Lingohr et al., 2002). The potential 
mechanisms leading to a loss of B-cell mass are complex and involve B-cell 
exposure to glucose, lipids and inflammatory cytokines as well as growth 
factors/hormones and oxygen availability. Indeed, the balancing effects of 
these factors determine B-cell mass by affecting B-cell proliferation, survival, 
size and islet neogenesis. During development and weaning, high rates of these 
four B-cell growth parameters shape the number and pattern of islets
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throughout the pancreas for adulthood (Bonner-Weir, 2000). During adulthood 
however, there is little islet neogenesis and B-cell mass is governed by the 
balance of low rates of proliferation and apoptosis, with replication of the 
adult B-cells providing the main source of new B-cells (Dor et al., 2004). 
Modulation of this balance, for example stimulation by lactogenic hormones 
during pregnancy (Sorenson and Brelje, 1997), placing a normal rat on a high 
fat diet (Lingohr et al., 2002) or subjecting a rat to partial pancreatectomy 
(Jonas et al., 1999), leads to increased B-cell proliferation and decreased 
apoptosis in a normal islet. This enlarges the B-cell population and insulin 
secretory capacity of the animal, compensating for the insulin resistance and 
increased demand for insulin. In the case of partial pancreatectomy, B-cell 
hypertrophy was found to contribute to the compensatory increased B-cell mass 
(Jonas et al., 1999). Defects in this hyperplastic mechanism such as impairing 
the ability of B-cells to suppress apoptosis and/or proliferate, may result in an 
inability of the B-cell population to compensate for increased insulin 
resistance; leading to a loss of glycaemic control and potentially T2DM. Indeed, 
reduced B-cell mass due to increased apoptosis or reduced proliferation has 
been reported as a key stage in the loss of glycaemic control and progression of 
T2DM in humans (Butler et al., 2003; Yoon et al., 2003) and in many mouse 
models of T2DM discussed in this chapter.
Following loss of glucose homeostasis, the subsequent hyperglycaemia and/or 
hyperlipidaemia can cause secondary deleterious effects on the survival of the 
remaining B-cells, creating a vicious negative feedback loop leading to B-cell 
“burn out” and overt T2DM. Islets in culture show increased apoptosis in the 
presence of high (33 mmol/1) glucose (Maedler et al., 2002) or the saturated 
fatty acid, palmitic acid (Maedler et al., 2003). It has been further 
demonstrated, using rodent primary and transformed B-cells, that high glucose 
activates specific apoptotic cellular pathways, involving BAX activation and 
mitochondrial binding, cytochromeC release from mitochondria and caspase3 
activation (Kim et al., 2005). Endoplasmic reticulum stress leading to sterol
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regulatory element binding protein activation has been proposed as a mediator 
of B-cell hyperglycaemic toxicity (glucotoxicity), and the associated pro- 
apoptotic changes in gene expression such as loss of Irs2 and Bcl-xL (Wang et 
al., 2005). As such, glucotoxicity may play a central role in apoptotic loss of B- 
cell mass during the progression of T2DM, along with other lipoproteins, leptin 
and cytokines (Donath et al., 2005).
1.8 Insulin and insulin-like growth fa c to r signalling in th e  8- 
cell
Autocrine signalling of insulin secreted from the B-cell, stimulating the B-cell, 
has been observed in a transformed B-cell line, where insulin applied 
exogenously or by glucose stimulation could cause INSR activation, subsequent 
IRS1 phosphorylation and recruitment of p85 (Rothenberg et al., 1995). This 
suggested that a possible autocrine feed back loop exists whereby B-cells are in 
fact insulin targets, and insulin may exert some physiological or molecular 
control over their function.
Studies using genetically modified mice have since proved valuable in 
investigating the role of the INSR and IGF1R signalling (IIS) pathway in 
sustaining a functional B-cell mass. There are now many informative studies 
using gene knock out and conditional gene targeting techniques that have 
demonstrated the role of IIS in maintaining an adequate B-cell mass and correct 
insulin secretion; these key studies are described below, following an overview 
of conditional gene targeting.
1.8.1 The cre/loxP system for conditional gene targeting
Conditional gene targeting in mice, also known as tissue specific knock-out (KO) 
technology, using the cre/loxP system (Sauer, 1993) gives much greater
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specificity and control over gene deletion than global KO technology, as genes 
can be deleted in a spatio-temporal manner. Global KO mice have the gene of 
interest deleted from the germ line, so that every cell in the body will not 
express that gene, potentially making interpretation of a resultant phenotype 
more complicated. The cre/loxP site-specific recombination technology has 
been derived from viral recombinant elements cloned from a P1-bacteriophage 
(Sauer and Henderson, 1988).
LoxP (sites of recombination) consist of two 13 base pair non-palindromic 
inverted repeat sequences separated by an 8bp spacer as shown:
LoxP site: ATAACTTCGTATA ATGTATGC TATACGAAGTTAT
The enzyme cre-recombinase promotes the recombination of two loxP sites 
within a DNA sequence, and can therefore be used to excise a section of DNA 
flanked by loxP sites (floxed) from a DNA sequence or genome. Therefore, a 
loxP site is inserted either side of the gene or DNA sequence to be deleted to 
generate a floxed mouse line with germline transmission of the floxed gene. 
This floxed mouse is then bred with a “ere” mouse containing a transgene 
expressing the cre-recombinase enzyme under the control of a promoter active 
in a specific tissue: for example the albumin gene promoter. The progeny of 
this cross, if homozygote for the floxed gene and possessing the cre-transgene, 
would have the floxed gene deleted in cells expressing albumin from the time 
point when the albumin promoter becomes active: ie. deletion in hepatocytes 
from embryonic day 12 onwards. Crucially, the lineage of cells originating from 
any progenitor cell in which the albumin promoter has been active, even 
transiently, will possess the gene deletion.
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1.8.2 Insulin receptor and IGF1 receptor knock out models
1.8.2.1 Insulin and Insulin receptor global knock outs
Mice null for both the insulin genes 1 and 2 show severe diabetic ketoacidosis 
and liver steatosis and die 48 hours after birth (Duvillie et al., 1997). 
Interestingly, the pancreas appears to develop normally, with an enlarged B- 
cell mass. Mice with global deletion of the Insr were born with slight growth 
retardation but die soon after birth due to severe diabetic ketoacidosis and B- 
cell failure (Accili et al., 1996). Clearly these two studies create a mouse with 
severe global loss of insulin action, resulting in severe diabetes and death. 
Therefore, conditional gene targeting of the Insr in the B-cell provided a more 
refined assessment of the requirement for insulin action in the B-cell.
1.8.2.2 Insulin receptor B-cell knock out
Due to the severe diabetic phenotype of the global Insr KO, conditional gene 
targeting was used to delete the Insr in pancreatic B-cells using a rat insulin 2 
promoter driven ere (RIPcre) mouse, enabling study of the specific B-cell role 
of this gene product. The mice were found to show progressive glucose 
intolerance, due to a loss of first phase GSIS and reduced pancreatic insulin 
content by 4 months of age (Kulkarni et al., 1999a). A subsequent study of 
these mice revealed reduced B-cell mass and impaired B-cell elevations of 
calcium following glucose stimulation (Otani et al., 2004). This demonstrated 
the necessity for autocrine stimulation of the B-cell by insulin, to maintain 
correct B-cell mass and function.
1.8.2.3 Iqf1 receptor global knock out
Mice globally null for either /g/f or /g/2 show growth retardation (60% of 
controls) and die after birth in some genetic backgrounds, and when both genes 
are deleted severe growth retardation (30% of controls) suggests non- 
redundancy of these genes (Liu et al., 1993). Global Ig f lr  knockout mice show 
growth retardation (45% of controls), hypoplastic defects in multiple organs
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including muscle and epidermis, delayed bone ossification and die at birth due 
to respiratory failure (Liu et al., 1993). Reduced B-cell pancreatic area has 
been reported in global /g /fr KO mice at birth (Withers et al., 1999).
1.8.2.4 /gff receptor B-cell knock out
Deletion of the /g /fr specifically in B-cells using the RIPcre mouse, causes 
impaired glucose tolerance with age, due to defective GSIS, but does not alter 
B-cell mass (Kulkarni et al., 2002; Xuan et al., 2002). This suggests that Insr 
and /g/fr signalling coordinate to sustain normal insulin secretion, while Insr 
sustains an adequate B-cell mass and insulin content. The finding that B-cell 
/g /fr KO mice have a normal B-cell mass demonstrates the power of the 
conditional KO approach in studying gene function in a (relatively) normal 
physiological in vivo context, as previous studies (discussed above) did not 
predict or suggest this effect. These earlier studies assessed IGF1 function by 
overexpression in islets (Giannoukakis et al., 2000), following pancreatic injury 
(Smith et al., 1991), exogenous IGF1 application to transformed B-cells (Hugl 
et al., 1998) and /g/2 expressed globally (Petrik et al., 1999). The results from 
these studies are still valid, but within the specific context of their 
experimental design. The finding of reduced B-cell mass in the global /g /fr KO 
pups at birth (Withers et al., 1999) may be due to /g/fr deletion in non-B-cell 
tissues, or due to absence of functioning IGFIRs throughout pancreatic 
development (from embryonic day E8.5). Where as in the conditional mutant 
the /g/fr gene is only deleted in B-cells (and hypothalamus) from E11 onwards 
after the gross morphological formation of the pancreas has taken place; again 
highlighting the investigative power of the conditional KO approach.
1.8.2.5 Insulin receptor and /gff receptor double B-cell knock out
A study of combined deletion of the /g/fr and Insr in the B-cell, reported a 
much more severe diabetic phenotype than that observed in the single 
mutants, with fasting and fed hyperglycaemia developing by 3 weeks of age 
(Ueki et al., 2006). This was characterised by reduced B-cell mass, and
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impaired first phase GSIS. Importantly the double knock out mice used in this 
study possessed normal B-cell mass 5 days after birth, but decreased B-cell 
mass by 14 days, indicating that IIS does not control the morphogenesis of the 
pancreas/islets in utero, but rather functional IIS is required for correct 
expansion and sustained function of B-cell mass after birth.
1.8.3 Insulin receptor substrate knock out models
1.8.3.1 Irs1 global knock out
The Irs1 global knock out mice show reduced somatic growth (birth weight 50% 
of control) and insulin resistance with impaired glucose uptake from the blood, 
but without progressive diabetes (Araki et al., 1994; Tamemoto et al., 1994). 
Further investigation revealed that these insulin resistant mice do not develop 
diabetes because of a compensatory expansion of B-cell mass and elevated 
second phase insulin secretion (Terauchi et al., 1997; Withers et al., 1998), 
with normal pancreatic insulin content, despite reduced islet insulin content 
and impaired in vivo first phase and in vitro  islet GSIS (Kulkarni et al., 1999b). 
Therefore IRS1 is not critical in mediating expansion of B-cell mass, but rather 
plays a role in insulin sensitivity of peripheral target tissues and first phase 
GSIS.
1.8.3.2 Irs2 global knock out
Global deletion of the Irs2 gene causes overt and progressive diabetes due to 
insulin resistance in peripheral insulin target tissues, combined with a failure of 
Irs2 null beta cells to mount a compensatory hyperplastic response (Withers et 
al., 1998). These mice were bred on a C57BL6/Sv129 mixed genetic background 
and showed normal growth and development, but with progressive diabetes and 
loss of glucose homeostasis, leading to overt diabetes and death in male mice 
after 10 weeks. B-cell mass of irs2 KO mice was about 40% of control animals, 
suggesting a severely insufficient B-cell capacity given that the Irs2 KO mice 
are far more insulin resistant than controls. Global deletion of !rs2 was
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achieved independently by another team (Kubota et al., 2000) and these mice, 
when bred onto a C57BL6/CBA mixed genetic background, reproduced the 
diabetic phenotype seen in the existing model, although less severe, with a B- 
cell mass 83% of control animals. Islets isolated from the Kubota global Irs2 KO 
showed normal GSIS at physiological glucose concentrations, and slightly 
enhanced in v itro  GSIS at high glucose concentrations, suggesting that IRS2 may 
be required for B-cell growth rather than insulin secretion.
The global Irs2 KO models suggested a unifying critical role for IRS2 in 
maintaining insulin sensitivity in peripheral target tissues, and in coordinating 
the INSR and IGF1R signals in the B-cell to sustain a functional B-cell mass.
1.8.3.3 Irs3 global knock out
Despite IRS3 being the most abundant IRS protein in adipocytes, mice with 
global deletion of the Irs3 gene showed no detectable alteration in growth, 
glucose homeostasis, glucose transport into adipocytes, IRS1/2 phosphorylation 
or IRS1/2 association with p85/PI3 kinase (Liu et al., 1999). However, global 
double knock out of Irs1 and Irs3 caused a phenotype more severe than Irs1 
global deletion alone, with lipoatrophy, and more severe insulin resistance, 
hyperglycaemia and hyperinsulinaemia (Laustsen et al., 2002). The B-cell mass 
of the double knock out was significantly greater than the Irs1 KO therefore 
indicating the ability of irs1/irs3 null B-cells to mount a compensatory 
hyperplastic response to severe peripheral insulin resistance.
1.8.3.4 Irs4 global knock out
Irs4 global KO mice show a mild phenotype with slightly reduced somatic 
growth in the male (90% of control size), modestly impaired reproductive 
capacity, and slightly lowered blood glucose levels (Fantin et al., 2000). 
Although as fasted and fed plasma insulin levels were unaltered from controls, 
the altered glucose homeostasis is unlikely to be caused by a B-cell phenotype. 
Combined global deletion of Irs1 and irs4 resulted in a phenotype identical to
45
that caused by global Irs1 deletion alone (Laustsen et al., 2002).
1.8.3.5 Irs2 and /gff receptor double global knock out
Deletion of one allele of the /g/fr and both Irs2 alleles globally (/g/fr'/+ /rs2'/ ) 
causes a more severe phenotype than Irs2 deletion alone (Irs2'/ ), with B-cell 
area only 2% of control area in the double KO (/g /fr /+ Irs2 / ') compared with 
40% in the global Irs2 KO (/rs2'/ ) (Withers et al., 1999). Yet when double knock 
out mice with one Irs2 allele and one /g/fr allele are generated (/g/fr'/+ /rs2'/+), 
B-cell mass is significantly recovered (Withers et al., 1999). The /g/fr 
heterozygote global KO (/g/fr /+) appears not to have a B-cell mass significantly 
different to that of controls, and the conditional B-cell /g/fr KO has a normal 8- 
cell mass (Kulkarni et al., 2002; Xuan et al., 2002). Therefore, this implies that 
functional /g /fr signalling is required for limiting a near complete loss of B-cell 
mass on an Irs2 null background, but is not involved in B-cell mass regulation 
under normal conditions. These studies also underscore the critical role of IRS2 
in sustaining an adequate B-cell mass.
1.8.3.6 Irs2 and insulin receptor double global knock out
A similar additive effect, as described for Irs2/I$f1r double mutation, was 
reported when one allele of the insulin receptor and both Irs2 alleles were 
globally deleted (I n s r /rs2'/ ), with diabetes ensuing that is more severe than 
Irs2 global deletion alone (/rs2'/ ), and with reportedly “barely detectable” 
islets, although this was not formerly quantified (Kitamura et al., 2002). This 
suggests that a fully functional INSR prevents catastrophic loss of B-cell mass in 
a similar way to the IGF1R described above.
1.8.3.7 Irs2 and Irs1 double global knock out
Irs1 and Irs2 double global KO mice are not viable and die early in embryonic 
development (Withers et al., 1999) indicating that both genes have critical 
roles during development. Global Irs2 KO mice with one allele of Irs1 globally 
deleted (/rs f/+ /rs2'/ ) show a more severe diabetic phenotype than Irs2
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deletion alone, with increased fasting blood glucose, decreased plasma insulin 
and a catastrophic loss of B-cell mass (<10 % of control B-cell mass) at 4 weeks, 
with death occurring at around 5 weeks (Withers et al., 1999). It is unclear 
whether the additional deletion of a single Irs1 allele causes a direct B-cell 
defect, or a secondary stress defect due to more severe insulin resistance and 
associated lipid and glucose dysregulation.
1.8.3.8 Irs2 B-cell/hvpothalamic knock out
Tissue specific deletion of the Irs2 gene in the B-cell and an uncharacterised 
population of hypothalamic neurons has reinforced that when challenged with 
peripheral insulin resistance, Irs2 null B-cells fail to mount a compensatory 
proliferative response (Choudhury et al., 2005; Kubota et al., 2004; Lin et al.,
2004). The hypothalamic deletion of Irs2 caused a hyperphagic, obese, insulin 
resistant phenotype which, coupled with a loss of Irs2 null B-cell mass (60% of 
controls), resulted in a glucose intolerant hyperglycaemic phenotype that did 
not progress to overt diabetes.
These studies have reinforced the concept that Irs2 null B-cells cannot 
proliferate/survive sufficiently to match the insulin demand of an insulin 
resistant animal. Therefore, to more precisely test the role of IRS2 in the 
development and function of the B-cell and pancreas, Irs2 deletion must be 
achieved in a model not complicated by peripheral insulin resistance or 
hypothalamic phenotype.
The B-cell Irs2 KO studies used the rat insulin 2 promoter driven cre- 
recombinase (RIPcre) transgenic mouse obtained from the Jackson Laboratory 
(Postic et al., 1999). The RIPcre transgene was found to be expressed not only 
in insulin producing B-cells, but also a small population of hypothalamic 
neurones, causing a hyperphagic, obese, hyperleptinaemic, insulin resistant 
phenotype complicating the specific study of the B-cell (Choudhury et al.,
2005). The B-cell Insr KO and B-cell /g /fr KO studies cited above (Kulkarni et
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al., 1999a; Kulkami et al., 2002) used the same RIPcre mouse, and as the 6-cell 
Insr KO has been shown to have significantly increased body mass over controls 
(Mauvais-Jarvis et al., 2000), these models may potentially have a 
hypothalamic phenotype complicating study of the 6-cell phenotype. However, 
the 6-cell phenotype has recently been replicated using a different pancreas 
specific ere line (Ueki et al., 2006).
Another potential complication with the tissue specific studies using the RIPcre 
mouse is that this transgenic line, when bred on a pure C576L/6 genetic 
background, has recently been reported to possess a 6-cell defect with glucose 
intolerance and impaired glucose stimulated insulin secretion, characteristic of 
a diabetic phenotype (Lee et al., 2006). Although the majority of authors have 
used the correct controls, it is essential that any future study controls for the 
presence of the ere transgene, to ensure that its presence does not confound 
the study of the deleted targeted allele.
1.8.3.9 Irs2 6-cell transgenic mouse
Further clarification for the 6-cell role of IRS2 came from transgenic 
overexpression of Irs2 in 6-cells of mouse models of T2DM, which caused 
enhanced 6-cell growth, survival and proliferation, resulting in the prevention 
of diabetes in global Irs2 KO mice, high fat diet induced obese mice and 
streptozotocin-treated mice (Hennige et al., 2003).
1 .8 .4 Knock out models of 6-cell IRS2 downstream signalling elements
1.8.4.1 Pl3 kinase
Class la PI3 kinases transduce the downstream effects of IRS mediated IIS via 
production of PIP3, and are implicated in mediating the metabolic actions of 
insulin in insulin target tissues (Cantley, 2002). Paradoxically, global deletion 
of single regulatory subunit isoform genes of class la PI3 kinases causes 
increased insulin sensitivity in these knock out mice (Chen et al., 2004; 
Terauchi et al., 1999), and even restored insulin sensitivity in Insr and Irs1 KO
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mouse models of diabetes (Mauvais-Jarvis et al., 2000). Global deletion of the 
p110a or p1103 catalytic subunits resulted in embryonic lethality (E10.5 and at 
the blastocyst stage respectively) therefore no in vivo metabolic data could be 
gained from these mice (Bi et al., 2002; Bi et al., 1999). Mice heterozygous for 
a global kinase dead p110a knock in were found to have reduced growth, 
insulin resistance, hyperinsulinaemia and enhanced GSIS due to a functional 
compensatory B-cell mass (Foukas et al., 2006). The p1105 global KO has not 
been reported to have a metabolic phenotype. The in vivo role of class la PI3 
kinase catalytic activity in the B-cell has not been reported, however in vitro  
studies have demonstrated that PI 3 kinase activity promotes B-cell survival by 
inhibiting apoptosis (Srinivasan et al., 2002). PI3 kinases have also been 
implicated in the regulation of B-cell insulin secretion (Hagiwara et al., 1995). 
Clarification of these processes by B-cell specific knock out studies will be 
essential to understand the role of class la PI3 kinases in the B-cell, and 
together with the Insr, I$f1r and Irs knock out models will be an important 
extension of our understanding of insulin action in the B-cell.
Global deletion of the G-protein activated p110y catalytic subunit (class lb PI3 
kinase) showed, as well as a complicated immunological phenotype, impaired 
insulin secretion (in vivo and in vitro), increased insulin sensitivity and 
increased B-cell mass resulting in near normal glucose homeostasis (MacDonald 
et al., 2004). This suggests p110y is required to sustain normal insulin secretion 
in the B-cell, but is not required for expansion of B-cell mass.
1.8.4.2 PDK1 B-cell KO
PDK1 is a serine/threonine kinase that is recruited to the plasma membrane by 
PIP3 and activates AKT (Alessi et al., 1997), therefore forming the next kinase 
node in the PI3 kinase arm downstream of the INSR, IGF1R and IRS proteins. B- 
cell deletion of Pdk1 results in severe progressive hyperglycaemia and 
hypoinsulinaemia, due to a severe loss of B-cell mass and pancreatic insulin 
content (Hashimoto et al., 2006). This indicates a critical role for PDK1 in
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sustaining 6-cell mass and glucose homeostasis. Interestingly, global 
haploinsufficiency for FoxOI partly recovered B-cell mass, insulin content and 
glucose homeostasis, suggesting that part of the 6-cell proliferative defect in 
the B-cell Pdk1 KO is due to impaired nuclear exclusion of the transcription 
factor F0X01 by IIS.
1.8.4.3 AKT global knock outs
Activation of AKT by IIS, via the PI3 kinase pathway and PDK1, represents a 
divergent node in the pathway controlling many processes in concert with other 
growth factors/signalling pathways. There are 3 Akt genes in mice, global 
deletion of Akt1 causes impaired growth and reduced lifespan but no metabolic 
phenotype (Cho et al., 2001b) and Akt3 deletion impairs neural development 
but again with no metabolic phenotype (Tschopp et al., 2005). Global deletion 
of Akt2 however causes insulin resistance, particularly in muscle and liver, with 
impaired glucose tolerance (Cho et al., 2001a). These Akt2 null mice showed 6- 
cell hyperplasia and compensatory hyperinsulinaemia suggesting that AKT2 
mediates insulin action in peripheral insulin target tissues rather than 
mediating IIS action in the 6-cell.
1.8.5 lnsulin/IGF1 controlled B-cell gene transcription
One of the downstream effects of IIS is to modulate gene transcription. Insulin 
secreted from the 6-cell maintains expression of the insulin gene in the B-cell 
by autocrine feedback via the INSR (Leibiger et al., 1998). This autocrine 
feedback has been suggested to act specifically via the INSR-A (splice variant 
without Insr gene exon 11), class la PI3 kinases, and p70S6 kinase pathways 
(Leibiger et al., 2001).
In the B-cell it has been demonstrated that IRS2 mediated IIS promotes 
phosphorylation of the forkhead transcription factor FOX01 via AKT. This 
results in nuclear exclusion of FOX01, relieving its inhibition of the Pdx1 gene
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promoter (Kitamura et al., 2002). PDX1 is a transcription factor that maintains 
B-cell identity post development by maintaining expression of the insulin and 
Giut2 genes, and inhibition of glucagon expression (Ahlgren et al., 1998). Pdx1 
is down regulated in the B-cells of Irs2 knockout mice, and Pdx1 overexpression 
(Kushner et al., 2002), Irs2 overexpression (Hennige et al., 2003) or FoxOI 
haploinsufficiency (Kitamura et al., 2002) restores B-cell PDX1 levels and 
reverses the diabetes in these Irs2 null animals. This suggests that B-cell PDX1 
expression is a critical target of IRS2 mediated IIS in maintaining B-cell mass 
and function.
During times of hyperglycaemia, glucose toxicity causes oxidative stress to the 
B-cell, and FOX01 is stabilised by acetylation, overriding insulin stimulated 
FOX01 phosphorylation. Stable FOX01 initiates the transcription of the 
transcription factors MafA and NeuroD: MAFA sustains Glut2 expression, 
NEUROD inhibits mitosis limiting cellular damage and apoptosis, and both act to 
sustain insulin gene transcription (Kitamura et al., 2005).
1.8.6 Relation of mouse IIS gene knock out studies to humans
The studies mutating the Irs2, Insr and /g/7r genes in mice, have contributed to 
the unifying molecular theory linking insulin resistance in peripheral insulin 
target tissues and B-cell failure. Expression of key IIS signalling elements in 
human B-cells including the Insr (isoforms a and b; without and with exon 11 
respectively), Irs1, Irs2, p110a/B, PI3 Kinase class 2a, Pdk1 and Akt 1/2/3 has 
been demonstrated (Muller et al., 2006). However, it is apparent that 
monogenic mutations of these key genes do not explain the prevalence of 
human T2DM or individual susceptibility, although it is possible that 
combinations of mutations in the IIS pathway contribute to the pathogenesis of 
the disease (Kahn, 2003). It has been shown that a familial mutation identified 
in the human Akt2 gene kinase domain has been linked to severe insulin 
resistance and diabetes in humans (George et al., 2004), although this is rare
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and therefore only explains a small proportion of T2DM cases. Interestingly, it 
has recently been shown that islets isolated from human T2DM patients show 
significantly reduced mRNA levels of the Insr, Irs2 and Akt2 genes (23%, 9% and 
16% of controls respectively) representing a significant downregulation of the 
gene expression of these three “critical nodes” in the IIS pathway (Gunton et 
al., 2005). Although the mechanism is not clear, it may involve direct or 
indirect regulation of 6-cell transcription factors. It has also been shown in 
mice that hyperinsulinaemia can cause downregulation of Irs1 and Irs2 in liver 
cells (Hirashima et al., 2003). Although an obvious trend for genetic mutations 
of the IIS pathway may not exist, the Gunton study shows that expression levels 
of key IIS genes are suppressed in human T2DM islets.
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1.9 Oxygen homeostasis
B-cells are dependent on an adequate supply of oxygen not only to generate 
ATP to trigger insulin secretion in response to glucose, but also to maintain 
core cellular processes such as gene transcription, protein translation, active 
transport and proliferation. B-cells also respond to a variety of growth factors, 
and require the correct balance of these factors to regulate proliferation, 
differentiation and survival to maintain a functional B-cell mass adequate for 
the prevailing insulin resistance. As B-cells require an efficient vascular supply 
of oxygen to sustain normal function (Carlsson et al., 1998), and as hypoxia 
causes impaired GSIS (Ohta et al., 1990) and apoptotic cell death in islets 
(Moritz et al., 2002), B-cell oxygen sensing mechanisms may integrate with 
growth factor signalling pathways to control growth and function of the B-cell 
population.
1.9.1 The molecular control of cellular oxygen homeostasis
Cells within metazoan organisms require an appropriate supply of oxygen to 
maintain ATP production and perform cellular functions. Deviation from a 
partial pressure of oxygen to which a cell or tissue is adapted can be 
detrimental and therefore cellular response mechanisms are initiated which act 
to enrich the supply of oxygen to the cell, promote anaerobic ATP production 
and prevent cellular damage. One key hypoxia response mechanism is the 
transcription factor hypoxia inducible factor (HIF). In normoxic cells (cells with 
a normal oxygen tension) the transcription factor HIF is inactivated by the von 
Hippel-Lindau gene product (VHL) in an oxygen dependent manner. During 
hypoxia HIF is active and initiates the transcription of hypoxia response genes 
involved in erythropoiesis, angiogenesis, glycolysis and metabolism. These 
transcriptional changes act to enrich the cellular/tissue oxygen supply and 
temporarily adapt the cell for anaerobic respiration and hypoxia (Kaelin, 
2005a; Wenger, 2002) as simplified in Fig. 1.7. Genetic mutation and
53
inactivation of the Vhl gene and protein can lead to constitutive activation of 
HIF, and it was this HIF activity in Vhl null renal carcinoma cell lines that led to 
the discovery that VHL regulates HIF in an oxygen dependent manner (Maxwell 
et al., 1999).
Hypoxia Vhl genetic mutation
\  /
f  Hypoxia Inducible Factor (HIF) activity
Oxygen delivery Glucose utilisation Adaptation to Hvpoxia
• V e g f 1 
• Pdgf i
•Erythropoeitin2 
•Endothelin3 
•Inos 3
• G lu tl4
•Hexokinases1/25 
•AldolaseA6 
•Gapdh6  
•Lactate
dehydrogenase 6
• CalX7 
• Igf28 
•lgfbp1-38 
•Reddl9
Figure 1.7: Schematic diagram o f simplified HIF activ ity. HIF is activated by 
a VHL inactivating genetic mutation or hypoxia and initiates transcription of 
hypoxia response genes. A selection of important HIF target genes are shown, 
involved in: Angiogenesis1, erythropoiesis2, vascular tone3, glucose uptake4*, 
glucose phosphorylation5, glycolysisf, pH regulation7, cell viability/survival8 
and energy conservation9. Full gene names can be found in the glossary.
1.9.2 The VHL/HIF system as an oxygen sensitive mechanism
The transcription factor HIF was discovered due to its hypoxia inducible binding 
to the 3’-hypoxia response element (HRE) of the erythropoietin gene, in a 
hepatoma cell line (Semenza and Wang, 1992). Subsequently, active HIF was 
shown to be a basic helix-loop-helix-PAS (Per Arnt Sim) family heterodimer
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which consists of two subunits; a labile oxygen sensitive HIFa subunit, and a 
constitutively stable HIFB subunit previously described and known 
synonymously as the aryl hydrocarbon (nuclear) receptor nuclear translocator 
(ARNT) (Wang et al., 1995). There are three known HIFa subunits (HIF1a, HIF2a 
and HIF3a) of which Hifla is thought to be constitutively expressed, and three 
HIFB subunits (HIF1B, HIF2B and HIF3B) as shown in Fig. 1.8; heterodimerisation 
is possible between any a-subunit and any B-subunit (Semenza, 1999).
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Figure 1.8: Structure o f the HIFa and HIFB binding partners. Domains shown 
are: basic helix-loop-helix (bHLH), Per-Arnt-Sim (PAS), amino-terminal 
transactivation domain (NTAD) and carboxyl terminal transactivation domain 
(CTAD). Hydroxylation o f HIFa CTAD asparagine (N) residues inhibits HIF 
activity. The NTAD is referred to as the oxygen degradation domain (ODD) 
reflecting that this is the site fo r VHL recognition of proline (P) hydroxylated 
HIFa, and therefore signals its destruction. Diagram from Kaelin 05.
During normoxia, cytoplasmic HIFa is hydroxylated on two proline residues (Pro 
402 and Pro 564) by prolyl hydroxylases (Ivan et al., 2001; Jaakkola et al.,
2001), subsequently characterised and named PHD1, PHD2 and PHD3 (Bruick 
and McKnight, 2001; Epstein et al., 2001). HIFa hydroxylation facilitates 
binding of VHL and its associated ubiquitin ligase complex, which 
polyubiquitylates the HIFa earmarking it for proteasomal degradation and 
therefore inactivation (Maxwell et al., 1999). The PHD enzymes are the oxygen 
sensors, utilising available cellular molecular oxygen to hydroxylate HIFa.
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Therefore during hypoxia, oxygen insufficiency results in reduced HIFa 
hydroxylation, reduced binding of VHL and reduced proteasomal destruction of 
HIFa. The stabilised HIFa translocates to the nucleus, via the endoplasmic 
reticulum, where it is able to bind with HIFB and form a transcriptionally active 
HIF heterodimer (Kaelin, 2005a), as shown in Fig. 1.9.
HIF activity in normoxic cells is also regulated by hydroxylation of asparagine 
residues in the HIFa carboxyl terminal transactivation domain (CTAD) by factor 
inhibiting HIF (FIH) using molecular oxygen. This prevents binding of the 
p300/CBP coactivator, and therefore reduces the transcriptional potency of the 
HIF heterodimer in the nucleus (Lando et al., 2002a; Lando et al., 2002b), as 
shown in Fig. 1.9.
The hydroxylation of HIFa by either FIH or PHD requires the presence of iron 
ions (Fe2*) and the TCA cycle product 2-oxoglutarate. The FIH and PHD prolyl 
hydroxylases possess a single iron atom core. Disruption of this iron atom, by 
iron chelators or cobalt ion substitution, inactivates the hydroxylase and 
stabilises HIFa, providing a potential mechanism for pharmacological activation 
of HIF (Jaakkola et al., 2001; Maxwell, 2004).
1.9.3 von Hippel-Lindau disease
The von Hippel-Lindau (VHL) disease is a rare two hit cancer syndrome 
originally described independently by von Hippel (1904) and Lindau (1927). It is 
usually characterised by highly vascularised tumours including retinal angioma, 
cerebellar haemangioblastoma and clear cell renal cell carcinoma (RCC) (Kaelin 
and Maher, 1998). Also common amongst VHL patients are non-secreting 
endocrine tumours of the adrenal gland (phaeochromocytoma) and pancreatic 
islet cells (Woodward and Maher, 2006). Tumourigenesis is thought to occur by 
inactivation of the Vhl tumour suppressor gene by the classic Knudsen’s two hit 
mutation hypothesis: one Vhl allele is inherited in the germ line already
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inactivated by genetic mutation; in cells in which the second allele undergoes a 
somatic mutation or inactivation (second hit), the lack of functioning VHL 
allows tumour formation to take place (Kaelin and Maher, 1998). The molecular 
link between HIF activation in Vhl null RCC cell lines, and the discovery that 
VHL mediates oxygen sensitive destruction of HIFa (Maxwell et al., 1999), 
explained the transcriptional changes driving angiogenesis in VHL tumour 
development and the vascular nature of these tumours originally observed by 
von Hippel and Lindau.
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Figure 1.9: Diagram showing oxygen dependent regulation o f HIFa. PHD
hydroxylation of HIFa NTAD proline residues (P) allows VHL to bind and 
polyubiquitylate HIFa, earmarking i t  fo r proteasomal destruction and 
therefore inactivation. FIH hydroxylation of HIFa CTAD asparagine residues 
(N) prevents the binding of the coactivator p300/CBP, reducing the potency of 
HIF as a transcription factor. Diagram taken from Kaelin 05.
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1.9.4 VHL regulated HIF transcriptional target genes
HIF1a is thought to be a constitutively expressed transcription factor and HIF 
potentially has the ability to modulate gene transcription in all cells. The 
number of established HIF target genes and their tissue specific activation is 
still growing. Over 200 putative HIF target genes have been identified by the 
presence of the HRE, and expression level sensitivity to hypoxia in microarray 
experiments (Wenger et al., 2005). Dozens of these have been validated as HIF 
target genes by HIF binding to the HRE upstream of the gene, in DNA binding 
assays, or by HIF activation of the gene promoter when cloned to a reporter 
gene (Wenger et al., 2005). Microarray analysis of Vhl null versus Vhl wild-type 
transformed RCC cell lines, exposed to normoxia (20 % Oi) or hypoxia (0.1 % O2 ) 
revealed genes regulated by VHL and their oxygen sensitivity in Vhl wild-type 
cells (Wykoff et al., 2000). The majority of VHL regulated genes were also 
oxygen sensitive in Vhl wild-type cells, confirming the accepted VHL/HIF 
mechanism, although this study also highlighted a minority of genes that were 
regulated by VHL but not oxygen sensitive, thereby suggesting regulatory roles 
for VHL aside from its main role in oxygen sensitive gene inactivation.
1.9.5 HIF, cellular energy homeostasis and growth
Protein synthesis, cell growth and proliferation are tightly controlled by the 
metabolic status of the cell. Insulin signals a metabolic status of increased 
circulating nutrients, and therefore an excess of potential energy, via receptor 
tyrosine kinase signalling cascades as described previously in the IIS sections of 
this chapter. This signal activates AKT which phosphorylates the tuberous 
sclerosis complex proteins (TSC1 and TSC2) relieving the TSC2 GAP (GTPase 
activating protein) inhibitory effect of the small G-protein Rheb, which is thus 
permitted to activate mTOR, the mammalian target of rapamycin (Harris and 
Lawrence, 2003). mTOR is a serine/threonine kinase that acts as a convergent 
point for signals of cellular energy status which, when activated, initiates 
protein translation and permits cell cycle progression via phosphorylation of 4E-
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BP1 (elF-4E binding protein 1) and p70S6 kinase (Fingar et al., 2004). Once 
activated, mTOR phosphorylates 4E-BP1 relieving its inhibition of elF-4E 
(eukaryotic initiation factor 4E), allowing formation of a functional elF-4F 
complex which binds to the 5’-end CAP mRNA sequence, facilitating 
recruitment of 40S and 60S ribosomal subunits to commence mRNA translation 
(Gingras et al., 2001). Activated mTOR phosphorylates and thereby activates 
p70S6 kinase, which in turn phosphorylates the S6 component of the 40S 
ribosomal subunit, allowing translation to progress (Fingar et al., 2004).
During times of low cellular energy or hypoxia, mTOR activity is inhibited. Low 
cellular energy is manifested as an increase in AMP which in concert with LKB1 
(serine/threonine protein kinase 11) activates AMP kinase (AMP activated 
protein kinase), which in turn phosphorylates TSC2, enhancing its inhibition of 
mTOR and preventing protein synthesis and cell proliferation (Carling, 2004). 
Hypoxic inhibition of mTOR occurs independently from AMP kinase, and 
requires the induction of the HIF target gene product REDD1 which acts via the 
TSC1/TSC2 complex (Brugarolas et al., 2004). REDD1/RTP801 {RTP801L in the 
mouse) plays a key role in hypoxic cell survival and has been linked to 
regulating apoptotic cell death, both positively and negatively depending on 
the experimental cell type (Shoshani et al., 2002).
Therefore, HIF has been shown to regulate protein synthesis, cell growth, 
proliferation and apoptosis via the same intracellular signalling nodes as growth 
factors and the energy sensor AMP kinase. The net effect of multiple pathways 
regulating cell growth and function is hard to predict, and the balance and 
hierarchy of these factors is likely to be dependent on the cell/tissue context 
being studied. In the B-cell proliferation and apoptosis are regulated by many 
different growth factors, and as the interaction between HIF activity and the B- 
cell has not been studied, this may provide new insights into mechanisms 
governing B-cell mass and function.
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1.9.6 Hypoxia independent regulation of HIF
It has been demonstrated in certain experimental cell types that growth 
factor/hormone signalling pathways can stabilise HIFa during normoxia by 
enhanced translation of the HIFa protein, thereby transiently saturating the 
degradation machinery (Wenger et al., 2005). These growth factors include 
insulin, IGF1, IGF2, FGF2, EGF and HGF (Feldser et al., 1999; Wenger et al., 
2005), all of which have been demonstrated to influence 8-cell mass and are 
expressed in the pancreas; as described earlier in this chapter. A role for HIF in 
a positive feedback mechanism upregulating growth factor signalling and 
cellular metabolism has been suggested, as insulin, IGF1 or IGF2 stimulation of 
mouse embryonic fibroblasts caused stabilisation of HIF1a and subsequent 
transcription of IGF2 and IGF binding proteins 2 and 3 (Feldser et al., 1999). 
IGF binding proteins stabilise circulating IGF and regulate interactions between 
IGF and the IGFR.
Growth factor signals mediated by PI3 kinase and/or MAP kinase pathways 
stimulate protein synthesis and mitosis, both oxygen consuming cellular 
processes, therefore HIF activation is thought to represent a pre-emptive 
mechanism to buffer the subsequent drop in oxygen tension. Interestingly, 
insulin and IGF1 have been shown to induce VEGF expression by upregulating 
HIF1a protein translation in transformed hepatocytes (Zelzer et al., 1998) and 
retinal epithelial cells (Treins et al., 2005; Treins et al., 2002), a mechanism 
suggested to be involved in diabetic retinopathy. HIF1a accumulation in 
multiple transformed cancer cell lines has been shown to be dependent on an 
activated PI3 kinase pathway, suggesting that this mechanism plays a role in 
tumorigenesis (Jiang et al., 2001).
Further evidence demonstrating integration of growth factor signalling and HIF 
activation has come from the study of heat shock proteins (HSP). It has been 
shown that PI3 kinase and AKT activation is required for the expression of
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Hsp70 and Hsp90 to sustain HIF1a levels in a Vhl null RCC cell line (Zhou et al.,
2004). This study also showed that PI3 kinase inhibition in transformed human 
embryonic kidney cells reduces hypoxia induced HIF1a stabilisation (Zhou et 
al., 2004).
Regulation of HIFa stability has also been linked to cellular signalling involving 
reactive oxygen species (ROS) generated by mitochondria, potentially in 
response to hypoxia, inhibiting PHD hydroxylation of HIFa (Kaelin, 2005b). 
Nitric oxide can alter HIFa stability and accumulation, and is also produced by 
the HIF targets iNOS and eNOS indicating a potential feedback loop (Kaelin, 
2005a).
The examples above illustrate the complexity and interconnected nature of 
classically distinct cellular signalling pathways in regulating cellular function, 
energy turnover and use.
1.10 H IF and islets
Considering the effect of HIF on modulating proliferation and apoptosis in other 
tissues, it is likely that it may play a role in the regulation of B-cell mass. 
Reports of HIF and islet function are limited, involving either studies of islet 
transplantation, studies of T2DM humans and a single mouse model; as 
discussed below.
1.10.1 Islet transplantation and HIF1a stabilisation/HIF activation
Apoptosis in hypoxic human islets following transplant to T1DM patients has 
been demonstrated to correlate with increased levels of HIF1a (Moritz et al.,
2002), and although this link is only correlative, it suggests that pancreatic 
islets utilise the HIF pathway to attempt to increase their supply of oxygen 
following transplant. Therefore treatment of islets prior to transplant to pre­
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emptively stabilise HIF1a, by pharmacological inhibition of PHD, hypoxic 
preconditioning, or B-cell specific inactivation of VHL, may promote faster 
revascularisation of the islets after transplant. This may minimise hypoxic 
damage and potentially limit apoptotic cell death. Another study has used 
histological techniques to monitor survival, anatomy and basic signalling in 
mouse islets transplanted to the sub-renal capsule region of streptozotocin 
treated diabetic mice (Miao et al., 2006). This study showed strong HIF1a 
stabilisation for 3 days following transplant, which correlated with increased B- 
cell apoptosis and reduced glucose tolerance compared to hyperbaric oxygen 
treated (HIF1 a inactivated) controls, suggesting loss of islet B-cells. By the 7th 
post transplant day however, HIF1a protein levels had decreased, and an 
increase in NGF, PDX1 and VEGF protein production was associated with 
increased islet remodelling and revascularisation (Miao et al., 2006).
1.10.2 HIF and diabetes
A study of a Japanese cohort of control and T2DM patients has revealed a single 
nucleotide polymorphism (SNP) mutation at the codon for proline 582 (P582, 
exon 12) of the H ifla  gene (Yamada et al., 2005). This P582 SNP has been 
previously identified in prostate cancer cells and linked to increased stability 
and activity of H ifla  during normoxia (Fu et al., 2005). This mutation was 
significantly negatively associated with T2DM patients versus non-diabetic 
controls, implicating increased HIF1a/HIF activity as being protective of T2DM 
(Yamada et al., 2005). However, the increased activity of mutant HIF1a was 
very subtle in human embryonic kidney cells, and only significantly greater 
than wild type HIF1a in response to hypoxia (Yamada et al., 2005).
Another study that used microarray gene expression profiling of human islets 
isolated from T2DM patients, revealed a 90% decrease in the HIFB mRNA levels 
from the T2DM islets when compared to control islets from non-diabetic human 
donors (Gunton et al., 2005). Gunton and colleagues went further: they showed
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that reducing HifB expression in a mouse insulinoma B-cell line (Min6) caused 
impaired GSIS, and an alteration in gene expression similar to that seen in 
T2DM islets, including down regulation of the IIS pathway nodes /nsr, Irs2 and 
Akt2. When HifB was deleted in mouse B-cells (and hypothalamus) it resulted in 
glucose intolerance, impaired GSIS and reduced islet Insr and Akt2 expression 
(Gunton et al., 2005).
Clearly the HIF pathway plays a role in correct GSIS and glucose homeostasis, 
and these studies suggest that upregulation/activation of the HIF pathway may 
enhance GSIS and be protective of T2DM.
1.11 Vhl knock out mouse models o f HIF ac tiva tion
Mouse global and conditional knock out models of Vhl deletion and subsequent 
HIF activation have been generated, revealing various phenotypes associated 
with VHL disease generally consisting of altered proliferation or apoptosis, and 
vascular abnormalities.
1.11.1 Global Vhl knock out models
Global Vhl homozygote null mice (Vhl''')  are embryonically lethal, with 
apparently normal development up to E9.5, at which stage placental 
hemorrhagic lesions cause death (Gnarra et al., 1997). Global Vhl KO 
heterozygote mice (V hl/+) show different phenotypes depending on the genetic 
background on which they are bred. On a mixed C57BL6/Sv129 background no 
phenotype is apparent (Gnarra et al., 1997), whereas when bred on a BALB/C 
background the majority of mice develop vascular abnormalities including liver 
hemangiomas (Haase et al., 2001). This may be due to different modification of 
gene transcription between these two genetic backgrounds, whereby if the 
remaining copy of Vhl becomes silenced, mutated or inactivated (second hit), 
HIFa will be stabilised and the vascular liver tumours may develop. Although it
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is possible that these phenotypic differences are due to the different methods 
used to independently generate these models.
A global mosaic knock out of Vhl, generated using conditional gene targeting 
with the floxed Vhl gene deleted using a B-actin promoter driven cre- 
transgene, revealed hepatic hemangiomas similar to those reported by Haase 
and colleagues, as well as vascular abnormalities is many organs (Ma et al., 
2003). Interestingly the pancreas showed an increased density of blood vessels 
with angiectasis present.
1.11.2 Tissue specific Vhl knock out models
There have been many conditional knock out models of Vhl generated, but here 
two pertinent studies are described that have demonstrated that the Vhl knock 
out phenotype is due to HIF activation.
Floxed Vhl deletion driven by ere expressed under the control of the 
lymphocyte protein tyrosine kinase promoter (expressed in the thymus), caused 
increased apoptosis of thymocytes (Biju et al., 2004). These authors clarified 
that this phenotype was due to HIF1a stabilisation as deletion of H ifla  reversed 
the thymocyte defects. Another study which described the deletion of floxed 
Vhl using a ere transgene under the control of the albumin promoter (expressed 
in hepatocytes) reported severe hepatic steatosis and the typical vascular 
abnormalities including cavernous hemangiomas (Haase et al., 2001). Deletion 
of H ifla  in this liver model did not alter the severity of the liver dysfunction, 
where as deletion of HifIB completely reversed the phenotype (Rankin et al.,
2005), suggesting that in the liver HIF1a stabilisation is not responsible for the 
Vhl disease-like phenotype, but as the phenotype is HIF mediated, HIF2a may 
be stable and active.
These studies of Vhl conditional gene targeting indicate that the defects
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induced by Vhl deletion (apoptosis in thymocytes, hemangiomas in the liver) 
are due to HIF activation, although the HIFa subunit stabilised may vary 
between cell types.
1.12 Summary and aims o f investigation
1.12.1 Summary of B-cell IRS2 literature
It is clear from the IIS literature published on the pancreatic B-cell, that IIS is 
essential for maintaining a functional B-cell mass of sufficient quality and 
quantity, relative to the given insulin resistance, to secrete insulin 
appropriately and control blood glucose levels. Disruption of components of the 
IIS pathway has revealed contrasting roles for apparently similar signalling 
molecules. The B-cell specific role of many of the commonly studied insulin 
signalling components has yet to be thoroughly examined with the use of 
knock-out and transgenic mice, and given the complexity of the insulin 
signalling network in pancreatic B-cells, the role of many previously studied 
genes needs clarification. One such gene is /rs2, which has been shown from 
global (Withers et al., 1998) and B-cell/hypothalamic (Choudhury et al., 2005; 
Kubota et al., 2004; Lin et al., 2004) knock out studies to have a non-redundant 
and critical role in maintaining a functional B-cell mass. However, these studies 
observed Irs2 null B-cell function in the presence of abnormal peripheral insulin 
resistance, which clearly augments any B-cell defect present and does not test 
the regulation of an Irs2 null B-cell mass in the absence of peripheral insulin 
resistance. Also there is only a small amount of data published on the effect of 
Irs2 deletion on glucose stimulated insulin secretion (Kubota et al., 2004; 
Kubota et al., 2000).
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1.12.2 Aims of investigation into pancreatic/B-cell IRS2 function
Based on the previous studies of IRS2 function in the B-cell, I propose the 
following hypothesis:
Pancreatic Irs2 is essential for maintaining a metabolically adequate B-cell 
mass and therefore correct glucose homeostasis.
To test this hypothesis, I will clarify the role of IRS2 in pancreatic 
development, in the maintenance of a normal B-cell mass, and investigate its 
role in B-cell insulin secretion. To achieve this, Irs2 will be deleted specifically 
in the pancreas using the cre-loxP system to generate P/rs2KO mice. To 
specifically delete Irs2 in the pancreas, a transgenic mouse will be used with 
cre-recombinase expression driven by the Pdx1 promotor (PDXcre), with 
expected expression in all pancreatic exocrine and endocrine cell types. The 
generation and study of these mice will further establish the role of IRS2 
mediated IIS signalling in the pancreas and B-cell without the complication of 
peripheral insulin resistance.
The following experimental aims will be addressed:
• Generation of a pancreas specific Irs2 KO; the P/rs2KO mouse
o Analysis of gene knock out efficacy and tissue specificity.
• Metabolic characterisation of P/rs2KO mice
o Body mass, food intake and insulin sensitivity to test for a CNS or 
other insulin resistant phenotype, 
o Glucose homeostasis, 
o Insulin secretion in vivo.
• Composition of the P/rs2KO mouse endocrine pancreas
o Pancreatic hormone content.
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o Islet structure, 
o B-cell and a-cell mass.
• Investigation of P/rs2K0 B-cell function
o Insulin secretion in vitro  
o Stimulus secretion coupling: Ca2+ flux 
o Transcription profile of key B-cell genes.
1.12.3 Summary and aims of investigation into B-cell VHL/HIF function
The literature documenting HIFa activation in islets is limited to subjective 
reports of HIF1a stabilisation and apoptosis in transplanted islets (Miao et al., 
2006; Moritz et al., 2002), and these studies do not analyse HIFa function. 
Studies of HifB deletion in B-cells (Gunton et al., 2005) suggest that activation
of HIF may enhance B-cell GSIS. Therefore I tentatively propose the following
hypotheses to be tested:
• B-cell Vhl deletion will cause HIF1a stabilisation and HIF activation.
• B-cell HIF activation will cause reduced B-cell mass.
• B-cell HIF activation will enhance GSIS.
Therefore to test these hypotheses and investigate the effects of activating the 
HIF hypoxia response pathway in normoxic B-cells, mouse models of B-cell and 
pancreatic Vhl deletion will be generated. Vhl deletion is predicted to prevent 
HIF1a degradation despite normal islet oxygen tension, and therefore stabilise 
and activate HIF1a, mimicking hypoxia. To achieve B-cell Vhl deletion the Vhl 
flox mouse will be bred seperately with the rat insulin 2 promotor ere mouse 
(RIPcre) and PDXcre mouse. This is predicted to result in B-cell/hypothalamic 
Vhl deletion (BVb/KO) and pancreatic Vhl deletion (PV7?/KO).
The following experimental aims will be addressed:
• Generation of B-cell and pancreatic Vhl knock out mice
67
o Confirmation of B-cell HIF1a activation 
Characterisation of in vivo metabolic phenotype
o Body mass, glucose homeostasis and insulin sensitivity. 
Analysis of pancreatic B-cell mass 
Assessment of islet/B-cell function in vitro 
o  Isolated islet insulin secretion 
Analysis of expression of key B-cell genes.
Chapter 2: Materials and methods
2 .1 Animals
All animal procedures were approved by the British Home Office Animals 
Scientific Procedures Act 1986 (Project License no. 70/5179). Animals were 
maintained under a controlled environment with temperature 21-23 °C, 12 hour 
light-dark cycle (lights on at 07:00), with ad libitum  access to food (RM1 diet 
SDS UK Ltd) and water. 12 week old male mice were used for all studies unless 
otherwise indicated. During all studies mice had free access to water.
2.1.1 Animal Sources
The PDXcre (PDX1Pr-cre: pancreatic duodenal homeobox 1 promotor driven cre- 
recombinase) transgenic mice were generated by and obtained from Pedro 
Herrera of the University of Geneva (Herrera, 2000). The RIPcre (Rat Insulin 2 
promotor driven cre-recombinase) transgenic mice (Postic et al., 1999) and Vhl 
floxed mice (Haase et al., 2001) were obtained from the Jackson laboratory 
(www.jax.org). The Irs2 floxed  mice were generated within the laboratory of 
Professor D.Withers (Choudhury et al., 2005). All mice were maintained on a 
mixed C57BL6/Sv129 genetic background. Cre transgenic mice and floxed mice 
were interbred to generate mice heterozygous for cre and floxed genotypes 
(cre+ floxed+/ ); these mice were then intercrossed to generate KO (cre* 
floxed*'*) and control mice (cre* flo xe d 1', c re 1' floxed*1*, c re 1' f l o x e d c r e ' 1' 
floxed ''). All genetic combinations of offspring were generated at the 
expected Mendelian frequency.
• PDXcre* Irs2 flo x e d '* = Plrs2KO (Pancreatic Irs2 knock out).
• RIPcre* Vhl f lo x e d '* = BVhlKO (B-cell and hypothalamic Vhl knock out).
• PDXcre* Vhl f lo x e d '* = PVhlKO (Pancreatic Vhl knock out).
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2.1.2 Reagent Sources
All chemicals were manufactured by BDH unless otherwise stated. All primers 
were synthesised by Eurogentec unless otherwise stated. All fluorescent dyes or 
fluorescent antibody dye conjugates were manufactured by Molecular probes 
(Invitrogen).
2.1.3 Genotyping of mice
Mice were tail tipped upon weaning (21 days of age) using ethyl chloride as 
local anaesthesia. DNA was extracted by placing the tail tip in 100 pi of 
digestion buffer, heating to 95 °C for 10 minutes then adding proteinase K to a 
final concentration of 1 mg/ml (5 pi of 20 mg/ml stock) and incubating 
overnight at 55 °C. Each sample was then heated to 95 °C for a further 10 
minutes to heat inactivate the proteinase K and samples spun at 12,000 RPM for 
5 minutes to sediment tail debris. To determine the genotype of the mouse 1 pi 
of supernatant was used per polymerase chain reaction (PCR) in a 96 well plate 
using a thermal cylcer (MJ Research) with lid heated to 105 °C. PCR products 
were resolved using 2 % agarose gel electrophoresis in TAE buffer (40 mmol/1 
Tris acetate pH 8.3, 1 mmol/l EDTA), and visualized by UV excited fluorescence 
of ethidium bromide stained DNA (1 in 50,000 dilution).
Tail digestion buffer
6.7 mmol/l Tris-HCl, pH 8.8, 1.66 mmol/l (NH4)2S04, 0.67 mmol/l MgCl2, 0.5 % 
Triton X-100 in water. 1 % B-mercaptoethanol was added prior to digestion.
2 .1.3.1 PDXcre transgenic mice
Presence of the PDXcre transgene was detected using a four primer reaction, 
with one pair amplifying a promoter specific 750 base pair (bp) sequence of the 
transgenic construct (Herrera, 2000), and the second pair amplifying a short 
sequence of the interleukin 2 (IL2) gene as a positive control
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PDXcre Primer sequences
PDXcre Forward (cre2): 5’ CGG TGA ACG TGC AAA ACA GG 3’
PDXcre Reverse (hGH1): 5’ AGG ACA CAT TGT GCC AAA GG 3’
IL2 Forward: 5’ TAG GCC ACA GAA TTG AAA GAT CT 3’
IL2 Reverse: 5’ GTA GGT GGA AAT TCT AGC ATC ATC C 3’
PDXcre PCR Reaction (18 y l)
1 )jl DNA template, 1.4 pmol/l PDXcre primers, 1.4 pmol/l IL2 primers, 16 pi 
Reddy mix taq (AB gene), 1.5 mmol/l MgC .^
PDXcre PCR Cycle
1. 94 °C, 2 minutes
2. 94 °C, 30 seconds
3. 55 °C, 30 seconds
4. 72 °C, 1 minute, cycle to step 2, 29 times.
5. 72 °C, 5 minutes
2.1.3.2 RIPcre transgenic mice
Presence of the RIPcre transgene was detected using a four primer reaction 
with one pair amplifying a promoter specific 550 bp sequence of the transgenic 
construct and the second pair (MIR) amplifying an internal positive control 
sequence.
RIPcre Primer sequences
RIPcre Forward (RIP3 ): 5' CTG TGG CCA TCT GCT GAT CC 3’
RIPcre Reverse (Cre 102): 5* CGC CGC ATA ACC AGT GAA AC 3'
MIR Forward (015): 5’ CAA ATG TTG CTT GTC TGG TG 3’
MIR Reverse (016): 5' GTC AGT CGA GTG CAC AGT TT 3'
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RIPcre PCR Reaction (13 y l)
1 pi DNA template, 5 pmol/l RIPcre primers, 1.9 pmol/l MIR primers, 10 pi 
Reddy mix taq (AB gene), 1.5 mmol/l MgCl2.
RIPcre PCR Cycle
1. 94 °C, 2 minutes
2. 94°C, 1 minute
3. 60 °C, 30 seconds
4. 72 °C, 30 seconds, cycle to step 2, 39 times.
5. 72 °C, 7 minutes
2.1.3.3 Irs2 floxed mice
Two primer PCR reactions were used to amplify across the integration site of 
the 3’ loxP site to determine if the mouse was wild type, heterozygous or 
homozygous for the presence of the targeting construct at this locus. If the 
locus is targeted with loxP sites a 250 bp band is amplified as opposed to the 
untargeted 200 bp wild type band.
Irs2 floxed Primer sequences
Forward (loxP-F): 5’ ACT TGA AGG AAG CCA CAG TCG 3’
Reverse (loxP-R): 5’ AGT CCA CTT TCC TGA CAA GC 3’
lrs2floxed PCR Reaction (12 yl)
1 pi DNA template, 4 pmol/l Irs2 floxed primers, 10 pi Reddy mix taq (AB 
gene), 1.5 mmol/l MgCl2.
Irs2 floxed PCR Cycle
1. 94 °C, 2 minutes
2. 94°C, 30 seconds
3. 65 °C, 30 seconds
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4. 72 °C, 1.5 minutes, cycle to step 2, 29 times.
5. 72 °C, 5 minutes
2.1.3.4 Vhl floxed mice
Two primer PCR reactions were used to amplify across the integration site of 
the targeting construct to determine if the mouse was wildtype, heterozygous 
or homozygous at this locus. If the locus is targeted, a 450 bp band is amplified 
as opposed to the untargeted 270 bp wild type band.
Vhl floxed Primer sequences
Forward (mVHL fw2): 5’ CTA GGC ACC GAG CTT AGA GGT TTG CG 3’
Reverse (mVHL rev): 5’ CTG ACT TCC ACT GAT GCT TGT CAC AG 3’
Vhl floxed PCR Reaction (25 y l)
2 pi DNA template, 2 pmol/l Vhl floxed primers, 0.5 units red taq (Sigma), 2 
mmol/l MgCb, 1x red taq buffer (Sigma).
Vhl floxed PCR Cycle
1. 94 °C, 2 minutes
2. 94 °C, 30 seconds
3. 62 °C, 1 minute
4. 72 °C, 1 minute, cycle to step 2, 34 times.
5. 72 °C, 5 minutes
2.1.4 Analysis of tissue specific gene deletion by PCR
100 mg of snap frozen tissue was incubated for 12 hours in 525 pi extraction 
buffer at 55 °C. The sample was briefly vortexed before adding 40 pi RNAse A 
(0.2 mg/ml) and incubating for 1 hour at 37 °C. 200 pi of 5 mol/l NaCl was 
added, and the sample mixed by shaking. 700 pi of chloroform-isoamyl alcohol
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(24:1 vol/vol) was added and tubes inverted several times to mix. The mixture 
was centrifuged for 10 minutes at 13,000 RPM and upper aqueous layer 
transferred to a new tube, mixed with 500 pi isopropanol and centrifuged again 
for 10 minutes. The resulting DNA pellet was washed once with 70 % ethanol, 
air dried and resuspended in 50 pi water overnight at 4 °C. 2 ng of DNA was
used as template for PCR amplification to detect recombination of the loxP
sites and therefore deletion of the floxed gene. Reactions were set up 
according to the floxed genotyping above.
Extraction buffer 
50 mmol/l Tris pH 8.0 
100 mmol/l EDTA 
100 mmol/l NaCl 
1 % SDS
0.65 mg/ml proteinase K.
Floxed Irs2 deletion primers
Forward: loxP-R 5’ AGT CCA CTT TCC TGA CAA GC 3’
Reverse: Del-F 5’ GGG AAC CTG ACA AGT GAA TG 3’
Floxed Vhl deletion primers
Forward: 5’ CAA ACT GCA TGC CTG GTA CCC AC 3’
Reverse: 5’ CTG ACT TCC ACT GAT GCT TGT CAC AG 3’
PCR Cycle
6. 95 °C, 3 minutes
7. 95°C, 1 minute
8. 52°C, 1 minute
9. 72 °C, 1 minute, cycle to step 2, 29 times.
10.72°C, 7 minutes
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2 .2  In vivo m etabolic  studies
2.2.1 Determination of fasting blood glucose levels and body mass
Mice were fasted for 15 hours overnight and blood glucose levels were 
determined via tail vein bleeds after local anaesthesia using a Glucometer Elite 
(Bayer). Mouse body mass was also measured following an overnight fast. 
BVhlKO mice were fasted for a shorter period (6-12 hours) due to the presence 
of fasting hypoglycaemia; this is reported in results chapter 6.
2.2.2 Glucose tolerance tests
Mice were fasted for 15 hours and fasting blood glucose measured as above. 
Mice were then injected with 2 g/kg D-glucose (in a 20 % solution) 
intraperitoneally (i.p.) and blood glucose measured at 15, 30, 60 and 120 
minutes after injection.
2.2.3 Insulin tolerance tests
Mice were studied during the middle of the light phase and had free access to 
food prior to study. Blood glucose was measured as above, and male mice were 
injected i.p. with 0.75 international units of recombinant human insulin per 
kilogram. Blood glucose was measured at 15, 30, 60 and 120 minutes after 
injection. If mice showed signs of hypoglycaemia an i.p. bolus of glucose was 
administered. Due to increased insulin sensitivity, BVhlKO mice were 
administered 50 % of the insulin dose used for other animals (0.37 units per kg).
2.2.4 In vivo glucose stimulated insulin secretion
Mice were fasted for 15 hours overnight before i.p. injection with 3 g/kg D- 
glucose (in a 20 % solution). Blood glucose measurements and blood samples 
were taken prior to injection and 2, 5 and 20 minutes after injection. 25 pi
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blood samples were obtained via tail vein bleeds into heparinised capillary 
tubes (Sarstedt). Tubes were kept on ice, and spun at 13,000 RPM at 4°C for 10 
minutes and plasma supernatant collected and stored at -80 °C. Insulin levels 
were determined from 10 pi plasma using a rat insulin ELISA (Linco) with mouse 
insulin standards.
2 .3  Is let isolation and p rim a ry  culture
2.3.1 Islet Isolation
Mice were killed by cervical dislocation and a laparotomy immediately 
performed. The duodenum/common bile duct junction was clamped and 
catheter inserted into the common bile duct above the pancreas but below the 
liver, to allow ductal perfusion of the pancreas with 2 ml of pancreatic 
digestion solution. The pancreas was then immediately removed and incubated 
in 2 ml pancreatic digestion solution at 37 °C for 18 mins, after which 20 ml ice 
cold quenching buffer was added and tube shaken to dissociate exocrine tissue 
from the islets. Digested tissue was spun down at 1000 RPM for 1 minute at 4°C 
in a 50 ml conical centrifuge tube, supernatant discarded, and pellet 
resuspended in 20 ml quenching buffer to wash islet/exocrine digest. This wash 
step was repeated, and the final pellet resuspended in 20 ml quenching buffer. 
Islets were hand picked from digested exocrine tissue in a 10 cm Petri dish 
using a 200 pi pipette. Picking was repeated with fresh quenching buffer until a 
suitably pure islet preparation was achieved. Islets were then frozen, lysed or 
cultured as described below.
Pancreatic digestion solution
Hanks’ balanced salt solution (HBSS; Gibco) + 0.25mg/ml Liberase Rl (Roche 
high purity collagenase)
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Quenching buffers
HBSS (Gibco) + 0.5% Bovine serum albumin (BSA; Sigma).
HBSS (Gibco) + 10% Fetal bovine serum (FBS; Gibco) + 100 units/ml penicillin + 
100 pg/ml streptomycin (Sigma) + 20 mmol/l Hepes (Sigma).
2.3.2 Islet picking for RNA extraction
Quenching buffer with 0.5 % BSA was used, with picking completed within 30 
mins at 4 °C. Islets were pelletted and RNA extracted immediately using an 
RNAeasy kit (Qiagen). RNA was stored at -80 °C in nuclease free water.
2.3.3 Islet picking for Protein extraction
Quenching buffer with 0.5 % BSA was used, with picking completed within 30 
mins at 4 °C. Islets were pelletted and washed twice with serum/BSA free 
HBSS. The final pellet was snap frozen and stored at -80 °C.
2.3.4 Islet picking for primary culture
Quenching buffer with 10% FBS was used. Islets were picked into overnight 
culture medium and incubated at 37 °C with 21 % 02, 5 % CO2 and high humidity 
for 20 hours before study.
Overnight culture medium
DMEM (Gibco 22320-022 Lot 3093341) containing 5.5 mmol/l D-glucose, L- 
Glutamine, 25 mmol/l HEPES, Pyruvate.
Supplemented with 10 % FBS (Gibco) and 100 units/ml penicillin, 100 pg/ml 
streptomycin (Sigma). If islets were to be used for insulin secretion 
experiments glucose was increased to 11 mmol/l.
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2.3.5 Dissociation of islets
Isolated islets were dissociated into clusters of single cells by incubation in 1X 
Trypsin-EDTA (Gibco) at 21 °C for 2.5 mins with gentle agitation. Cells were 
washed once with overnight culture media before being allowed to attach to 
Poly-L-Lysine (Sigma) treated 22 mm diameter coverglass (VWR). Cells were 
then cultured in overnight culture medium (as described above) for 48 hours 
prior to study.
2.3.6 In vitro  glucose stimulated insulin secretion: Perifusion
Islets were isolated and cultured overnight as described above in media 
containing 11 mmol/l glucose. 40 islets were loaded per chamber of the 
perifusion apparatus, and Gey and Gey buffer (Gey and Gey, 1936) passed over 
islets at 2 ml/minute. Islets were pre-perifused for 1 hour with 2 mmol/l 
glucose containing Gey and Gey buffer. A 50 minute protocol was used with 2 
mmol/l glucose for 10 mins, 20 mmol/l glucose for 20 mins, and 20 mmol/l 
glucose + 500 nmol/l phorbol myristate acetate (PMA) for 20 mins, with 
perifusate collected in 2 min/2 ml fractions. Insulin concentrations were 
determined by radioimmunoassay (Jones et al., 1988).
Gey and Gey buffer 
111 mmol/l NaCl 
27 mmol/l NaHC0 3  
4.96 mmol/l KCl
1.03 mmol/l MgCl2.6H20  
0.5 mmol/l NaHP0 4 .2 H2 0
0.28 mmol/l MgS04.7H20
0.22 mmol/l KH2PO4 
2 mmol/l D-glucose 
2 mmol/l CaCl2 
pH 7.4 with 5% C02
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2.3.7 In vitro glucose stimulated insulin secretion: Static incubation
Islets were isolated and cultured overnight as described above in media 
containing 11 mmol/l glucose. One hour prior to experiment islets were placed 
into secretion buffer with 2 mmol/l glucose. Islets were then pooled into 
groups of 8 which were in turn placed in 1.5 ml centrifuge tubes on ice, 
containing 150 pi secretion buffer (2 mmol/l glucose). After islet loading, open 
tubes were transferred to a 37 °C incubator with 21 % 02, 5 % C02 and high 
humidity and left for 30 mins. Tubes were pulse spun and 50 pi of the 2 mmol/l 
secretate removed and frozen. 50 pi of secretion media containing 29 mmol/l 
glucose was added to the islet tubes to give a final concentration of 11 mmol/l 
glucose. After another 30 mins of incubation, tubes were again pulse spun and 
50 pi of the 11 mmol/l secretate removed and stored at -80 °C with the 2 
mmol/l secretate. Neat and 1 in 2 diluted secretates were assayed for insulin 
content using a rat/mouse insulin ELISA with mouse standards (Linco).
Secretion buffer
HBSS (Gibco) + 20 mmol/l HEPES + 0.5 % BSA (Sigma) + 2 mmol/l D-glucose.
2 .4  Live B-cell imaging
Single B-cells were prepared by dissociating islets as described above, and 
cultured in overnight culture medium for 48 hours (37 °C with 21 % 0 2, 5 % C02 
and high humidity) before study. Buffer was changed to imaging buffer (2 
mmol/l glucose) for 1 hour prior to cell imaging. If a cell permeant dye was to 
be used, cells were loaded in 500 pi imaging buffer with 0.025 % pluronic 
detergent and the dye for 30 mins (37 °C with 21 % 02, 5 % C02 and high 
humidity). Media was changed to 500 pi fresh imaging buffer prior to study. 
Confocal imaging was performed using a Biorad TE300 inverted confocal 
microscope (for Plrs2KO Fluo3am calcium imaging) or Zeiss LSM 510 inverted
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confocal microscope (for BVhlKO and PVhlKO mitochondrial redox and 2-NBDG 
imaging), both using 40x oil immersion objective lenses, Zeiss control software 
and heated stages set to 37 °C. BVhlKO and PVhlKO Fura2am Ca2+ imaging was 
performed using a Nikon epifluorescence inverted microscope fitted with a 
computer controlled excitation band pass filter wheel alternating between 340 
nm and 380 nm every 10 seconds (shutter used to block excitation beam 
intermittently), with emitted light above 515 nm (long-pass filtered) collected 
by a fast cooled charge-coupled device (CCD) camera. Fura2am images were 
captured using Kinetic Imaging software (Kinetic Imaging/Andor) and heated 
stage set to 37 °C throughout experiments. B-cells were identified by their 
granulated appearance and post staining with dithizone (described below), 
after which regions of interest were drawn as appropriate. Microscope settings 
and dye loading concentrations for all live B-cell imaging are summarised in 
table 2.1. Dye loading and imaging was carried out according to manufacturers 
(Molecular Probes/1nvitrogen) guidelines.
2.4.1 Mitochondrial redox imaging
Redox states of the mitochondrial pyridine nucleotides NADH (Nicotinamide 
adenine dinucleotide), NADPH (Nicotinamide adenine dinucleotide phosphate; 
referred to here in as NADH) and flavoprotein FADH2 (Flavin adenine 
dinucleotide) were measured in response to glucose using live confocal 
imaging. This technique utilised the autofluorescent (NADH, FAD++) versus non- 
autofluorescent (NAD+, FADH2 ) forms of each hydrogen carrier (Duchen et al.,
2003). As the pool is increasingly reduced with the addition of hydrogen ions, 
NADH shows increased blue autofluorescence as it replaces the non-fluorescent 
NAD+, whilst FAD++ green autofluorescence decreases as it is replaced by the 
non-fluorescent FADH2 (table 2.1). The mitochondrial uncoupler FCCP was used 
in some experiments to drive the hydrogen carriers to their maximum oxidised 
states, NAD+ and FAD++, producing minimum and maximum autofluorescence for 
each carrier respectively (Duchen et al., 2003).
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2.4.2 Secretogogues
All secretogogues used during these experiments are listed in table 2.2 along 
with their site of action and optimal working concentration. Methyl succinate is 
a cell permeable B-cell secretogogue that stimulates mitochondrial complex II, 
bypassing glycolysis and triggering insulin secretion (MacDonald and Fahien, 
1988; Maechler et al., 1997). Once in the 6-cell methyl succinate is hydrolysed 
to succinate (MacDonald and Fahien, 1988), a product/intermediate of the TCA 
cycle, which is oxidised by succinate dehydrogenase (mitochondrial complex II) 
donating H+ and electrons to the electron transport chain, thereby driving the 
production of ATP (Michal, 1999).
Imaging Buffer
HBSS without phenol red (Gibco) + 20 mmol/l HEPES + 2 mmol/l D-glucose.
Fluorescent
substrate/dye:
Fluo3am
cell
permeant
Fura2am
cell
permeant
2-NBDG FAD++auto-
fluoresence
NADH auto- 
fluoresence
Fluorescent 
Indicator for:
Intracellular
free
calcium
Intracellular
free
calcium
Fluorescent
Glucose
analogue
Oxidised
FAD~
Reduced
NADH
Supplier: Molecular
probes
Molecular
probes
Molecular
probes
n/a n/a
Loading
concentration:
10 pg/ml 
30 mins
10 Mg/ml 
30 mins
18 nmol/l 
real time
n/a n/a
Microscope: Biorad
TE300
inverted
confocal
Nikon fluo­
rescence 
inverted 
with CCD 
camera.
Zeiss LSM 
510
inverted
confocal
Zeiss LSM 
510
inverted
confocal
Zeiss LSM 
510
inverted
confocal
Excitation
wavelength:
488 nm 
Argon laser
340/380 nm 
alternating
458 nm 
Argon laser
458 nm 
Argon laser
350 nm 
UV laser
Peak
emission:
526 nm 510 nm 520 nm 550 nm 450 nm
Filtered
emission:
>500 nm >515 nm >505 nm >505 nm 430-470 nm
Other: 0.025%
pluronic
during
loading.
0.025%
pluronic
during
loading.
0.25 mM
basal
glucose.
Laser power 
<20% to 
avoid cell 
damage.
Table 2.1: Fluorescent indicators used fo r live B-cell imaging.
Basal glucose was 2 mmol / l  fo r all experiments except 2-NBDG uptake 
which used 0.25 mmol/ l  glucose basal, n/a = not applicable. 2-NBDG = 2-[N- 
(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy-D-glucose.
Secretagogue Target Working Concentration
D-Glucose 8-cell GSIS 2-30 mmol/l
Methyl-succinate Mitochondrial complexll 10 mmol/l
FCCP Mitochondrial uncoupler 1 pmol/l
Tolbutamide
(sulfonylurea)
Sulfonylurea: closes KATP 
channel, depolarizes cell.
200 pmol/l
Table 2.2: Secretogogues used during live B-cell imaging. Concentrations 
are indicated. FCCP = cyanide p-trifluoromethoxyphenylhydrazone.
2.4.3 Dithizone staining
Dithizone (Fluka) stock solution (10 mg/ml in DMSO) was thawed and diluted 1 
in 100 into imaging buffer which, after filtration, was used to replace the 
medium on the microscope stage. After 10 mins, cells were carefully washed 
once with imaging buffer and red cells scored as B-cells using bright field 
imaging. This method has been previously described (Shiroi et al., 2002).
2.5 Pancreatic Im m unocytochem istry
2.5.1 Preparation of pancreata
Mice were killed by cervical dislocation and a laparotomy immediately 
performed. The pancreas was removed, washed once in phosphate buffered 
saline (PBS), blotted to dry, weighed using a fine balance and placed in a tissue 
cassette with biopsy sponge for fixation.
2.5.2 Bouin’s fixation for paraffin embedding
The pancreas was incubated in Bouin’s fixative for 3 hours at room 
temperature. The organ was then washed once with 70 % ethanol and left in 70 
% ethanol overnight at 4 °C prior to tissue processing. Tissue processing was 
performed at room temperature as follows, prior to embedding in molten
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paraffin wax by cooling on ice.
1. 90 % ethanol, 1 hour, room temperature.
2. 95 % ethanol, 1 hour, room temperature.
3. 100 % ethanol, 1 hour, room temperature.
4. 100 % ethanol, 2 hours, room temperature.
5. Histoclear I (or Xylene), 1 hour, room temperature.
6. Histoclear II (or Xylene), 2 hours, room temperature.
7. Paraffin wax I, overnight, 60 °C.
8. Paraffin wax II, 2 hours, 60°C.
Bouin’s fixative
78.5 % picric acid (saturated aqeous)
26.25 % formalin (40 % aqueous formaldehyde)
5.25 % glacial acetic acid
2.5.3 Immunostaining for fluorescent detection
5 pm pancreatic sections were cut, and float mounted onto Poly-L-lysine 
coated coverslips (Sigma) and dried at 37 °C. Sections were deparaffinised as
follows:
1. 5 minutes Histoclear I (or xylene)
2. 1 minute Histoclear II (or xylene)
3. 30 seconds pure ethanol
4. 30 seconds 90 % ethanol
5. 30 seconds 70 % ethanol
6. 5 minutes distilled water
7. [antigen retrieval step for KI67 or GLUT1]
8. 5 minutes PBS
9. 5 minutes PBS + 0.05% Tween 20 (Sigma)
10.5 minutes PBS + 1 % Triton X-100 (Sigma)
11.3x5 minutes PBS + 0.05 % Tween 20 (Sigma)
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Deparaffinised sections were incubated for 30 mins at room temperature with 
blocking solution (PBS containing 2 % BSA and 5 % chicken serum) before 
incubation overnight at 4 °C in blocking solution containing the primary 
antibody. Sections were then washed 3 times for 5 mins with PBS containing 
0.05 % Tween 20, and incubated for 1 hour at room temperature in darkness 
with PBS + 2 % BSA containing the secondary antibody. After a further 3 PBS + 
0.05 % Tween 20 5 min washes, coverslips were mounted onto the sections 
using vectorshield (Vector Laboratories) containing the fluorescent nuclear 
stain DAPI. Primary and secondary antibody sources and concentrations are 
shown in table 2.3.
2.5.4 Antigen retrieval
KI67 and GLUT1 immunostaining required acidic antigen retrieval at step 7 in 
the immunocytochemistry protocol listed above. Deparrafinised/rehydrated 
sections were placed in Citrate buffer (pH 6.0) at 95 °C for 10 mins. Buffer was 
cooled on ice for 10 mins and sections treated according to step 8 onwards of 
the protocol above.
500ml Citrate buffer (pH 6.0)
9 ml 0.1 mol/1 citric acid monohydrate 
41ml 0.1 mol/1 trisodium citric acid dehydrate 
450ml distilled water
2.5.5 Immunostaining for horseradish peroxidase detection of GLUT1
For GLUT1 staining, fixed paraffin embedded pancreata were cut and 
deparaffinised as described above (steps 1-11), processed and visualised using a 
Dakocytomation Envision HRP-DAB kit with a rabbit anti-mouse GLUT1 
polyclonal primary antibody (alpha diagnostica) used 1 in 1000. Counterstaining 
was performed by 5 mins staining in hematoxylin, before washing twice in 
water, destaining in acid ethanol, washing in water again, soaking in blueing
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solution (0.037 mol/l ammonia), washing and mounted using DPX mounting 
medium.
2.5.6 Imaging of immunofluoresence
A Biorad TE300 inverted confocal microscope was used to capture fluorescent 
images of immunostained pancreatic sections. The DAPI nuclear stain was 
excited at 405 nm (blue diode, 20 % power) and light emitted between 420-480 
nm collected. Alexa fluor 488 nm conjugated secondary antibody (against 
rabbit: anti glucagon, anti somatostatin, anti pancreatic polypeptide, anti 
GLUT2, anti KI67 and anti active caspase3) was excited at 488 nm (argon 488 
laser, 30 % power), and light emitted between 500-540 nm collected. Alexa 
fluor 594 nm conjugated secondary antibody (against mouse: anti insulin and 
anti glucagon) was excited at 543 nm (Green 543 helium/neon laser, 30 % 
power), and light emitted above 600 nm collected. Alexa fluor 546 nm 
conjugated secondary (against guinea pig anti insulin) was excited at 543 nm 
(Green 543 helium/neon laser, 30 % power), and light emitted between 560-600 
nm collected.
When staining for multiple antigens, antibody combinations were chosen that 
could be sequentially imaged with different laser lines/detector channels: for 
example mouse anti insulin (with secondary excited at 543 nm) costained with 
rabbit anti GLUT2 (with secondary excited at 488 nm).
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2.5.7 Pancreatic morphometry
For measurement of 6-cell and a-cell area, images were captured using an 
Olympus fluorescent microscope with Simple PCI control software (Cimaging), 
using fluorescent filter channels DAPI, FITC (for Alexa fluor 488 nm) and TRITC 
(for Alexa fluor 594 nm). A 10x objective lens was used for 6-cell images, a 20x 
lens was used for a-cell images. Pancreatic 6-cell or a-cell area was measured 
using the Simple PCI programme (Cimaging) with manually selected regions of 
interest. 6-cell or a-cell mass was calculated by multiplying % cell area of the 
pancreas by pancreatic mass, and dividing the product by 100.
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Primary Anti
Insulin
Anti
Insulin
Anti
Glucagon
Anti
Glucagon
Anti
Somato­
statin
Anti Ppy Anti
GLUT2
Anti KI67 Anti active 
caspase3
DAPI
nuclear
marker
Animal
source
Mouse
Monoclonal
Guinea pig 
Polyclonal
Rabbit
Polyclonal
Mouse
Monoclonal
Rabbit
Polyclonal
Rabbit
Polyclonal
Rabbit
Polyclonal
Rabbit
Polyclonal
Rabbit
Polyclonal
n/a
Supplier Sigma 
1-2018. Lot 
113K4866
Abeam 
Ab7842- 
500. Lot 
49409
Abeam 
Ab9379- 
500. Lot 
799A. (Not 
Lot 31107)
Sigma
G-2654. Lot 
98H4865
Chemicon
AB5494.
Lot
23120593
Euro-
diagnostica 
2263PPP 
lot GN2162
Kind gift 
from 
Bernard 
Thorens
Abeam 
Ab833-500. 
Lot 82464
BD
biosciences
/Pharm-
ingen
557035
Vector
laborato­
ries
Concentra­
tion
1 in 1000 1 in 200 1 in 200 1 in 1000 1 in 200 1 in 200 1 in 200 1 in 50 1 in 100 Neat mount 
solution
Secondary Anti
mouse IgG
Anti
guinea pig 
IgG
Anti rabbit 
IgG
Anti mouse 
IgG
Anti rabbit 
IgG
Anti rabbit 
IgG
Anti rabbit 
IgG
Anti rabbit 
IgG
Anti rabbit 
IgG
n/a
Animal
source
chicken goat chicken chicken chicken chicken chicken chicken chicken n/a
Supplier ^ Molecular 
Probes 
A-21201. 
Lot 93D1-1
Molecular 
Probes 
A-11074. 
Lot 84D1-1
Molecular 
Probes 
A-21441. 
Lot 93D1-1
Molecular 
Probes 
A-21201. 
Lot 93D1-1
Molecular 
Probes 
A-21441. 
Lot 93D1-1
Molecular 
Probes 
A-21441. 
Lot 93D1-1
Molecular 
Probes 
A-21441. 
Lot 93D1-1
Molecular 
Probes 
A-21441. 
Lot 93D1-1
Molecular 
Probes 
A-21441. 
Lot 93D1-1
n/a
Concentra­
tion
1 in 300 1 in 300 1 in 300 1 in 300 1 in 300 1 in 300 1 in 300 1 in 300 1 in 300 n/a
Fluo­
rescent
conjugate
Alexa fluor 
594 nm
Alexa fluor 
546 nm
Alexa fluor 
488 nm
Alexa fluor 
594 nm
Alexa fluor 
488 nm
Alexa fluor 
488 nm
Alexa fluor 
488 nm
Alexa fluor 
488 nm
Alexa fluor 
488 nm
n/a
Excitation 
/laser line
543 nm
Green
HeNe
543 nm
Green
HeNe
488 nm 
Argon
543 nm
Green
HeNe
488 nm 
Argon
488 nm 
Argon
488 nm 
Argon
488 nm 
Argon
488 nm 
Argon
405 nm 
Blue Diode
Peak
Emission
617 nm 573 nm 519 nm 617 nm 519 nm 519 nm 519 nm 519 nm 519 nm 460 nm
Filtered
Emission
>600 nm 560-600 nm 500-540 nm >600 nm 500-540 nm 500-540 nm 500-540 nm 500-540 nm 500-540 nm 420-480 nm
Table 2.3: Primary and secondary antibodies used fo r  immunocytochemistry on pancreatic sections. Excitation and 
emission wavelengths are settings used fo r imaging on a Biorad TE300 confocal microscope.
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2.6 Im m unoprecipitation (IP) and Western b lo tting  o f IRS2
2.6.1 Tissue Lysis
Islets were isolated, washed and frozen as described above. Each islet pellet 
was lysed in 100 pi Triton lysis buffer by passing through a 0.33 mm syringe 
needle 10 times, followed by gentle homogenisation with a plastic Dounce 
homogeniser and incubation for 1 hour on ice to allow solubilisation of 
proteins. Insoluble material was cleared from the lysate by centrifugation and 
protein content of the supernatant was quantified by Bradford assay (Biorad) 
with BSA standards. Pancreatic lysates were prepared as above, but tissue was 
homogenised at 12,000 RPM instead of the needle/Dounce method.
2.6.2 IP and western blotting of IRS2 protein
For IP, islet protein lysate was pooled and 300 pg made up to 400 pi with PBS 
and 10 pi of sheep anti Irs2-GST purified antibody (Choudhury et al., 2005). The 
reactions were gently mixed at 4 °C for 2 hours, after 1 hour 20 pi of protein A 
agarose beads were added. After completion of incubation agarose beads were 
pelletted and washed 3 times with ice cold PBS. Beads were finally 
resuspended in 30 pi Laemmli buffer (Laemmli, 1970), boiled for 10 mins, spun 
down and the supernatant loaded onto an 8 % SDS-polyacrylamide resolving gel. 
The gel was run at 150 volts for 1.5 hours at room temperature using a Tris- 
glycine-SDS buffer. Proteins were transferred to a hydrophobic PVDF membrane 
(Amersham) by wet electrophoretic transfer in a Tris-glycine buffer; 100 volts 
for 1 hour at 4 °C.
Western blotted membranes were placed in blocking solution for 1 hour at 
room temperature with agitation, after which polyclonal rabbit anti Irs2 
(Upstate) was added (1 in 1000) and the membrane left at 4 °C with gentle 
agitation overnight. Membranes were washed 3 times for 5 minutes in washing
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solution before incubation with anti rabbit horseradish peroxidase (HRP) 
conjugated secondary antibody (Dako) in blocking solution (1 in 10,000), for 1 
hour at room temperature. Membranes were again washed 3 times for 5 
minutes and bound HRP conjugated antibody detected using ECL plus detection 
(Amersham).
Triton lysis buffer
10 mmol/l Tris/HCl, 5 mmol/l EDTA, 50 mmol/l NaCl, 30 mmol/l sodium 
pyrophosphate, 50 mmol/l NaF, 100 pmol/l Na3V04, 1% Triton X-100, pH 7.6. 1 
mmol/l phenylmethylsulfonyl fluoride (PMSF) and protease inhibitor tablets 
(Roche) added before use.
2x Laemmli buffer
2 % SDS, 10 % glycerol, 100 mmol/l DTT, 60 mmol/l Tris (pH 6.8), 0.001 % 
Bromophenol Blue in distilled water. 1 mmol/l PMSF and protease inhibitor 
tablets (Roche) added before use.
Western blocking solution
Phosphate buffered saline with 0.05 % Tween 20 and 5 % non-fat dried milk 
(Tesco).
Western washing solution
Phosphate buffered saline with 0.05 % Tween 20.
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2 .7  Is let gene expression analysis
Islet RNA was harvested as described above, and quality/quantity determined 
using a Bioanalyser 2100 capillary gel pico chip (Agilent).
2.7.1 TaqMan Retrotranscription (Applied Biosystems; ABI)
500 ng of islet RNA was diluted to 25 pi with nuclease free DEPC treated water. 
The following ABI TaqMan reverse transcription reagents (ABI: N8080234) were 
added as supplied, to give a final reaction volume of 64 pi.
• 6.4 pi RT buffer (1 Ox)
• 14plMgCl2
• 12.8 pi dNTP
• 3.2 pi oligo dT
• 1.3 pi RNAse inhibitors
• 1.3 pi Reverse transcriptase
The reverse transcription reaction was incubated at 48 °C for 30 mins, followed 
by 94 °C for 5 mins. The cDNA product was stored at -20 °C.
2.7.2 Real time polymerase chain reaction (RT-PCR)
cDNA was diluted 1 in 3.2, and 4.8 pi of this dilution used per 12 pi RT-PCR 
reaction as follows:
• 4.8 pi cDNA template
• 1.2 pi Primer pair (TaqMan)
• 6 pi TaqMan Universal PCR master mix (ABI 4364340)
ABI TaqMan FAM/TAMRA fluorescent labelled primers used are listed in table
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2.4. RT-PCR reactions were run in duplicate on a 384 well optical plate, using 
an ABI prism 7900HT sequence detection system with SDS2.1 software. 
Fluorescence thresholds used to determine Ct values were assigned 
automatically. All gene transcript Ct values were normalised to the reference 
gene HPRT1 to calculate ACt, which was converted to a ratio scale using the 
formula x=2'ACt, before comparisons between control and Plrs2KO transcripts 
were made.
The HPRT1 (hypoxanthine phosphoribosyltransferase 1) gene is a nuclear 
encoded “housekeeping” gene involved in the cellular recycling of purines. 
Other potential reference genes such as GAPDH (glyceraldehyde-3-phosphate 
dehydrogenase), B-actin and Cyclophilin A were rejected as these genes do not 
have stable mRNA expression levels in transplanted islets (Rodriguez-Mulero 
and Montanya, 2005) and GAPDH is a Hif target (Graven et al., 1999) and may 
be regulated in B-cells to alter glycolytic flux. This left 18S and HPRT1 as 
potential reference genes: HPRT1 was chosen as it has previously been reliably 
used to normalise mRNA expression of islet genes (Kulkarni et al., 2002; 
Kulkarni et al., 2004).
2 .8  S tatis tica l analysis o f  d a ta
All data is presented as mean values, +/- standard error of the mean (SEM) 
unless otherwise indicated, n = sample size are indicated in figure text. 
Statistical analysis was carried out using an unpaired two-tailed students t-test 
or two-way ANOVA (analysis of variance) with Bonferroni post-tests as 
appropriate; P values <0.05 (*), <0.01 (**) and <0.001 (***) were recorded as 
significant. Raw data was collated in Microsoft Excel and exported to Graphpad 
Prism 4 (Graphpad software) for graphical representation, calculation of 
mean/SEM, and statistical analysis.
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Gene name/symbol Primer product number
Insulin II Mm00731595_gH
Glucagon Mm00801712_m1
Somatostatin Mm00436671_m1
Pancreatic polypeptide Mm00435889_m1
Irs1 Mm00439720_s1
Irs2 4332078 (custom primers)
Slc2a1 (Glutl) Mm00441473_m1
Slc2a2 (Glut2) Mm00446224_m1
Glucokinase Mm00439129_m1
Fox01 Mm00490672_m1
PDX1 Mm00558275_m1
NeuroD Mm01280117_m1
Nkx6.1 Mm00454962_m 1
Tcf1 (Hnfla) Mm00493434_m1
Foxa2 (Hnf38) Mm00839704_mH
Hnf4a Mm00433964_m1
E-cadherin (Cadherinl) Mm00486906_m1
Kcnj11 (Kir6.2) Mm00440050_s1
HPRT1 Mm01545399_m1
Table 2.4: RT-PCR Taqman primers. ABI primer pair product numbers used 
fo r RT-PCR analysis o f islet gene transcription profiles. Gene name or symbol 
is shown with aliases used within this thesis included in parentheses as 
appropriate.
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Chapter 3: Physiological characterisation of 
Plrs2KO mice
3 . 1 1ntroduction
As described in chapter 1, to establish the precise in vivo role of IRS2 in the 
pancreas, it is necessary to study 8-cell Irs2 deletion in an animal without the 
complication of peripheral insulin resistance or obesity due to deletion in other 
tissues. Other published studies of mouse models of Irs2 null 6-cells have been 
complicated by either severe progressive diabetes (Withers et al., 1998) or a 
hyperphagic, obese, hyperleptinaemic, insulin resistant phenotype (Choudhury 
et al., 2005; Kubota et al., 2004; Lin et al., 2004) potentially causing 8-cell 
defects secondary to the B-cell Irs2 deletion. Therefore to generate a 6-cell 
Irs2 null model without these complicating features, pancreatic Irs2 KO 
(Plrs2KO) mice were bred by crossing PDXcre mice (pancreatic and duodenal 
homeobox factor 1 promoter driven cre-recombinase mice) and Irs2 floxed 
mice (posses Irs2 gene flanked by loxP sites) as described in chapter 2. The 
results presented in this chapter aim to establish if the Plrs2KO mouse is a 
reliable model of 8-cell Irs2 deletion: by assessment of Irs2 deletion efficacy 
and tissue specificity. Metabolic studies were then conducted to analyse 
glucose homeostasis and in vivo glucose stimulated insulin secretion (GSIS) to 
establish the function of the Irs2 null B-cells in vivo, whilst excluding 
hypothalamic or insulin resistant phenotypes.
3 .2  Analysis o f deletion  o f lrs2 in Plrs2KO mice
The following experiments were performed to confirm excision of the gene and 
significant reduction of the Irs2 mRNA transcript and protein in islets and the 
pancreas.
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3.2.1 Specificity of Irs2 deletion
PCR amplification of the 1.3 kilo base pair product (Fig. 3.1 A) from tissue DNA 
indicated deletion of the Irs2 gene following recombination of the loxP sites 
flanking the gene in Plrs2KO mice. Clear deletion was present in the pancreas 
and isolated islets, but crucially not in the hypothalamus, brain or insulin 
target tissues of the Plrs2KO mice. Interestingly a small proportion of Irs2 gene 
deletion was present in DNA extracted from the duodenum (Fig. 3.1B). These 
results indicate that the PDXcre transgene is expressed in pancreatic endocrine 
and exocrine tissue, and a small proportion of the duodenum; confirming the 
expected expression pattern of the PDX1 gene, and predicted pattern of Irs2 
gene deletion.
3.2.2 Efficacy of Irs2 deletion
To confirm effectiveness of Irs2 deletion, real time quantitative PCR (RT-PCR) 
amplification of cDNA reverse transcribed from islet or hypothalamic RNA taken 
from Plrs2KO mice was performed. This showed significant reduction of the Irs2 
mRNA transcript in islets (Fig. 3.2A) but not in the hypothalamus (Fig. 3.2B). 
Although some Irs2 mRNA appeared to be present in Plrs2KO islets, this is likely 
to be from pancreatic tissue not expressing the PDXcre transgene such as blood 
vessels, blood cells and nerve cells, and was picked up by RT-PCR assay due to 
the highly sensitive amplification used by this technique. Irs2 is also a single 
exon gene, and therefore RT-PCR primers may amplify any residual genomic 
DNA carried through from RNA extraction, which may have contributed to the 
small amount of Irs2 expression seen in the Plrs2KO. However, subsequent IP 
and western blotting for IRS2 from islet and pancreatic lysates (Fig. 3.2C and D 
respectively) confirmed essentially complete ablation of IRS2 protein.
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5 Hypothalamus 13 Lung
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Figure 3.1: Analysis o f tissue specificity o f cre-mediated recombination o f 
the floxed Irs2 gene by PCR. DNA extracted from the indicated tissues was 
used as a template for PCR amplification using a primer set flanking the Irs2 
gene, amplifying a 1.3 kbp PCR product i f  the Irs2 gene is excised by cre- 
mediated recombination of the loxP sites. IL2 is a control primer pair used to 
confirm the presence of DNA template in all samples. This experiment was 
repeated twice to confirm results. A: Tissue panel of Irs2 gene deletion 
analysis with IL2 control. B: Enhanced image of lanes 1-5 of PIrs2KO tissues.
Irs2 gene 
deletion
IL2
control
Irs2 gene 
deletion
IL2
control
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Figure 3.2: Analysis o f efficiency o f Irs2 deletion by assay o f IRS2 protein 
and transcript in Plrs2KO pancreas and islets. A and B: Irs2 mRNA 
expression quantified by real-time PCR amplification of cDNA reverse 
transcribed from islet (A, n = 5) or hypothalamic (B, n = 3) RNA using the 
taqman system (ABI). Data shown is mean +/- SEM, with t-test ***P = <0.001 
indicated. C and D: IRS2 was immunoprecipitated from islet (C) or pancreatic 
(D) lysate using sheep anti Irs2-GST antisera, then western blotted against 
using a rabbit polyclonal anti IRS2 antibody (Upstate). This western blot was 
repeated twice to confirm results.
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3 .3  M etabo lic  studies in Plrs2K0 mice
Studies were performed to establish that the Plrs2K0 mice do not have a 
hypothalamic phenotype leading to increased body mass and insulin resistance.
Plrs2K0 mice developed and grew normally. At 12 weeks of age both male and 
female Plrs2K0 body mass was normal, suggesting that growth, fat mass and 
weight gain were unaltered by pancreatic Irs2 deletion (Fig.3.3A and B). Food 
intake was also unaltered in 5 week old female mice (Fig.3.3C). Male and 
female Plrs2K0 mice were fertile and produced litters of normal size, with 
Plrs2KO pups born at a frequency comparable to their litter mate controls 
(Table 3.4) indicating that pancreatic Irs2 deletion does not alter reproductive 
function. Fasting insulin levels in male Plrs2K0 mice were unaltered from 
control animals and did not show hyper/hypoinsulinaemia, in part suggesting 
normal insulin sensitivity without signs of insulin resistance (Fig. 3.3D). The 
insulin tolerance test (ITT) showed that insulin sensitivity of the Plrs2KO mouse 
is comparable to controls, indicating that insulin target tissues respond 
appropriately to insulin and act to lower blood glucose levels (Fig. 3.3E). By the 
final time point (120 mins), during the recovery phase of the ITT, the Plrs2KO 
mice showed decreased blood glucose indicating either increased insulin 
sensitivity, decreased clearance of insulin from the circulation or impaired 
glucagon secretion.
These data indicate that the Plrs2KO mice do not show signs of a central 
nervous system phenotype such as weight gain and associated insulin resistance 
or infertility, which may confound the study of B-cell mass and function.
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Figure 3.3: Assessment o f hypothalamic phenotypes and insulin action in 
Plrs2K0 mice. Fasted body mass in 12 week old male (A: n=18 Plrs2K0 vs n=13 
control) and female (B: n=5 Plrs2K0 vs. n=5 control) mice. C: Daily food intake 
in 5 week old female mice (n=6 Plrs2K0 vs. n=8 control) D: 12 week male 
fasted plasma insulin, assayed by ELISA (n=6 Plrs2K0 vs. n=10 control). E: 
Insulin tolerance test: insulin injected i.p. and blood glucose measurements 
made before and a fte r injection, in 12 week male mice (n=8 Plrs2K0 vs. n=9 
control). Data shown is mean +/- SEM, with t-test **P = <0.01 indicated.
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Number of males weaned 30
Number of females weaned 24
Number of lrs2floxed/PDXcre {Plrs2KO) weaned 26
Number of lrs2floxed weaned 28
Table 3.1: Sex and genotype of 54 mice weaned from 1 breeding trio.
Breeding trio set up to generate Plrs2K0 and control offspring in equal 
numbers, consisted of a male Pirs2K0 mouse (lrs2floxed*/+ PDXcre*) and 2 
female Irs2 floxed homozygote mice (lrs2floxecT/+).
3 .4  Glucose homeostasis o f  P lrs2K0 mice
To assess glucose handling and 6-cell function of Plrs2K0 mice, fasted, random 
fed and post glucose injection (glucose tolerance test) blood glucose 
concentrations were measured. To test 6-cell insulin secretion in Plrs2KO mice, 
in vivo glucose stimulated insulin secretion (GSIS) was performed.
3.4.1 Fasting/Fed blood glucose
Fasting blood glucose levels were not significantly altered at 12 weeks of age 
(Fig. 3.4A), indicating that Plrs2KO mice are capable of correctly regulating 
blood glucose when not challenged with feeding or glucose.
Random fed blood glucose measurements however were significantly elevated 
in the Plrs2KO mouse, indicating an inability to correctly regulate blood glucose 
levels after feeding, and suggesting glucose intolerance (Fig. 3.46).
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3.4.2 Glucose tolerance testing
To further investigate glucose handling in Plrs2KO mice glucose tolerance tests 
(GTTs) were performed. Following glucose injection Plrs2KO mice showed a 
highly significant and consistent elevation of blood glucose throughout the 
glucose tolerance test shown in Fig. 3.4C. PDXcre controls showed no glucose 
intolerance and were indistinguishable from Irs2 floxed controls. As Plrs2KO 
mice show severe glucose intolerance, significantly elevated blood glucose 
after feeding, yet are not insulin resistant, this indicates a potential defect in 
insulin secretion.
3.4.3 Glucose stimulated insulin secretion in vivo
To examine a potential insulin secretory defect, P/r2KO mice were subjected to 
in vivo glucose stimulated insulin secretion (GSIS). This revealed that although 
fasted insulin levels were unaltered in Plrs2KO mice (Fig. 3.3D), GSIS was 
significantly impaired, with a complete loss of first phase secretion, and 
impaired second phase insulin secretion (Fig. 3.4D). PDXcre control mice 
showed normal first and second phase insulin secretion which was 
indistinguishable from Irs2 floxed  control animals. These results suggest that 
the glucose intolerance seen in the Plrs2KO mouse is due to severely impaired 
6-cell insulin secretion in response to glucose.
100
A) B)
^ 12.5* O
E 
E 10.0-
7.6-■o 70) to
4 - t IS )
wj Ofl O 5 0-
L l. a
on
•a o
J2 o.o
2.5-
C o n tro l Plrs2K0 Plrs2K0
C)
30- 
E 25-
01
8 ,5- 
3  10-  
on 
TJ 5- O 
£  0 
CO
‘ I  •+-Pkrs2KO
i r s 2  floxed 
-a- PDXcre
30 —I—60 “1—90 —T“120
Time after injection (mins)
_  D)
Irs2 floxed 
PDXcre
Q. 60-
3  50-
JS 30- Q- 0 5 10 15 20
Time after injection (mins)
Figure 3.4: Glucose homeostasis and GSIS in Plrs2K0 mice.
A: 16 hour fasted blood glucose levels (n=18 Plrs2K0 vs. n=21 control). B: 
Random fed blood glucose levels (n=8 Plrs2K0 vs. n=9 control). C: Glucose 
tolerance test with blood glucose levels measured via tail bleeds before and 
after i.p. 2g/kg glucose injection (n=18 Plrs2K0 vs. n=7 PDXcre control vs. n=13 
Irs2 floxed control). D: in vivo GSIS, assayed from tail bleeds before and 
following i.p. glucose injection (n=9 Plrs2K0 vs. n=8 PDXcre control vs. n=11 
Irs2 floxed control). Male 12 week old mice were used throughout. Data shown 
is mean +/- SEM, with t-test (A and B) or AN OVA with Bonferroni post test 
analysis (C and D), *P = <0.05, **P = <0.01, ***P = <0.001 indicated.
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3.5 Chapter 3 discussion
The experiments presented in this chapter have investigated Irs2 deletion, 
peripheral metabolic capacity and in vivo glucose homeostasis of the Plrs2KO 
mouse. These studies have revealed that the Plrs2KO mouse is a reliable model 
for studying Irs2 null 6-cell function, and does not show the complications that 
have affected previous studies as discussed below.
3.5.1 The Plrs2KO mouse as a model for studying Irs2 null B-cell 
function
Plrs2KO mice show the expected pattern of Irs2 gene deletion as predicted 
using the PDXcre mouse, namely efficient deletion in pancreatic exocrine and 
endocrine (islet) cells, as well as a small proportion of cells in the duodenum. 
This pattern of deletion was expected as although expression of Pdx1 is 
restricted to 6-cells in the adult mouse, it is expressed in all pancreatic 
progenitor cells during development from day E8.5, and will therefore drive 
cre-recombinase expression, deleting Irs2 from all pancreatic progenitor cells 
and their progeny. Importantly, no Irs2 gene deletion could be found in any 
other tissues studied; in particular no deletion was found in the hypothalamus, 
brain or metabolic insulin target tissues (muscle/liver/fat). Plrs2KO mice also 
showed no obvious alteration in body mass associated with hyperphagy, and no 
signs of insulin resistance were present. This sets the Plrs2KO mouse apart from 
the severely diabetic global Irs2 KO (Withers et al., 1998) and previous 
attempts to conditionally delete Irs2 in the 6-cell using the RIPcre mouse, 
which resulted in additional hypothalamic Irs2 deletion and subsequent 
hyperphagia, obesity and peripheral insulin resistance (Choudhury et al., 2005; 
Kubota et al., 2004; Lin et al., 2004). Therefore Plrs2KO mice provide a more 
precise way to study IRS2 function in the 6-cell as they do not suffer from 
complicating peripheral insulin resistance or diabetes that may alter 8-cell 
mass and function per se.
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3.5.2 Glucose homeostasis of the Plrs2KO mouse
Although Plrs2KO mice have normal fasting blood glucose levels, the fed and 
post glucose injection levels are significantly elevated when compared to 
control animals. The glucose intolerance of Plrs2KO mice following glucose 
injection is broadly comparable to that seen in the B-cell/hypothalamic Irs2 KO 
mouse (Choudhury et al., 2005).
The lack of insulin resistance in Plrs2KO mice suggests that the glucose 
intolerance is due to B-cell dysfunction. Further experiments confirmed this as 
Plrs2KO mice had severely impaired in vivo GSIS, with a complete loss of first 
phase insulin secretion, and significantly perturbed second phase secretion.
3.5.3 Summary
These data show that the Plrs2KO mouse is a reliable model with which to 
study Irs2 null B-cell function. These data also show that pancreatic Irs2 
deletion, with no peripheral insulin resistance or other confounding metabolic 
phenotype, results in glucose intolerance due to impaired GSIS. This GSIS 
defect may be due to an insufficient B-cell mass and/or impaired GSIS per B- 
cell. These two factors are examined in chapters 4 and 5.
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Chapter 4: Composition of the Plrs2KO mouse 
endocrine pancreas
4 .1 1ntroduction
The experimental results reported in chapter 3 show that Plrs2KO mice develop 
normally, are of normal body mass and are not insulin resistant. Therefore 
Plrs2KO mice are a reliable model with which to study Irs2 null 6-cell function. 
Plrs2KO mice are glucose intolerant due to severely impaired GSIS. To 
investigate this B-cell insulin secretory defect further and to assess the effect 
of Irs2 deletion on other islet cell types, islet structural organization (islet 
anatomy), pancreatic hormone content, transcription of principal islet 
hormones as well as the endocrine cellular composition of the Plrs2KO pancreas 
was studied.
The widely reported 6-cell defect present in other models of 6-cell Irs2 
deletion is a loss of 6-cell mass or area (Choudhury et al., 2005; Kubota et al., 
2004; Kubota et al., 2000; Lin et al., 2004; Withers et al., 1998). Therefore the 
6-cell mass of Plrs2KO mice was measured and morphological and structural 
characteristics of Plrs2KO islets examined. As the Plrs2KO mouse deletes Irs2 in 
all pancreatic cell types, it is possible that a-cell, 6-cell, 6-cell or pancreatic 
polypeptide cell (PP-cell) types may be altered. Therefore the anatomical 
organisation of the cells within the islet, and hormone expression of these cell 
types was studied.
4.2 Analysis of islet structure
To investigate the effect of pancreatic Irs2 deletion on islet structure and 
development, the organisation of a, 6, 6 and PP cells within Plrs2KO islets was
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qualitatively assessed using immunocytochemistry and confocal laser scanning 
microscopy.
Pancreatic sections were immunostained for either:
• Insulin and glucagon to identify 8 and a-cells (Fig. 4.1).
• Insulin and somatostatin to identify 6 and 6-cells (Fig. 4.2).
• Insulin and pancreatic polypeptide to identify B and PP-cells (Fig. 4.3).
All sections were co-stained with the fluorescent nuclear marker DAPI.
Islet cell staining revealed normal islet cell organisation in pancreata from 
Plrs2KO mice, with a, 6 and PP-cells predominantly forming a mantle 
surrounding a B-cell core (Figs. 4.1 to 4.3). This suggested that developmental 
organisation of islet endocrine cells is not disrupted with pancreatic Irs2 
deletion. Sections from 4 different levels throughout each pancreas were 
analysed and normal islet architecture was found throughout. The images 
shown in Figs. 4.1 to 4.3 are representative of typical islets observed from the 
respective genotypes. It was noted during imaging of sections immunostained 
for insulin, glucagon and somatostatin, that adequate imaging of Plrs2KO islets 
required consistently higher laser power and detector gain than for control 
islets. It was also apparent that there were notably fewer 6-cells in the Plrs2KO 
islets, although this has not been formerly assessed.
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Figure 4.1: Insulin (6-cell) and glucagon (a-cell) immunostaining of 
pancreatic sections. Pancreatic sections stained for Insulin (red), Clucagon 
(green) and nuclear DNA (blue). Images were taken using a confocal 
microscope with a 40x lens and are representative of islets examined from 
multiple levels within 4 independent pancreata. Scale bars are 50 pm. A clear 
a-cell mantle and 6-cell core was seen in all islets.
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Figure 4.2: Insulin (B-cell) and somatostatin (6-cell) immunostaining o f 
pancreatic sections. Pancreatic sections stained fo r Insulin (red), 
Somatostatin (SST; green) and nuclear DNA (blue). Images were taken using a 
confocal microscope with a 40x lens and are representative of islets examined 
from multiple levels within 4 independent pancreata. Arrows indicate 6-cells 
in the Plrs2KO islets. Scale bars are 50 pm. A clear 6-cell mantle and B-cell 
core was seen in all islets.
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Figure 4.3: Insulin (B-cell) and pancreatic polypeptide (PP-cell)
immunostaining o f pancreatic sections. Pancreatic sections stained for 
Insulin (red), pancreatic polypeptide (PPY, green) and nuclear DNA (blue). 
Images were taken using a confocal microscope with a 40x lens and are 
representative of islets examined from multiple levels within 4 independent 
pancreata. Scale bars are 50 pm. A clear PP-cell mantle and B-cell core was 
seen in all islets.
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4.3 Islet hormone content o f Plrs2K0 pancreata
To measure the pancreatic protein levels of insulin and glucagon, these 
hormones were assayed in whole pancreatic lysates (Fig. 4.4A to D) by 
radioimmunoassay (kindly performed by Dr. Henry Asare-Anane at King’s 
College London). Both insulin and glucagon content were found to be 
significantly reduced in the Plrs2KO pancreata, when expressed as both total 
pancreatic content (Fig. 4.4A and C), or content per mg of pancreas (Fig. 4.4B 
and D). Reduced pancreatic insulin content has previously been reported but in 
a model complicated by severe progressive diabetes (Kubota et al., 2000). 
Reduced pancreatic glucagon content in IIS mutant animals has not been 
previously reported.
Expression of islet hormone mRNA was assayed by RT-PCR of cDNA reverse 
transcribed from RNA extracted from isolated islets (Fig. 4.4E). Gene 
transcripts for insulin, glucagon, and somatostatin were found to be 
significantly reduced in the Plrs2KO islets when compared to control levels 
(88.62%, 66.15% and 37.83% respectively). This has not previously been 
reported and suggests that IRS2 mediated IIS in a, B and 6 cells may be 
required for sustained transcription of these islet hormones in their respective 
cell types. Expression of pancreatic polypeptide (Ppy) mRNA from Plrs2KO islets 
was not found to be significantly altered to that of control islets, although the 
standard error of this RT-PCR data is larger than for the other hormones 
assayed. Ppy expression is highly regulated by fasting/feeding, and during islet 
isolation mice are killed throughout the light phase of the day. Therefore the 
different fed states of the mice may explain the high variability of the Ppy 
mRNA data.
The significant reduction of pancreatic insulin and glucagon content, although 
potentially caused in part by the reduction in hormone transcription within the 
islet, also suggested a reduced B-cell and a-cell mass.
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Figure 4.4: Pancreatic islet hormone contnt.
A-D: Whole Plrs2K0 pancreata homogenised in acid ethanol were 
radioimmunoassayed fo r insulin and glucagon content and expressed as total 
content (A and C) or normalised using pancreatic mass (B and D), n=5 animals 
studied per genotype. E: RT-PCR assay (ABI Taqman) of islet hormone gene 
expression from RNA extracted from islets isolated from n=5 animals per 
genotype. Data was normalised to HPRT1 expression and presented as % of 
mean control expression levels. Data shown is mean +/- SEM, with t-test *P = 
<0.05, **P = <0.01, ***P = <0.001 indicated. Radioimmunoassays were 
performed by Dr.Henry Asare-Anane at King’s College London.
4 .4  M orphom etric q uantification  o f a and B-cell mass
Reduced B-cell mass has been reported in Irs2 null mice by multiple research 
groups (Choudhury et al., 2005; Kubota et al., 2004; Kubota et al., 2000; Lin et 
al., 2004; Withers et al., 1998), however none of these studies have assessed B- 
cell mass in mice without the complicating effects of peripheral insulin 
resistance. Measurement of a-cell mass in Irs2 null mice has not been reported. 
Therefore morphometric analysis of pancreatic sections stained for insulin 
expressing B-cells or glucagon expressing a-cells was performed, to quantify 
the mass of these cell types within the Plrs2KO pancreas.
4.4.1 B-cell mass of Plrs2KO mice
Pancreatic B-cell mass was significantly reduced in the Plrs2KO mouse (Fig. 
4.5A) compared to controls (mean values: 1.91 mg versus 2.66mg respectively; 
t-test: P=<0.05). This confirms that pancreatic IRS2 mediated IIS is required to 
maintain an adequate B-cell mass. Pancreatic mass was not altered in the 
Plrs2KO mice used for this analysis (Fig. 4.5C), indicating that pancreatic IRS2 
is not required for pancreatic growth.
4.4.2 a-cell mass of Plrs2KO mice
Pancreatic a-cell mass was significantly reduced in the Plrs2KO mouse (Fig. 
4.5B) when compared to controls (mean values: 0.08mg versus 0.15mg 
respectively; t-test: P=<0.010). This indicates that pancreatic IRS2 is required 
to maintain an adequate mass of a-cells.
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Figure 4.5: Morphometric analysis o f B-cell and a-cell mass. A-B: Insulin and 
or glucagon stained pancreatic sections (from 4 different levels within each 
pancreas) were photographed using a fluorescent microscope, and the 
parameters shown were calculated by manually selecting regions of interest 
using simple PCI software. A: B-cell mass o f the pancreas: control n=7, Plrs2K0 
n=6. B: a-cell mass o f the pancreas: control n=3, Plrs2K0 n=3. C: Pancreatic 
mass: control n=7, Plrs2K0 n=6. Data shown is mean +/- SEM, with t-test *P = 
<0.05, **P = <0.01 indicated.
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4.4.3 B-cell proliferation and apoptosis in Plrs2K0 mice
Pancreatic sections stained for insulin and the proliferating cell marker KI67, or 
the apoptotic cell marker active Caspase3, were analysed using confocal 
microscopy. This revealed that a significantly smaller proportion of Plrs2K0 B- 
cells are proliferating than in control pancreata; 2.12% versus 0.76% 
respectively, t-test: P=<0.05 (Fig. 4.6A). The apoptotic rate however, was not 
significantly altered between genotypes (Fig. 4.6B). This shows that the 
reduced B-cell mass caused by Irs2 deletion is due to impaired B-cell 
proliferation.
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Figure 4.6: Immunostaining o f proliferating and apoptosing B-cells. 
Pancreatic sections were immunostained fo r insulin (red) and either the 
proliferating cell marker KI67 (green) or apoptosing cell marker active 
Caspase3 (green), and DNA (blue). A: Quantification of Plrs2KO B-cell nuclei 
positively stained for KI67 with cytoplasm positively stained fo r insulin. B: 
Quantification of Plrs2K0 B-cell nuclei positively stained fo r active Caspase3 
with cytoplasm positively stained fo r insulin. Data shown is mean +/- SEM, 
with t-test *P = <0.05. Quantification was performed by counting at least 1000 
B-cells from 2 independent pancreata per genotype and scoring as marker 
positive or negative. C and D: Examples o f immunostaining fo r KI67 (C) or 
active Caspase3 (CASP3, D); marker positive B-cells indicated with arrows.
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4 .5  Chapter 4  discussion
From the data presented in chapter 4 it is clear that the principal defect of 
reduced pancreatic insulin and glucagon content in the Plrs2KO mouse, is 
caused by two contributing factors: reduced a-cell/8 -cell mass, and reduced 
islet expression of insulin and glucagon.
4.5.1 Plrs2KO Islet anatomy
Pancreatic sections analysed from Plrs2KO mice have shown that normal islet 
cellular organisation is preserved in Plrs2KO mice with a/5/PP-cells 
predominantly forming a mantle around a 8 -cell core. This is important as it 
shows that there is no obvious abnormality in islet development when deleting 
Irs2 in pancreatic progenitor cells, during formation of the organ from the 
foregut, using the PDXcre mouse. This preservation of islet architecture is in 
keeping with published literature describing the global and 6 -cell deletion of 
Irs2 (Choudhury et al., 2005; Kubota et al., 2004; Kubota et al., 2000; Lin et 
al., 2004; Withers et al., 1998) as well as 8 -cell deletion of the Insr and /g/fr, 
abrogating all IIS signalling in 8 -cells (Ueki et al., 2006).
4.5.2 Reduced B-cell and a-cell mass
The 6 -cell and a-cell mass of the Plrs2KO mouse are significantly reduced in 
comparison to control animals. This reduction in B-cell mass is in line with 
published literature describing animals with Irs2 null 8 -cells. However, as the 
Plrs2KO mouse is uniquely uncomplicated by peripheral insulin resistance or 
diabetes, the loss of 8 -cell mass is directly attributable to the pancreatic Irs2 
deletion and, more specifically, 6 -cell Irs2 deletion. Upon further investigation 
it was demonstrated that this loss of 8 -cell mass was due to a significantly 
reduced proliferation rate amongst Plrs2KO 8 -cells, and this defect led to the 
reduced 8 -cell mass and glucose intolerant phenotype. These data indicate that
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IRS2 mediated IIS is required to sustain adequate B-cell proliferation in the 
adult animal, but is not required to inhibit B-cell apoptosis.
The loss of a-cell mass reported here implicates a requirement for IRS2 
mediated IIS in the a-cell to sustain a normal a-cell mass.
4.5.3 Reduced pancreatic hormone gene expression in Plrs2KO islets
Plrs2K0 islets show reduced expression of insulin, glucagon and somatostatin, 
implicating IRS2 mediated IIS in sustaining transcription of these genes in islet 
B-cell, a-cell and 5-cells (respectively). It has been previously demonstrated in 
vitro  that autocrine/paracrine feedback of insulin on the B-cell via the IR/IRS2 
pathway sustains expression of the insulin gene (Leibiger et al., 1998). 
However, the altered B-cell and a-cell mass of Plrs2KO mice complicates 
conclusive interpretation of these data.
4.5.4 Summary
The data in this chapter demonstrates that the role of IRS2 mediated IIS in the 
pancreas does not involve maintaining anatomical/cellular organisation of the 
endocrine pancreas, or growth of the organ, but rather in sustaining a 
metabolically sufficient endocrine cell mass and hormone content. The 
reduction in B-cell mass and pancreatic insulin content documented in this 
chapter is, however, unlikely to fully account for the severe impairment of GSIS 
seen in vivo. Therefore it was necessary to carry out analysis of core 
mechanisms involved in maintaining B-cell function: GSIS stimulus secretion 
coupling, and expression of critical B-cell genes. These studies are presented in 
chapter 5.
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Chapter 5: Investigation of underlying defective B- 
cell GSIS in Plrs2KO mice.
5 . 1 1ntroduction
The characterisation of the metabolic phenotype of the Plrs2KO mouse in 
chapters 3 and 4 has revealed multiple defects leading to impaired glucose 
homeostasis. The core defect is severely impaired in vivo glucose stimulated 
insulin secretion (GSIS) which is, in part, explained by the reduced pancreatic 
insulin content and reduced 6 -cell mass. However, of these parameters the 
Plrs2KO mouse (as % of control) still possesses 68.5 % pancreatic insulin peptide 
content, 71.8 % 6 -cell mass and 8 8 . 6  % islet insulin gene expression. Therefore 
the complete ablation of first phase, and severely impaired second phase 
insulin secretion (Chapter 3, Fig. 3.4D) cannot be satisfactorily explained by 
the morphological/hormone content defects presented in chapter 4. Therefore 
investigation at the level of the islet and 6 -cell is required to establish if there 
is a further functional defect in these Irs2 null 6 -cells.
It has been established in chapter 3 that Plrs2KO mice represent a reliable 
model with which to study Irs2 null 6 -cell function. Therefore it is now possible 
to investigate the effect that Irs2 deletion has on in vitro  GSIS, glucose 
stimulated calcium influx and modulation of 6 -cell gene transcription in a 
model uncomplicated by obesity, insulin resistance or diabetes: factors that 
alone can alter these important 6 -cell mechanisms and parameters.
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5.2 Analysis o f Plrs2K0 islet B-cell GSIS in vitro  (ex vivo)
Islets isolated from Plrs2KO mice by collagenase digestion of the pancreas, 
were used to measure GSIS in vitro (ex vivo) by static incubation, as seen in 
Fig. 5.1. The cumulative insulin secretion in response to 2 mmol/l or 11 mmol/l 
D-glucose was assayed, and to avoid bias due to islet size and therefore 8 -cell 
number, responses to 1 1  mmol/l glucose were normalised as % of basal 
secretion (response to 2 mmol/l glucose). Both control and Plrs2KO islets 
showed significant increases in insulin secretion in response to 1 1  mmol/l 
glucose. However the fold change over basal secretion from P!rs2KO islets was 
significantly lower than that of control islets. Mean fold changes in secretion 
were 13.98 for control and 1.88 for Plrs2KO islets, and the difference between 
these fold changes was highly significant (t-test: P value = <0.001).
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Figure 5.1: Defective in v itro  GSIS in ex vivo Plrs2KO islets. Accumulated 
insulin secretion over 30 mins from groups of 8 isolated islets in response to 
glucose (concentrations indicated) was measured by ELISA. Islets were isolated 
from at least 2 animals per genotype. Results were normalised as % of basal (2 
mmol/lj secretion. Data shown is mean +/- SEM, with t-test *P = <0.05, **P = 
<0.01, ***P = <0.001 indicated.
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5 .3  in v itro  imaging o f calcium fluxes in ex vivo Plrs2K0 6- 
cells
Live primary 8 -cells dissociated from Plrs2K0 mouse islets were used to 
measure glucose stimulated calcium ion (Ca2+) influx in vitro, by measuring 
fluorescence of intracellular free Ca2+ bound Fluo3am using laser scanning 
confocal microscopy (Fig. 5.2A). In response to 11 mmol/l glucose the Plrs2KO 
B-cells showed significantly impaired Ca2+ influx, with a small initial influx 
which was not sustained. Control cells showed robust and sustained glucose 
stimulated Ca2+ influx. When the glucose concentration was raised to 20 
mmol/l, control B-cells showed no further increase in calcium influx suggesting 
the GSIS triggering mechanism was operating at maximum capacity in response 
to 11 mmol/l glucose. Plrs2KO B-cells however, showed another transient influx 
of Ca2+ in response to 20 mmol/l glucose, which was not sustained but fell away 
to a steady level above basal. In response to tolbutamide and glucose, clear 
Ca2+ influx was observed in the Plrs2KO B-cells, although it was lower than the 
control response. This indicates that the Plrs2KO B-cells possess functional 
KATP and L-type voltage dependent calcium channels (VDCC) which are capable 
of raising the B-cell intracellular free Ca2+ concentration, although the capacity 
of this system appears lower than that of control B-cells.
When single B-cell traces generated from the first round of recordings were 
plotted individually (Fig. 5.2B), it is obvious that control B-cells show a 
heterogenous response to glucose, despite being of identical genotypes (/rs2  
floxed), indicating different levels of responsiveness in the B-cell population. It 
has previously been documented that when forming an intact islet, this 
heterogeneous response is lost as B-cell electrical activity and calcium 
oscillations are coordinated throughout the islet (Gilon and Henquin, 1992; 
Santos et al., 1991).
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Figure 5.2: Defective in v itro  glucose stimulated calcium influx in ex vivo 
Plrs2KO B-cells. Intracellular free calcium in B-cells loaded with Fluo3am 
(Molecular Probes) was measured using a Biorad TE300 inverted confocal 
microscope with heated stage, in response to glucose and tolbutamide. A: Data 
represents at least 4 repetitive experiments imaging at least n = 50 B-cells 
isolated from 2 separate animals per genotype. Data shown is mean +/- SEM. 
B: Single cell traces from 7 cells per genotype from the firs t round of 
recordings. Basal glucose is 2 mmol/l.
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5.4 Gene expression in Plrs2K0 islets
Gene expression of key 6 -cell genes in Plrs2K0 and control islets was measured 
by quantitative RT-PCR of cDNA reverse transcribed from RNA extracted from 
isolated islets. Fig. 5.3 shows the RT-PCR results expressed as % of control.
5.4.1 InsuLin/lgf 1 receptor signalling (IIS)
Mean expression of insulin receptor substrate 1 (irs1) was not significantly 
altered from control values following pancreatic deletion of /rs2 , suggesting 
that Irs1 expression is not compensating for Irs2 deletion, thereby confirming 
the non-redundant role of IRS2 in the 6 -cell.
5.4.2 Glucose sensing
In Plrs2KO islets, expression of Clut2, the principal 6 -cell glucose transporter, 
was highly significantly reduced (mean value 54.25 % of control levels, t-test: 
P=<0.001). The functional implications of this may represent a rate limiting 
defect in the uptake of glucose into the 6 -cell, and will therefore require 
further investigation. Expression levels of glucokinase (Gck), regarded as the 6 - 
cell glucose sensor (De Vos et al., 1995), was unaffected suggesting that the 
phosphorylation of glucose and priming of glycolysis is functional in the Pirs2KO 
6 -cell. 6 oth of these genes have been reported to be transcriptional targets 
downstream of PDX1 (8 rissova et al., 2002).
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5.4.3 B-cell Transcription factors
The IRS2 mediated IIS pathway phosphorylation target Fox01 was significantly 
downregulated at the mRNA level in Plrs2K0 islets (mean value 77.6% of 
controls, t-test: P=<0.01). This suggests that IRS2 is required to maintain 
expression of this important B-cell transcription factor. However, the Fox01 
target gene NeuroD was not downregulated.
The expression of Pdx1 in Plrs2KO islets was found to be normal, which is 
surprising given that the PDX1 target genes insulin and Glut2 (Ahlgren et al., 
1998) are downregulated, and that several independent research groups have 
reported downregulation of Pdx1 in Irs2 null B-cells, albeit from global knock 
out mice (Hennige et al., 2003; Kitamura et al., 2002; Kushner et al., 2002).
The transcription factor and PDX1 transcriptional target gene Nkx6.1 was 
significantly downregulated in Plrs2KO islets (mean value 74.5% of controls, t- 
test: P=<0.05). Loss of NKX6.1 modified gene transcription may potentially 
impair islet neogenesis and maintenance of correct insulin production and GSIS; 
therefore this may represent a critical mechanistic defect responsible for the 
Plrs2KO B-cell phenotype.
5.5 Glut2 immunostaining o f Plrs2KO pancreata
To investigate the production and localisation of GLUT2 in Plrs2KO B-cells 
further, immunocytochemistry was performed on pancreatic sections co­
stained with insulin to identify B-cells (Fig. 5.4). This revealed a qualitative 
reduction in GLUT2 protein, consistent with the mRNA expression data (Fig. 
5.3), but importantly it showed that remaining GLUT2 is still membrane 
localised (Fig. 5.4), suggesting that the transporter is functional.
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Gene transcript
Figure 5.3: Transcription o f key B-cell genes in Plrs2K0 islets. cDNA reverse 
transcribed from isolated islet RNA was used fo r RT-PCR (ABI Taqman) assay. 
Data was normalised using HPRT1 expression. Islets from n=5 animals per 
genotype were used. Data was normalised to HPRT1 expression and presented 
as % of mean control expression levels. Data shown is mean +/- SEM, with t- 
test *P = <0.05, **P = <0.01, ***P = <0.001 indicated.
A) Control GLUT2
50 microns
Figure 5.4: GLUT2 and insulin immunostaining o f Plrs2KO pancreatic 
sections. Confocal images of pancreatic sections stained fo r GLUT2 (green), 
Insulin (red) and nuclear DNA (blue). A/B: GLUT2. C/D: GLUT2/Insulin/DNA 
merged. Images are representative of islets examined from multiple levels 
within 4 independent pancreata.
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5.6 Chapter 5 discussion
Islets isolated from Plrs2KO mice were used to study B-cell function, including 
GSIS, GSCI and gene transcription.
5.6.1 Plrs2KO B-cell insulin secretion
In vitro  GSIS was carried out to investigate how the B-cells secrete insulin. 
Consistent with the in vivo GSIS data, in vitro  GSIS from Plrs2KO islets was 
severely impaired in response to 11 mmol/l glucose. This suggests that there is 
a secretory defect within the islet B-cells, and that although Plrs2KO B-cells 
are capable of raising GSIS significantly above basal, it is still severely impaired 
compared to controls. Investigation into glucose stimulated calcium influx 
(GSCI), as a GSIS triggering mechanism, in individual Plrs2KO B-cells revealed 
that these cells cannot raise and sustain their intracellular free calcium 
concentration to the level observed in control B-cells. However, in response to 
pharmacological KATP channel closure (using tolbutamide) a robust response is 
seen in the Plrs2KO, although sub-optimal compared to controls. This suggests 
that the GSIS triggering signal in the Plrs2KO B-cell is defective upstream of the 
KATP channel due to the severely impaired GSCI, but with potential defects 
downstream of the KATP channel due to the modestly impaired tolbutamide 
enhanced GSCI.
Clearly this defect in calcium influx will contribute significantly to the severely 
impaired in vitro  and in vivo GSIS observed in the Plrs2KO mouse. It has been 
previously demonstrated that IRS1 is involved in the regulation of B-cell 
calcium flux: Irs1 deletion caused impaired GSCI (Borge and Wolf, 2003; 
Kulkarni et al., 2004) and Irs1 overexpression increased intracellular free Ca2+ 
levels following GSCI (Borge and Wolf, 2003; Kulkarni et al., 2004). Therefore a 
similar role for IRS2 in regulating B-cell calcium flux would explain the Plrs2KO 
GSCI data, and this aspect is discussed further in chapter 8 .
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5.6.2 Gene expression in Plrs2K0  B-cells
B-cell function is ultimately controlled by gene transcription, and part of the 
mechanism by which IRS2 mediated IIS exerts its effects on B-cells is to 
modulate the activity of transcription factors and therefore alter gene 
transcription (as discussed in the introductory chapter). The Plrs2KO gene 
expression data shows the expression level of a panel of genes that play a role 
in B-cell function. Of particular interest was the finding that Pdx1 expression is 
unaltered, and that both FoxOI and Nkx6.1 were significantly down regulated 
following pancreatic Irs2 deletion. Pdx1 has been reported to be down 
regulated in B-cells of global Irs2 KO models (Hennige et al., 2003; Kitamura et 
al., 2002; Kushner et al., 2002). Yet in the Plrs2KO mouse, a model 
uncomplicated by severe and progressive diabetes, Pdxl expression is 
unaltered. FoxOI is a phophorylation target of the IRS2 mediated IIS pathway. 
Its subsequent down regulation is interesting, and the potential implications of 
this are discussed in chapter 8 . NKX6.1 is a transcription factor which has been 
shown to be critical in sustaining B-cell identity: principally B-cell/islet 
neogenesis during development (Sander et al., 2000) and insulin production and 
correct GSIS in primary and transformed murine B-cells (Schisler et al., 2005). 
Therefore, downregulation of Nkx6.1 may be a cause of B-cell failure in Plrs2KO 
mice, due to loss of B-cell function.
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5.6.3 Glucose sensing in Plrs2KO B-cells
Glucose sensing in the B-cell is critical for correct GSIS. Entry of glucose into 
wild type B-cells via GLUT2 is non-rate limiting, with the subsequent
phosphorylation by glucokinase regarded as the rate limiting step in glucose 
sensing (De Vos et al., 1995). In Plrs2KO B-cells, Glut2 is downregulated both at 
the mRNA and protein level, suggesting a potential reduction in the ability of B- 
cells to maintain non rate limiting glucose transport. However,
immunocytochemistry has shown that the remaining GLUT2 is still membrane 
localised, and therefore would be expected to be capable of facilitating the 
uptake of glucose into the Plrs2KO B-cell.
5.6.4 Summary
The work described in this chapter has established that the impaired in vivo 
GSIS of the Plrs2KO mouse is due not only to reduced insulin content and 
reduced B-cell mass (as presented in chapter 4), but also to severely impaired 
islet GSIS. This secretory defect is due, at least in part, to impaired
intracellular free Ca2+ elevation in response to glucose. It has also been shown
that the loss of B-cell mass and B-cell GSIS may be attributable in part to the 
reduced expression of the B-cell transcription factor NKX6.1.
127
Chapter 6: Metabolic phenotyping of the BVhlKO  
and PVhlKO  mouse.
6 .1 1ntroduction
The transcription factor HIF mediates the adaptive transcriptional response to 
hypoxia. Under normoxic conditions the oxygen sensitive labile HIFa subunit is 
destroyed by hydroxylation, polyubiquitylation by the VHL ubiquitin ligase 
complex and subsequent proteosomal degradation. During hypoxia however, 
hydroxylation is reduced due to the lack of molecular oxygen from which the 
hydroxyl group is derived, and therefore HIFa is stable and free to form a 
transcriptionally active heterodimer (HIF) with a constitutively stable HIF6  
binding partner. Many of the genes activated by HIF are involved in the control 
of cellular metabolism, growth, proliferation, apoptosis and growth factor 
signalling. HIFB has been implicated in sustaining normal B-cell function 
(Gunton et al., 2005) and HIFa activation in transplanted islets correlates with 
increased B-cell apoptosis (Miao et al., 2006; Moritz et al., 2002).
Therefore to investigate the effect of HIFa stabilisation and HIF activation in 
the B-cell, Vhl was deleted in the B-cell and pancreas using the cre/loxP 
system with ere expression under the control of the rat insulin 2  promoter 
(BVhlKO) or Pdx1 promotor (PVhlKO). As discussed in the introduction (chapter 
1), deletion of Vhl should result in HIFa stabilisation, as without VHL meditated 
polyubiquitylation HIFa cannot be degraded by the proteosome. The data 
presented in this chapter reports the characterisation of the BVhlKO and 
PVhlKO mice as a model of B-cell HIF1a activation, and the investigation of the 
glucose homeostasis and metabolic phenotype of these mice.
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6.2 Analysis of Vhl deletion and H ifla  stabilisation
6.2.1 Vhl gene deletion
To confirm deletion of the Vhl gene in BVhlKO and PVhlKO mice, PCR analysis 
was performed across the remaining loxP site following recombination and 
therefore deletion. This analysis revealed a deletion band present when using 
DNA extracted from islets isolated from both the BVhlKO and PVhlKO mice, 
indicating recombination of the loxP sites and deletion of exon 1 of the Vhl 
gene (Vhl deletion), shown in Fig. 6.1 A. No Vhl deletion was found in brain 
(without hypothalamus) DNA from either model, whereas Vhl deletion was 
found in hypothalamic DNA from BVhlKO mice, but not from PVhlKO mice (Fig.
6.1 A). This tissue deletion profile agrees with what was predicted from 
literature describing the activity of the RIPcre transgene (Choudhury et al.,
2005) and concurs with the pattern of deletion found in the Plrs2KO mouse also 
using PDXcre (chapter 3, Fig. 3.1 A).
6.2.2 HIF1a stabilisation
To confirm that 8 -cell and pancreatic Vhl deletion resulted in stabilisation of 
HIF1a, immunocytochemistry was performed to stain for HIF1a in pancreatic 
sections (HIF1 a staining was performed by Dr. Frauke Forstreuter and Deepa 
Shukla at the Renal Unit of Imperial College London). Clear upregulation of 
HIF1a staining was observed in nuclei of BVhlKO islets (Fig. 6.1D) compared to 
controls (Fig. 6.1B), whereas upregulation of HIF1a staining was observed in 
nuclei of both the islets and exocrine tissue of the PVhlKO pancreatic sections 
(Fig. 6.1E) when compared to controls (Fig. 6 .1C). The presence of HIF1a in the 
nuclei of these islet cells show that stable HIF1a has translocated to the 
nucleus and therefore is likely to be bound to a contitutively stable HIF1B 
binding partner to form active HIF.
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Lane: Tissue: Lane: Tissue:
1 Vhl null cell line DNA 6 KO islet DNA
2 Vhl control cell line DNA 7 Control brain DNA
3 Wild type mouse genomic tail DNA 8 KO brain DNA
4 No DNA 9 Control Hypothalamic DNA
5 Control islet DNA 10 KO Hypothalamic DNA
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Figure 6.1: Confirmation o f Vhl gene deletion and HIF 1a activation.
A: Confirmation of Vhl deletion by PCR amplification across the Vhl gene exon
1. Lanes 1-4 are control reactions. Lanes 5-10 are analytical reactions using
genomic DNA extracted from tissues of either BVhlKO/control or
PVhlKO/control mice. B-E: T Pancreatic sections stained fo r HIF1a (brown) and
counterstained with haematoxylin (blue). HIF1a upregulation in BVhlKO islets
(D), PVhlKO islets and exocrine tissue (E), respective controls are shown (A
and B). Images are representative of islets examined from multiple levels
within 4 independent pancreata per genotype. Scale bars are 50 microns.
THIF1a staining was performed by Dr. Frauke Forstreuter and Deepa Shukla at 
the Renal Unit of Imperial College London.
6 .3  Assessment o f body mass and insulin sensitiv ity
To characterise the basic growth and metabolic state of the BVhlKO and 
PVhlKO mice, body mass was measured at 12 weeks, and insulin tolerance tests 
(ITT) performed.
BVhlKO mice were proportionately dwarfed with a mean 12 week old body mass 
55 % of control animals (12.21 g vs 22.21 g, t-test P = <0.001) as shown in Fig. 
6.2A. PVhlKO mice however showed normal body mass, unaltered from control 
mice (Fig. 6.2B), suggesting that the growth abnormality seen in the BVhlKO 
model is due to the hypothalamic Vhl deletion and not B-cell Vhl 
deletion/HIF1a activation. This was investigated further and found to be due to 
a defective growth hormone/insulin-like growth factor 1 axis, as presented 
later in this chapter.
Insulin sensitivity was found to be improved in these mouse models. BVhlKO 
mice showed significantly decreased blood glucose levels at every time point 
following intraperitoneal injection of insulin (Fig. 6.2C), suggesting increased 
glucose clearance from the blood stream by insulin target tissues and therefore 
increased insulin sensitivity. ITTs performed on BVhlKO mice required an insulin 
dose 50 % of that normally used to prevent hypoglycaemic coma, indicating 
increased insulin sensitivity in these animals. PVhlKO mice also showed 
increased insulin sensitivity (Fig. 6 .2D), although this was not as pronounced as 
that seen in the BVhlKO mouse, and insulin induced decrease in blood glucose 
was only significant at the 30 min and 120 min time points. This may be due to 
increased insulin sensitivity, decreased insulin clearance or impaired glucagon 
secretion caused by Vhl deletion in a-cells. PVhlKO mice were able to tolerate 
the normal dose of insulin.
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Figure 6.2: Body mass and insulin tolerance o f PVhlKO and BVhlKO mice.
Body mass measurements o f 12 week old male mice revealed significant 
dwarving of BVhlKO (n=19) vs control (n=26) mice (A), whereas PVhlKO (n=17) 
mice were of normal body mass compared to controls (n=12) (B). Insulin was 
injected IP into 12 week old male BVhlKO (0.37 units/kg) or PVhlKO (0.75 
units/kg) mice, and blood glucose measurements of ta il vein bleeds were made 
before and after injection. This revealed improved insulin sensitivity in the 
BVhlKO (n=9) vs control (n=8) mice (C) and a slight but significant 
improvement in PVhlKO (n=7) vs control (n=5) insulin sensitivity (D). Data 
shown is mean +/- SEM, with t-test *P = <0.05, **P = <0.01, ***P = <0.001 
indicated.
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6 A  D w a rf phenotype o f BVhlKO mice
It has previously been established that the RIPcre transgene (used to generated 
the BVhlKO mouse) is expressed in the hypothalamus, albeit in an 
uncharacterised neuronal population, referred to as RIPcre neurons (Choudhury 
et al., 2005). The normal size and body mass observed in the PVhlKO mice 
suggests that the dwarfing seen in the BVhlKO (Fig. 6.2A, Fig. 6.3A) is due to 
Vhl deletion in the RIPcre neurons.
To investigate this, pituitary glands from BVhlKO and control mice were 
assayed for growth hormone content (by Dr. Melanie Clements at the Division 
of Molecular Neuroendocrinology, NIMR), which revealed a highly significant 
growth hormone deficiency in the BVhlKO pituitary, an order of magnitude 
below that of control mice (Fig. 6.3B). Subsequent assay of fasting blood 
plasma (by Dr. Melanie Clements at the Division of Molecular 
Neuroendocrinology, NIMR) revealed that as well as being severely growth 
hormone deficient, BVhlKO mice have significantly reduced circulating insulin­
like growth factor 1 (IGF1) levels (Fig. 6.3C). This impairment of IGF1 levels is 
likely to be a direct consequence of growth hormone deficiency, as circulating 
IGF1 is released from the liver in response to growth hormone stimulation. 
Growth hormone receptor KO mice show increased insulin sensitivity (Liu et al., 
2004). Therefore, this defect in the growth hormone/IGF1 axis explains both 
the dwarf phenotype and increased insulin sensitivity of the BVhlKO model. 
This model suggests that Vhl deletion in the hypothalamus impairs the 
expression of growth hormone in the pituitary.
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Figure 6.3: BVhlKO mouse dwarfism is due to severe p itu ita ry  growth 
hormone deficiency. A: Photograph of a typical 12 week old BVhlKO male 
mouse and its litte r mate control. B: Pituitary glands were isolated from 12 
week old male BVhlKO mice after morning lights on and growth hormone 
content measured by radioimmuno assayT. C/D: Circulating plasma IGF1 levels 
were measured in 6 week (C) and 12 week (D) old male animals by R!Ar of 
fasted blood plasma obtained by cardiac puncture. n=9 mice of each genotype 
per assay. Data shown is mean +/- SEM, with t-test *P = <0.05, **P = <0.01, ***P 
= <0.001 indicated.
T Growth hormone and IGF1 assays were performed by Dr. Melanie Clements 
at the Division of Molecular Neuroendocrinology, National Institute fo r 
Medical Research, M ill Hill, London.
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6 .5  Assessment o f  glucose homeostasis
To assess the function of 6 -cell insulin secretion and the clearance of glucose 
by peripheral insulin target tissues, fasted and fed blood glucose measurements 
and glucose tolerance tests were performed. During the course of studying the 
BVhlKO mice, it was found that after a 16 hour fast they became severely 
hypoglycaemic and lethargic, requiring immediate administration of glucose 
and re-feeding. This is due to the increased insulin sensitivity of these animals, 
likely caused by the downregulated growth hormone and IGF1 levels present, as 
presented in the previous section. In this hypoglycaemic state it is not possible 
to take a blood sample as it would be stressful for the animal and against UK 
home office animal care regulations. Therefore, for experiments requiring a 
fasted state, such as glucose tolerance testing and measurement of fasted 
blood insulin, BVhlKO mice were only fasted for 6  hours to avoid 
hypoglycaemia. For simple measurement of fasted blood glucose levels, BVhlKO 
mice were fasted for 12 hours. PVhlKO mice were found to be indistinguishable 
from controls after a 16 hour fast and therefore were studied after this length 
of fast.
6.5.1 Fasted blood glucose
Fasted blood glucose levels were significantly decreased in BVhlKO mice 
compared to controls (Fig. 6.4A) after a 12 hour fast. Fasting blood glucose 
levels in the PVhlKO were not significantly altered from controls (Fig. 6.4B) 
after a 16 hour fast. This suggests that the fasting hypoglycaemia seen in the 
BVhlKO mice is likely to be a product of the increased insulin sensitivity of 
these mice due to the hypothalamic Vhl deletion, which is not present in the 
PVhlKO model.
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6.5.2 Fed blood glucose
Random fed blood glucose levels were found to be significantly elevated in 
both the BVhlKO and PVhlKO mice when compared to their respective controls 
(Fig. 6.4C and D).
6.5.3 Glucose tolerance testing
Both BVhlKO and PVhlKO mice showed significantly elevated blood glucose 
levels following glucose injection (Fig. 6.4E and F). These data confirmed that 
B-cell Vhl deletion/HIF1a activation results in glucose intolerance. As these 
mice were not insulin resistant, this glucose intolerance indicates impaired 
insulin secretion.
6.6 Assay o f c ircu la ting  insulin levels
6.6.1 Fasted blood plasma insulin levels
After a 6  hour fast, BVhlKO mice had significantly reduced circulating insulin 
levels compared to littermate controls (Fig. 6.5A). However, PVhlKO mice after 
a 16 hour fast had insulin levels comparable to controls (Fig. 6.5B) 
demonstrating that B-cell Vhl deletion/HIF1a activation does not alter basal 
insulin secretion, and that the reduced fasting insulin levels in the BVhlKO are 
likely to be a facet of the hypothalamic phenotype and increased insulin 
sensitivity.
6.6.2 Fed blood plasma insulin levels
Random fed blood plasma insulin levels measured after feeding showed that 
both BVhlKO and PVhlKO mice have significantly deficient circulating insulin 
levels when compared to controls (Fig. 6.5C and D respectively). This suggested 
that the glucose intolerance seen in these animals is due to insufficient 
secretion of insulin during the fed state.
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Figure 6.4: Glucose homeostasis in PVhlKO and BVhlKO mice. A and B:
Fasted blood glucose levels measured via ta il bleeds following a 12 hour fast 
(BVhlKO, A) or 16 hour fast (PVhlKO, B). C and D: Fed blood glucose levels. E 
and F: Glucose tolerance tests with blood glucose levels measured before and 
after intra peritoneal injection of glucose (2 g/kg). Male mice studied at 12 
weeks: BVhlKO (n=14) vs. control (n=18), PVhlKO (n=17) vs. control (n=12). 
Data shown is mean +/- SEM, with t-test *P = <0.05, **P = <0.01, ***P = <0.001 
indicated.
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Figure 6.5: C irculating plasma insulin levels in fasted and random fed  
BVhlKO and PVhlKO mice. Insulin content of blood plasma obtained via ta il 
bleeds or cardiac puncture from 12 week old male mice was measured by 
ELISA. A: 12 hour fasted BVhlKO (n=6) vs control (n=8). B: 16 hour fasted 
PVhlKO (n=10) vs control (n=5). C: Random fed BVhlKO (n=6) vs control (n=5). 
D: Random fed PVhlKO (n=8) vs control (n=15). Both fed BVhlKO and PVhlKO 
mice showed impaired insulin secretion in response to feeding. Data shown is 
mean +/- SEM, with t-test *P = <0.05, **P = <0.01, ***P = <0.001 indicated.
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6 .7  Analysis o f  is le t structure
To analyse the cellular organisation and anatomy of islets in BVhlKO and 
PVhlKO mice, immunocytochemistry was performed on pancreatic sections to 
stain 6 -cells for insulin and a-cells for glucagon. This revealed normal islet 
organisation in PVhlKO islets (Fig. 6.7), and control islets for both models (Fig. 
6 . 6  and 6.7), with a-cells predominantly forming a mantle around the outside 
of a B-cell core. However, in BVhlKO pancreatic sections the normal islet 
anatomical organisation was largely preserved but with some a-cells scattered 
throughout the islet core (Fig. 6 .6 ).
6 .8  M orphom etric q uan tifica tio n  o f 8-cell mass
To assess the 6 -cell mass of BVhlKO and PVhlKO mice, quantification of 
pancreatic sections stained for insulin was performed. This revealed that in the 
BVhlKO mouse the 6 -cell mass was significantly reduced compared to controls 
(Fig. 6 .8 A), but when normalised for body mass it was not found to be altered 
(Fig. 6 .8 C), indicating that the reduced 6 -cell mass was proportionally normal 
for the dwarfed phenotype. The 6 -cell mass and 6 -cell mass/body mass 
parameters did not show significant deviation from control animals in PVhlKO 
mice (Fig. 6 .8 B and D). Pancreatic mass was significantly reduced in the 
BVhlKO mice (Fig. 6 .8 E) due to the dwarf phenotype. Pancreatic mass was 
unaltered in PVhlKO mice (Fig. 6 .8 F). This indicated that 6 -cell Vhl 
deletion/HIF1a activation does not alter the regulation of B-cell mass required 
to support the given body mass of an animal.
139
Insulin
Glucagon
BVhlKO
Glucagon
Insulin
Glucagon
Figure 6.6: Insulin and glucagon 
immunostaining o f BVhlKO pancreatic 
sections. Pancreatic sections stained 
fo r insulin (red), glucagon (green) and 
nuclear DNA (blue). Images were taken 
using a con focal microscope with a 40x 
lens and are representative of islets 
examined from multiple levels within 4 
independent pancreata. Altered a-cell 
organisation can be seen in the BVhlKO 
islets.
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Figure 6.7: Insulin and glucagon 
immunostaining o f PVhlKO pancreatic 
sections. Pancreatic sections stained 
fo r insulin (red), glucagon (green) and 
nuclear DNA (blue). Images were taken 
using a confocal microscope with a 40x 
lens and are representative o f islets 
examined from multiple levels within 4 
independent pancreata.
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Figure 6.8: Morphometric analysis o f BVhlKO and PVhlKO B-cell mass. 
Insulin stained pancreatic sections were photographed using a fluorescent 
microscope and 10x lens, and the respective parameters shown were 
calculated using simple PCI software. A and B: B-cell mass. C and D: B-cell 
mass/body mass. E and F: Pancreatic mass. A/C/E: BVhlKO. BID/F: PVhlKO. 
Female mice studied at 12 weeks: BVhlKO and controls (n=4), PVhlKO and 
controls (n=3). Data shown is mean +/- SEM, with t-test *P = <0.05, **P = <0.01, 
***P = <0.001 indicated.
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6.9 No evidence o f p an creatic  tumour developm ent
VHL acts as a tumour suppressor in many tissues and inactivation of VHL leads 
to the formation of vascular tumours due to HIFa stabilisation in renal cells 
(Maxwell et al., 1999) amongst others. Therefore, as one of the classic VHL 
tumours consists of a non-secreting islet cell type (Woodward and Maher,
2006), it was predicted that B-cell or pancreatic deletion of Vhl may result in 
the formation of islet/pancreatic tumours. However, apart from finding no 
alteration in B-cell mass in these models, no macroscopic evidence of tumour 
formation was observed. During the course of the experiments presented in this 
chapter and chapter 7, over 200 BVhlKO mice and 100 PVhlKO mice were killed 
at 1 2  weeks of age for either pancreatic histology or islet isolation, both 
techniques that required careful inspection and removal of the pancreas. 
Therefore if B-cell/pancreatic Vhl deletion/HIF1a activation were to 
predispose these mice to tumour formation, this would have been recorded 
given the high numbers of mice studied. Moreover, it can be concluded that if 
these mice do form pancreatic/islet cell tumours, the incidence must be less 
than 0.5% in BVhlKO and 1% in PVhlKO mice bred on a mixed C57BL6/Sv129 
genetic background. A further microscopic histological examination was made 
of 12 control and 12 BVhlKO pancreata removed from 12 month old animals, by 
Dr. Frauke Forstreuter and Prof. Patrick Maxwell at the Renal Unit, Imperial 
College London. This laboratory specialises in tumour biology and found no 
evidence of tumour formation in the pancreata studied. Therefore BVhlKO and 
PVhlKO mice are not complicated by tumour development and represent good 
models in which to study Vhl null/HIF1a active B-cell function.
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6 .1 0  C hapter 6 discussion
The BVhlKO mouse displayed a complicated dwarf phenotype characterised by 
reduced body size, increased insulin sensitivity, glucose intolerance, 
insufficient insulin secretion and a minor alteration in islet cellular 
organisation. The PVhlKO mouse however was of normal body mass, and 
showed slightly increased insulin sensitivity, glucose intolerance and 
insufficient insulin secretion.
6.10.1 Vhl deletion
The data presented in this chapter has established that Vhl deletion in the 6 - 
cell or pancreas results in the upregulation and nuclear aggregation of HIF1a, 
indicating activation of HIF in 6 -cells or pancreatic cells respectively. This is in 
agreement with previous studies of Vhl deletion in other tissues such as 
hepatocytes (Haase et al., 2001; Rankin et al., 2005) and in line with the 
general consensus that VHL associated ubiquitin ligase activity is responsible 
for mediating HIFa destruction and inactivation.
6.10.2 Metabolism
The finding of significantly improved insulin sensitivity in the BVhlKO, which 
was not reproduced to the same degree in the PVhlKO, suggests that this is a 
facet of hypothalamic RIPcre neuronal deletion of Vhl and, potentially, HIF 
activation. The finding of severely perturbed growth hormone levels in the 
dwarfed BVhlKO mice, provide an explanation for this increased insulin 
sensitivity. Growth hormone receptor null mice show, aside from similar 
dwarfism to the BVhlKO mouse (ie. 50% of control size) and decreased IGF1 
levels, an increase in insulin sensitivity with glucose and insulin levels 
significantly decreased from controls (Liu et al., 2004). This increased insulin 
sensitivity is also likely to explain the hypoglycaemic state of the BVhlKO mice
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after a 16 hour fast, and significantly reduced blood glucose (Fig. 6.3A) and 
insulin levels (Fig. 6.4A) after 12 hour and 6  hour fasts respectively. This 
concept is further supported by the normal 16 hour fasted PVhlKO blood 
glucose (Fig. 6.3B) and insulin levels (Fig. 6.4B), in a mouse model with B-cell 
Vhl deletion/HIFa activation, but crucially without the hypothalamic RIPcre 
neuronal deletion.
6.10.3 Islet architecture in the BVhlKO mouse
The finding of modestly altered islet architecture in the BVhlKO mouse is 
interesting as it is not present in the PVhlKO mouse. This suggests that it is 
either a product of reduced growth hormone and IGF1 levels acting on the B- 
cell, or due to a disruption of intra islet paracrine signalling as a result of HIF1a 
being active in the B-cells and not a-cells. Altered islet architecture similar to 
that seen in the BVhlKO mouse has been reported in mice heterozygous for the 
MODY genes H nfla  and Hnf3B when deleted on a Pdx1 global heterozygote null 
background (Shih et al., 2002). Another study reported loss of islet architecture 
when a dominant negative form of Hnfla  was expressed specifically in mouse 
B-cells. Therefore expression of the MODY genes in BVhlKO islets were assayed 
and results examined in chapter 7.
6.10.4 B-cell mass
Suprisingly B-cell mass, when normalised for body weight, was unaltered in 
both the BVhlKO or PVhlKO models when compared to respective controls. As 
HIF1a activity is associated with apoptosis in transplanted islets (Miao et al., 
2006; Moritz et al., 2002), it was expected that HIF1a activation in normoxic B- 
cells of BVhlKO or PVhlKO mice may alter B-cell mass. However it is possible to 
conclude from the BVhlKO and PVhlKO models that Vhl deletion/HIF1a 
upregulation in B-cells does not alter B-cell mass in relation to body mass.
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6.10.5 Summary
The data presented in this chapter has demonstrated glucose intolerance and 
circulating insulin deficiency after feeding in both models studied. Although 
complicated by an altered growth hormone/IGF1 axis, the BVhlKO glucose 
intolerance and impaired fed insulin levels have been reproduced in the PVhlKO 
model which does not have hypothalamic deletion of Vhl or fasting 
hypoglycaemia. Both models showed no evidence of tumour formation that may 
have complicated the study of metabolism and B-cell function. As B-cell mass is 
normal in both of the models studied, this suggests that the glucose intolerance 
and fed insulin deficiency observed is likely due to impaired glucose stimulated 
insulin secretion from the B-cell; this is investigated in chapter 7.
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Chapter 7: Investigation of insulin secretion in 
BVhlKO and PVhlKO mice
7 .1 1ntroduction
The data presented in chapter 6  demonstrated that BVhlKO and PVhlKO mice 
are glucose intolerant due to insufficient insulin levels when fed. The normal 6 - 
cell mass in these models suggested that the reduced insulin levels may be due 
to impaired glucose stimulated insulin secretion (GSIS) from the B-cell. To 
investigate this further, GSIS and the GSIS mechanism was studied in islets and 
B-cells isolated from BVhlKO and PVhlKO mice and the data presented in this 
chapter.
7.2 In v itro  insulin secretion
GSIS was assessed in islets isolated from BVhlKO and PVhlKO animals. Perifusion 
apparatus was used to monitor dynamic secretion from BVhlKO islets at 2 min 
intervals. GSIS was then tested in PVhlKO islets by static incubation to see if 
the GSIS from BVhlKO islets is replicated in the PVhlKO model, using this 
technically less demanding technique. Results were normalised as % of basal to 
correct for variations in islet size.
BVhlKO islets showed only showed a 3 fold increase in GSIS over basal levels in 
response to 2 0  mmol/l glucose, a response which was significantly impaired 
compared to the 16 fold increase in secretion from control islets (ANOVA 
P=<0.001) as shown in Fig. 7.1 A. The phorbol ester PMA (phorbol myristate 
acetate) was used to potentiate insulin secretion by activating DAG sensitive 
protein kinase C. BVhlKO islets showed a significantly reduced response to PMA 
(43 fold over basal) when compared to control islets (142 fold over basal, 
ANOVA P = <0.001) as shown in Fig. 7.1B. PMA potentiates GSIS by promoting
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insulin vesicle exocytosis, therefore these data suggest that insulin vesicle 
exocytosis is functional in BVhlKO 8 -cells.
PVhlKO islets did not show a significant increase in insulin secretion over basal 
levels in response to 20 mmol/l glucose. In contrast, control islets showed a 
significant increase in insulin secretion over basal levels (Fig. 7.1C). This 
confirms that Vhl deletion/HIF1a activation in 6 -cells and the pancreas impairs 
in vitro GSIS.
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Figure 7.1: In v itro  islet GSIS. A and B: BVhlKO islet GSIS assessed using 
perifusion apparatus, n * 4 groups of 40 islets were used per genotype. A: GSIS 
in response to 20 mmol/l D-glucose. B: GSIS in response to 20 mmol/l D-glucose 
and 500 nmol/1 PMA (phorbol myristate acetate). C: PVhlKO islet GSIS in 
response to 20 mmol/l D-glucose, assessed by static incubation, n = 10 groups 
of 10 islets were used per genotype. Islets were isolated from at least 2 
animals per genotype. Insulin was assayed by RIAT fo r perifusion, or ELISA fo r 
statics. Data shown is mean +/- SEM, with t-test **P = <0.01 indicated.
rThe radioimmunoassay (RIA) was performed by Dr. Henry Asare-Anane at 
King’s College London 1 4 9
7 .3  B-cell glucose m etabolism  (m itochondrial redox im aging)
The redox state of the predominantly mitochondrial pool of hydrogen carriers 
NAD7NADH (pyridine nucleotides) and FAD++/FADH2 (flavoproteins) were 
measured in live 6 -cells by excitation of NADH and FAD++ autofluorescence 
using confocal microscopy. In response to glucose, control 6 -cells showed an 
increase in NADH and decrease in FAD++ autofluorescence indicating increased 
reduction of these nucleotide/flavoprotein hydrogen carriers with the addition 
of hydrogen ions. This indicated increased mitochondrial metabolism associated 
with 6 -cell GSIS (Fig. 7.2A and 6 ). When 6 -cells isolated from BVhlKO or PVhlKO 
animals were studied, there was no change in the NADH or FAD++ 
autofluorescence in response to glucose. This indicated that the 
nucleotide/flavoprotein pool is not being reduced with the addition of 
hydrogen ions, therefore reflecting impaired mitochondrial metabolism in 
response to glucose (Fig. 7.2C and D). The mitochondrial uncoupler FCCP was 
used as a control during the redox experiments studying PVhlKO 6 -cells, and 
this revealed viable mitochondria in both control and PVhlKO 6 -cells, with a 
change of NADH and FADH levels to the oxidised state.
These results indicate that mitochondrial glucose metabolism is defective in 
BVhlKO and PVhlKO 6 -cells. Moreover, a key mediator of the GSIS stimulus- 
secretion coupling, reduction of the mitochondrial NAD7FAD++ pool, is impaired 
in BVhlKO and PVhlKO 6 -cells.
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Figure 7.2: Confocal imaging o f mitochondrial redox state in live B-cells. 
Glucose stimulated reduction of the mitochondrial pyridine nucleotide (NAD* 
to NADH) and flavoprotein pool (FAD** to FADH), was measured by 
autofluorescence of NADH and FAD** versus the non-fluorescent NAD* and 
FADH2. A: BVhl control. B: PVhl control. C: BVhlKO. D: PVhlKO. Basal is 2 
mmol/l D-glucose. D-Glucose mM *  mmol/l. Mitochondrial uncoupler FCCP ~ 
IpmolH. Data represents at least 4 repetitive experiments imaging at least n = 
40 B-cells isolated from 2 separate animals per genotype. Data shown is mean 
+/- SEM.
151
7 .4  B-cell in trac e llu la r calcium  imaging
To further investigate the GSIS defect, the GSIS triggering pathway was 
stimulated with glucose, methyl succinate or tolbutamide whilst continuously 
imaging intracellular free calcium ion (Ca2+) levels in live B-cells. Methyl 
succinate is a cell permeable B-cell secretogogue that stimulates mitochondrial 
complex II, thereby bypassing glycolysis (MacDonald and Fahien, 1988; Maechler 
et al., 1997). Tolbutamide closes ATP sensitive potassium channels (KATP) on 
the B-cell membrane depolarising the cell and stimulating Ca2+ influx, thereby 
bypassing glycolysis and mitochondrial metabolism.
Glucose stimulation of BVhlKO B-cells revealed severe impairment of Ca2+ influx 
when compared to control B-cells, as Fura2am bound intracellular Ca2+ levels 
did not rise above basal levels (Fig. 7.3A). When tolbutamide was added to 
close KATP channels and depolarise the B-cells, intracellular free Ca2+ levels 
were elevated in both control and BVhlKO B-cells. This indicated that the cells 
are viable and that the distal components of the GSIS pathway (downstream of 
the KATP channels) are functional (Fig. 7.3A). PVhlKO B-cells were found to be 
equally unresponsive to glucose, whereas their respective controls showed 
elevations of intracellular Ca2+ in response to glucose (Fig. 7.3B). Tolbutamide 
also induced elevated Ca2+ levels in both PVhlKO and control B-cells (Fig. 7.3B).
Methyl succinate was used to stimulate mitochondrial complex II. There was an 
equivalent increase in intracellular free Ca2+ levels in both BVhlKO (Fig. 7.3C) 
and PVhlKO (Fig. 7.3D) B-cells, which appeared unaltered from control cells. 
Tolbutamide induced Ca2+ responses in BVhlKO and PVhlKO B-cells from both 
experiments were unaltered from controls, which indicated viable B-cells with 
functional distal secretory mechanisms downstream of the KATP channels.
152
In summary, the calcium imaging data show that glucose stimulated Ca2+ influx 
is severely impaired in BVhlKO and PVhlKO B-cells, yet stimulation of 
mitochondrial complex II evoked comparably normal increases in intracellular 
free Ca2+ levels in these B-cells. Therefore it is likely that the defect causing 
impaired mitochondrial metabolism, Ca2+ influx and insulin secretion, is 
upstream of the mitochondrial component of the GSIS triggering pathway.
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Figure. 7.3: In v itro  intracellu lar free calcium imaging. Calcium (Ca2*) influx 
into B-cells loaded with Furolam was measured using an inverted fluorescent 
microscope with cooled CCD camera. Intensity of light emitted at 510 nm in 
response to alternate excitation of Fura2am at 340 nm (Ca2* bound) and 380 
nm (Ca2* unbound), was expressed as a ratio of 340/380. A and B: BVhlKO (A) 
and PVhlKO (B) B-cells stimulated with D-glucose (at indicated concentrations) 
followed by tolbutamide (200 pm ol/l) to close KATP channels and depolarise B- 
cells. C and D: BVhlKO (C) and PVhlKO (D) B-cells stimulated with methyl- 
succinate (10 mmol/l) to stimulate mitochondrial complex II, followed by 
tolbutamide (200 pmol/l). Data represents at least 4 repetitive experiments 
imaging at least n = 40 B-cells isolated from 2 separate animals per genotype. 
Data shown is mean +/- SEM. Basal glucose is 2 mmol/l. D-Glucose mM = 
mmol/l.
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7.5 B-cell glucose uptake
To investigate the defective supply of glucose derivatives to mitochondrial 
metabolism in BVhlKO and PVhlKO 8 -cells, glucose uptake was assesssed by 
imaging uptake of the fluorescent glucose analogue 2-NBDG into live 8 -cells 
using confocal microscopy. Following addition of 18 nmol/l 2-NBDG there is an 
influx of the analogue into the 8 -cell which gradually equilibrates to a steady 
state; this represents the point of equilibrium where fluorescence of 2-NBDG in 
the 6 -cell was no longer increasing; indicating that the rate of glucose uptake 
had sufficiently levelled off to reach equilibrium. 2-NBDG fluorescence was 
measured in arbitrary fluorescent units. The total steady state levels of 2-NBDG 
in B-cells was expressed as % of mean control cell fluorescence. The rate of 
uptake of 2-NBDG is expressed as a % of the mean time control B-cells took to 
reach total steady state levels.
In the BVhlKO B-cells, both the rate of uptake (Fig. 7.4C) and total steady state 
levels of 2-NBDG (Fig. 7.4E) were significantly reduced from those measured in 
control B-cells. When multiple additions of 2-NBDG were made to the cell 
imaging media, and cell recordings plotted as a mean trace, repeated fluxes 
could be seen in the control B-cells, with a sigmoidal shape in the trace 
following each addition of the analogue representing rapid influx, quickly 
reaching equilibrium across the cell membrane (Fig. 7.4A). The BVhlKO B-cells 
however, showed a slow uptake of 2-NBDG, with no alteration in the rate of 
uptake after second or third additions of 2-NBDG, suggesting that the 
mechanisms transporting glucose into the B-cell were operating at maximum 
capacity and taking longer to reach equilibrium (Fig. 7.4A). PVhlKO B-cells also 
showed a significantly decreased rate of uptake (Fig. 7.4D) and total steady 
state (Fig. 7.4F) levels of 2-NBDG. Therefore, as the total steady state 
fluorescence of 2-NBDG in the BVhlKO and PVhlKO B-cells was approximately 
half of control cells, this indicates a lower rate constant for the transport of 
glucose into these B-cells.
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Figure 7.4: Uptake o f the fluorescent glucose analogue 2-NBDG into live B- 
cells. 2-NBDG added in 18 nmol/l increments to medium containing 0.25 
mmol/l D-glucose, and fluorescence quantified as arbitrary fluorescent units 
using a confocal microscope. A: BVhlKO real time uptake trace. B: Total steady 
state 2-NBDG in BVhlKO B-cells. C and D: rate of 2-NBDG uptake. E and F: 
total steady state 2-NBDG. Data represents at least 4 repetitive experiments 
imaging at least n = 40 B-cells isolated from 2 separate animals per genotype. 
Data shown is mean +/- SEM. Significance by t-test is indicated as *P = <0.05, 
**P= <0.01.
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7.6 B-cell gene expression
Glucose sensing by the BVhlKO and PVhlKO 6 -cells is clearly defective as 
demonstrated by the impaired uptake of 2-NBDG (Fig. 7.4). Therefore to 
investigate this GSIS defect further, and to profile key 6 -cell genes that may be 
involved in the BVhlKO and PVhlKO mouse phenotypes, real time polymerase 
chain reaction (RT-PCR) of cDNA reverse transcribed from mRNA extracted from 
isolated islets was performed, and results presented as percentage of control 
levels in Fig. 7.5.
7.6.1 Expression of B-cell glucose sensing genes
The RT-PCR data revealed a marked alteration in gene expression of the 
facilitative glucose transporters G lutl and Glut2 in BVhlKO and PVhlKO 6 -cells 
(Fig. 7.5A and C). In control islets G lutl levels were very low with a ratio to 
HPRT of 0.2 (+/- 0.0198 SEM), compared to 9.2 (+/- 0.867 SEM) for Glut2. 
However, with Vhl deletion and HIF1a activation in BVhlKO and PVhlKO islets, 
Glut2 expression was significantly decreased, whereas G lutl expression was 
increased highly significantly over control levels by 4.9 fold (+/- 0.375 SEM) in 
BVhlKO islets and 3.6 fold (+/- 0.283 SEM) in PVhlKO islets. This change in 
expression of glucose transporter type in BVhlKO and PVhlKO islets is likely to 
play a role in the defective glucose uptake into these 6 -cells observed in the 2 - 
NBDG experiments above (Fig. 7.4). The different affinities for glucose and 
transport characteristics reported for each of these glucose transporters may 
provide an explanation for the altered 2-NBDG uptake. GLUT2 has a Km (17 
mmol/l) and rodent 6 -cell Vmax (32 mmol/l/min; (Johnson et al., 1990) above 
physiological glucose concentrations, whereas GLUT1 has a Km (2.3-2. 6  mmol/l) 
and human 6 -cell Vmax (3 mmol/l/min; De Vos et al., 1995; Woodrow et al., 
2000) at the lower end of physiological glucose concentrations. Therefore, this 
suggests that at physiological glucose concentrations GLUT2 is unlikely to be
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rate limiting whereas GLUT1 would be expected to be operating at maximum 
capacity and therefore potentially limiting the rate of glucose transport.
Islet expression levels of glucokinase (the 8 -cell hexokinase) was significantly 
reduced in BVhlKO islets to 80.65% (+/- 6.27 SEM, t-test; P=<0.05) of control 
levels (Fig. 7.5A), which may represent a further rate limiting defect in the 
priming of glycolysis. However, although expression of glucokinase in PVhlKO 
islets was decreased to 80.86% of controls (+/- 6.037 SEM), a similar quantity to 
that of BVhlKO islets, it was not significant.
7.6.2 Expression of islet hormones
In islets isolated from the BVhlKO mouse, expression levels of insulin were 
significantly decreased where as levels of glucagon significantly increased 
(Fig.7.5A). In the PVhlKO mouse insulin and glucagon mRNA levels were 
unaltered from control islet mRNA (Fig. 7.5C). This suggests that the 
alterations seen in the BVhlKO islet mRNA are due to the hypothalamic Vhl 
deletion phenotype, such as a response to the increased insulin sensitivity.
7.6.3 Expression of 6-cell transcription factors
To investigate the control of 6 -cell function and the altered islet architecture 
in the BVhlKO pancreas, a panel of transcription factors were assayed. 
Expression of the MODY genes Hnfla, Hnf3B, Hnf4a and NeuroD were unaltered 
from controls (Fig. 7.5B), indicating that changes in expression of these 
transcription factors are not the cause of the altered islet cellular organisation 
seen in the BVhlKO. Interestingly, the transcription factor Nkx6.1 was 
significantly downregulated in BVhlKO (Fig. 7.5B) and PVhlKO (Fig. 7.5C) islets 
to 51.5% (+/- 11.48 SEM) and 56.6% (+/- 3.41 SEM) of controls respectively. 
NKX6.1 has been implicated in sustaining B-cell GSIS (Schisler et al., 2005). 
Downregulation of this gene in BVhlKO/PVhlKO islets suggests that NKX6.1 may 
play a role in the regulation of GSIS in these models.
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7.6.4 Expression of Kir6.2 and E-cadherin
Expression of the KATP channel pore forming, Kir6.2, was unaltered in BVhlKO 
islets (Fig. 7.5B) suggesting normal capacity and function, in agreement with 
the tolbutamide signal generated during calcium imaging of BVhlKO B-cells.
E-cadherin is an adherens junction forming protein that has been shown be 
downregulated by HIF activation, by a reduction in mRNA expression levels 
(Esteban et al., 2006). Therefore expression of E-cadherin was assayed, and 
found to be significantly decreased in both BVhlKO (Fig. 7.5A) and PVhlKO (Fig. 
7.5C) islets, to 47.67% (+/- 5.06 SEM) and 39.65% (+/- 2.00 SEM) of controls 
respectively.
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Figure 7.5: Gene transcrip tion in Vhl null islets. cDNA reverse 
transcribed from 500ng islet RNA was used fo r RT-PCR using TaqMan 
(ABI). BVhlKO (A and B): islets from n=6 animals per genotype were 
used, PVhlKO (C): n=5. Data was normalised to HPRT1 expression and 
presented as % of mean control expression levels. Data shown is mean 
+/- SEM, with t-test *P = <0.05, **P = <0.01, ***P = <0.001 indicated.
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7 .7  C ellu lar localisation  o f slucose transpo rte r expression
To investigate the change in balance of glucose transporter types expressed in 
BVhlKO and PVhlKO islets further, immunocytochemistry was performed on 
pancreatic sections to study cellular localisation of GLUT1 and GLUT2 and 
qualitatively assess the level of protein present.
Immunostaining for GLUT1 (by Dr. Frauke Forstreuter and Deepa Shukla of 
Imperial College London) showed barely detectable levels of this glucose 
transporter in islets of control animals of both crosses (Fig. 7.6A and C). There 
was strong induction of GLUT1 protein levels in both BVhlKO and PVhlKO islets 
(Fig. 7.6B and D). There was no significant GLUT1 induction present in PVhlKO 
exocrine cells, seen around the islet in Fig. 7.6D, indicating that the marked 
induction of GLUT1 seen in islet cells is an active HIF1a effect specific to the 
endocrine cell types.
Fluorescent immunostaining for GLUT2 revealed strong membrane localisation 
of the transporter in control islets from both crosses (Fig. 7.7A and B, Fig. 7.8A 
and B). Reduction of GLUT2 staining was marked in BVhlKO B-cells (Fig. 7.7C to 
F) and PVhlKO B-cells (Fig. 7.8C to F) with a loss of signal reflecting the 
reduced expression of this glucose transporter, but also a loss of membrane 
localisation of GLUT2. Reduced membrane localisation suggests reduced 
functionality of GLUT2.
This confirms the change of glucose transporter type in BVhlKO and PVhlKO 
islets, quantified by RT-PCR and validated at the protein level by 
immunocytochemistry.
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Figure 7.6: 0LUT1 immunostaining o f BVhlKO and PVhlKO pancreatic 
sections. GLUT1 = brown, nuclei = blue. A: BVhl control. B: BVhlKO. C: PVhl 
control. D: PVhlKO. Images are representative o f islets examined from 
multiple levels within 4 independent pancreata. GLUT1 staining was 
performed by Dr. Frauke Forstreuter and Deepa Shukla at the Renal Unit of 
Imperial College London.
162
G L U T 2C) BVh KO
50 microns
D) BVhlKO
Insulin
50 microns
E) BVhlKO
(
50 microns
Figure 7.7: GLUT2 and insulin immunostaining o f BVhlKO pancreatic 
sections. Confocal images of pancreatic sections stained for GLUT2 (green), 
insulin (red) and nuclear DNA (blue). A and B: control, C to F: BVhlKO. A/C/E: 
GLUT2. B/D/F: GLUT2/insulin/DNA merged. Images are representative of 
islets examined from multiple levels within 4 independent pancreata. 1,
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Figure 7.8: GLUT2 and insulin immunostaining o f PVhlKO pancreatic 
sections. Con focal images of pancreatic sections stained for GLUT2 (green) 
and insulin (red). A and B: control, C to F: PVhlKO. AICIE: GLUT2. B/DIF: 
GLUT!I insulin/DNA merged. Images are representative of islets examined 
from multiple levels within 4 independent pancreata.
7 .8  Discussion
The results presented in this chapter have demonstrated that the glucose 
intolerance and insulin deficit identified in BVhlKO and PVhlKO mice in chapter 
6  is caused by defective 8 -cell insulin secretion. GSIS in BVhlKO and PVhlKO 8 - 
cells is severely perturbed due to impaired glucose sensing.
7.8.1 Impaired GSIS
It was found that GSIS was severely deficient in islets isolated from both 
BVhlKO and PVhlKO mice. As this data was normalised as % of basal, it corrects 
the secretion for biases of cell number. Therefore it shows that in a transition 
from 2  mmol/l to 2 0  mmol/l glucose, the 8 -cells from each model cannot 
increase their insulin output appropriately in comparison to control 8 -cells. As 
BVhlKO 6 -cells robustly responded to protein kinase C activation (using the 
phorbol ester PMA) in the presence of 20 mmol/l glucose, this indicates that 
secretory mechanisms governing insulin vesicle dynamics are functional.
7.8.2 Dissection of GSIS pathway
Further investigation has indicated that glucose stimulated mitochondrial 
metabolism and calcium influx is severely disrupted in BVhlKO and PVhlKO 6 - 
cells. Yet calcium influx in response to methyl succinte or tolbutamide is 
normal. This pharmacological dissection of the GSIS triggering pathway 
indicates that mitochondrial and distal secretory mechanisms are functional 
due to the normal induction of calcium influx following addition of tolbutamide 
(KATP channel regulator) and addition of methyl succinate (mitochondrial 
complex II stimulator) respectively. Therefore this suggests that the functional 
GSIS defect is proximal to B-cell mitochondrial metabolism of glucose 
derivatives.
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7.8.3 Defective glucose uptake
The data in this chapter has demonstrated that uptake of the fluorescent 
glucose analogue, 2-NBDG, is impaired in BVhlKO and PVhlKO B-cells. This 
defect is likely to make a substantial contribution to the impaired B-cell 
glucose sensing phenotype of these mice. The impaired uptake of glucose was 
found to be due to reduced expression and membrane localisation of the non­
rate limiting high Km and Vmax GLUT2, and increased expression of the 
potentially rate limiting low Km and Vmax GLUT1. The D-glucose Km of rodent 
GLUT2 has been demonstrated to be 17 mmol/l (Johnson et al., 1990) allowing 
a wide range of physiological blood glucose concentrations to be sensed 
appropriately by the B-cell. Human GLUT1 however has been shown to have a 
Km for D-glucose of 2.3-2.6 mmol/l (Woodrow et al., 2000) and to confer a 
human B-cell Vmax of 3 mmol/l/min (De Vos et al., 1995) compared to a rodent 
B-cell GLUT2 Vmax of 32 mmol/l/min (Johnson et al., 1990). This suggests that 
BVhlKO and PVhlKO B-cells relying on GLUT1 to supply glucose into the B-cell 
would sense very little difference between 2  mmol/l and 2 0  mmol/l glucose, as 
GLUT1 would be facilitating glucose transport at near maximum capacity for 
both of these concentrations. Therefore, the change in rodent glucose 
transporter type is likely to be responsible for the impaired glucose uptake.
Loss of GLUT2 membrane localisation due to impaired glycosylation has been 
reported to impair GSIS and glucose homeostasis (Ohtsubo et al., 2005) 
resulting in a phenotype similar to the loss of glucose homeostasis seen in the 
BVhlKO and PVhlKO mice. This supports the hypothesis that the change in 
glucose transporter type is responsible for the loss of B-cell glucose sensing in 
these mice.
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7.8.4 Ecadherin
E-cadherin expression has previously been shown to be reduced in transformed 
Vhl null/HIFa active renal carcinoma cell lines (Esteban et al., 2006), and the 
finding of reduced expression of this intercellular adhesion molecule in both 
BVhlKO and PVhlKO islets is interesting and may have important functional 
implications. E-cadherin is a Ca2+ sensitive adhesion molecule that forms the 
transmembrane/intercellular connections of an adherens junction in epithelial 
cells, whilst binding intracellular B-catenin, which in turn connects the 
complex to the actin cytoskeleton via a-catenin (Hinck et al., 1994). E-caderin 
has been shown to be critical in the formation of pseudo islets from 
transformed mouse B-cells (Min6 ), a process that is critical in permitting 
responsiveness of these cells to nutrient stimuli including glucose; the 
mechanism inferred is by promoting B-cell to B-cell communication (Hauge- 
Evans et al., 1999). Therefore loss of E-cadherin in the BVhlKO and PVhlKO 
islets may cause a loss of B-cell to B-cell communication, which may contribute 
to the GSIS defect seen. E-cadherin has also been implicated in regulating 
proliferation and apoptosis in Min6  cells (Luther et al., 2005), but as BVhlKO 
and PVhlKO islets have a normal compliment of B-cells, this effect would not 
be expected to occur in these models of HIF1a upregulation. Loss of islet cell 
adhesion through reduction of E-cadherin expression may have been thought to 
contribute to the altered islet cellular organisation seen in the BVhlKO model, 
but as the PVhlKO model showed a similar reduction in E-cadherin expression, 
yet had preserved islet cellular organisation, this is unlikely to be the case.
7 .8 .5  Summary
In summary, the glucose intolerance and post prandial insulin deficiency 
observed in the BVhlKO and PVhlKO mice (chapter 6 ) is due to impaired B-cell 
GSIS, principally caused by impaired glucose uptake. Glucose uptake in the 
BVhlKO and PVhlKO B-cells was functionally impaired due to a change in
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glucose transporter type from the non-rate limiting GLUT2 to the rate limiting 
GLUT1. Mitochondrial and distal secretory pathways appeared to be functional 
as normal calcium influx was induced by non-glucose secretagogues targeted to 
mitochondrial complex il or KATP channels, and as robust secretion was 
observed when insulin vesicle exocytosis was potentiated using a phorbol ester.
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Chapter 8: Discussion
8 .1  Discussion o f the Plrs2KO mouse
8.1.1 Overview of the Plrs2KO mouse
This study has been informative in terms of clarifying the role of IRS2 in the 
pancreas. It has shown that the pancreatic 6 -cell defect caused by Irs2 deletion 
results in a phenotype characterised by glucose intolerance and impaired 
glucose stimulated insulin release in vivo. The Plrs2KO mouse has normal 
fasting blood glucose and insulin levels, normal body mass, normal food intake 
and normal peripheral insulin sensitivity, indicating that there is no peripheral 
insulin resistance or central nervous system phenotype, and that the phenotype 
observed is principally due to pancreatic Irs2 deletion. Other investigators have 
studied Irs2 null 6 -cell function in mouse models complicated by more severe 
diabetic phenotypes caused by Irs2 deletion in other tissues (reviewed in the 
introduction). In this study it has been demonstrated that PDXcre driven Irs2 
deletion (Plrs2KO) is found only in the pancreas (and small proportion of the 
duodenum), and therefore the phenotype is attributable to pancreatic Irs2 
deletion and not influenced by a secondary defect caused by lipid or 
hyperglycaemic stress on the 6 -cell, obesity or 6 -cell compensation for 
peripheral insulin resistance.
8.1.2 Tissue specificity and efficiency of deletion in Plrs2KO mice
The pattern of Irs2 deletion found in the Plrs2KO mouse confirms the predicted 
expression pattern of the Pdx1 promoter driven cre-recombinase (PDXcre) 
transgene. Theoretically it is possible that the Pdx1 promoter is active in the 
hypothalamus, as insulin expression has been suggested in the hypothalamus 
due to activation of the rat insulin promoter driven cre-transgene (Choudhury 
et al., 2005), and PDX1 promotes insulin expression. However, as there is no
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hypothalamic/brain deletion of Irs2 in the Plrs2KO mice, this would suggest 
that either the Pdx1 promoter or PDXcre transgene is not activated in this 
tissue.
Effective deletion of Irs2 has been demonstrated in the pancreas and islets of 
Plrs2KO mice, at the mRNA transcript and protein level.
8.1.3 Peripheral glucose handling of Plrs2KO mice
The Plrs2KO mice showed no sign of a peripheral phenotype from the 
experiments reported in this thesis. Unaltered body mass and food intake 
indicated normal energy homeostasis, and would suggest food intake to match 
energy expenditure, with no obvious signs of altered adipose deposition, 
although this was not formally examined. The insulin sensitivity of these mice 
is also unaltered from the controls at most time points and the Plrs2KO mice 
showed no sign of insulin resistance, again indicating absence of a peripheral 
phenotype.
8.1.4 Impaired glucose tolerance and insulin secretion in Plrs2KO 
mice
The significant glucose intolerance in Plrs2KO mice was found to be due to 
severely impaired in vivo GSIS, with first phase GSIS absent and second phase 
GSIS significantly perturbed, yet fasting plasma insulin levels were unaltered. 
This impairment of both first and second phase insulin secretion is in contrast 
to the Insr knock out mice, which show a loss of first phase, but sustained 
second phase GSIS (Kulkarni et al., 1999a). Therefore pancreatic Irs2 is 
required for maintaining both first and second phase in vivo GSIS. One 
explanation is that IRS2 mediated IGF1R signals are responsible for correct 
second phase insulin secretion. Two key papers have examined insulin secretion 
in the /g /fr B-cell and pancreatic knockouts (Ueki et al., 2006; Xuan et al., 
2 0 0 2 ), however the data presented in these papers cannot implicate or rule out
170
IGF1R signalling in 8 -cell second phase insulin secretion. The earlier study 
(Xuan et al., 2002) performs secretion experiments on isolated islets, which by 
their nature do not show the pronounced biphasic insulin secretion pattern 
seen in vivo, and the later study (Ueki et al., 2006) presents the in vivo first 
phase secretion data up to 5 minutes after injection, but not the second phase. 
So it remains possible that 6 -cell IRS2 mediated signals from the IGF1R, or 
other receptors potentially upstream of IRS2, are responsible for maintaining a 
sustained second phase GSIS response.
8.1.5 Glucose homeostasis and insulin secretion in PDXcre mice
An important finding in the work presented in this thesis, is that it has 
demonstrated that the PDXcre transgenic mouse, used to generate the Plrs2KO 
and PVhlKO mice, has no metabolic phenotype, and to be indistinguishable 
from Irs2 floxed controls. This is a pertinent finding as the diabetes research 
field using the cre-loxP system was recently alerted by a paper demonstrating 
glucose intolerance and impaired GSIS in the RIPcre transgenic mouse (Lee et 
al., 2006). Importantly, both glucose tolerance and in vivo GSIS in PDXcre mice 
is unaltered from Irs2 floxed mice, ensuring that the deleted allele in the 
Pirs2KO and PVhlKO mice, and other studies using the PDXcre mouse, is being 
correctly tested using reliable controls. This proves that the expression of cre- 
recombinase does not alter 6 -cell function per se. The most likely reason for 
the discrepancy between the results presented in this report and those of Lee 
et al., is that the Plrs2KO, PVhlKO and BVhlKO study colony is maintained on a 
mixed C576L6/Sv129 genetic background, whereas the Lee et al. study used 
the RIPcre mouse on a pure C57BL6/J background as made available by the 
Jackson Laboratory (www.jax.org). This C57BL6/J strain has been reported to 
be predisposed to impaired 6 -cell insulin secretion and glucose intolerance due 
to a spontaneous 5 exon deletion of the nicotinamide nucleotide 
transhydrogenase (Nnt) gene on choromosome 13 (Freeman et al., 2006b), 
resulting in uncoupled mitochondrial metabolism and impaired GSIS (Freeman
171
et a l., 2006a).
8.1.6 Plrs2KO B-cell insulin secretion and calcium flux
To test the function of Plrs2KO B-cells, we performed GSIS on isolated islets 
and measured intracellular free Ca2* concentrations (using the fluorescent 
calcium indicator Fluo3am) in response to GSCI in single B-cells. Consistent 
with the in vivo GSIS data, the in vitro  insulin secretion from isolated Plrs2KO 
islets in response to 1 1  mmol/l glucose was significantly reduced in comparison 
to control islet GSIS. Ca2+ influx was pronounced in control B-cells in response 
to glucose and tolbutamide, yet consistent with the GSIS data, Ca2+ influx into 
Pirs2KO B-cells in response to glucose was severely impaired.
In vivo GSIS, in vitro  islet GSIS and single B-cell measurements of intracellular 
free Ca2* concentrations, and oscillations, provide three different readouts of 
Plrs2KO B-cell function, with each technique providing distinct information on 
GSIS. When forming part of the pancreas of a whole animal, B-cells within the 
islets are well perfused and, as such, exposed to physiological concentrations 
of circulating hormones, growth factors, amino acids, nutrients and minerals, 
as well as being under the influence of the autonomic nervous system. During 
islet isolation this regulatory microenvironment and endocrine communication 
between islet cells are perturbed. However GAP junctions, adherens junctions 
and islet cell to cell communication is preserved which facilitates coordinated 
synchronous secretory responses (Gilon and Henquin, 1992; Santos et al., 
1991). When islets are dissociated to single cells, this coordinated response is 
lost enabling glucose responsiveness of individual B-cells to be assessed by 
measuring intracellular Ca2+ oscillations and observing GSCI.
The observations of impaired GSIS in vivo and in vitro  show that the insulin 
secretory defect caused by Irs2 deletion is intrinsic to the islet, as the islets 
appear dysfunctional when in their in vivo tissue compartment and when
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isolated. The further observation of impaired cytoplasmic free Ca2+ elevation by 
GSCI into single dissociated 6 -cells suggests that this defect is, at least in part, 
responsible for the impaired GSIS seen in Plrs2KO islets and mice. The 
mechanism where by glucose stimulation is coupled to insulin secretion is 
complex, and there could potentially be multiple defects resulting in the 
observed impaired Ca2+ influx. Mean intracellular free Ca2+ levels in Plrs2KO B- 
cells did not rise significantly above mean basal levels in response to glucose, 
yet tolbutamide had a potent effect. This suggests that the KATP channels and 
L-type voltage dependent calcium channels (VDCCs) are functional, thereby 
pointing to a triggering defect upstream of KATP channel closure. Potential 
sites for impairment of the insulin secretory triggering signal include glucose 
uptake, glucose phosphorylation, glycolysis, mitochondrial metabolism and the 
generation of ATP.
8 .1.6.1 SERCA function in Plrs2KO B-cells
Another possible cause for the impaired GSCI and therefore GSIS response in 
Plrs2KO 6 -cells may be a defect in the regulation of sarco(endo)plasmic 
reticulum Ca2+ ATPase (SERCA) function. SERCA is an enzyme responsible for 
sequestering cytosolic free Ca2+ into the endoplasmic reticulum (ER) lumen 
against a Ca2+ gradient. It has been inferred, from measurements of 
intracellular free Ca2+, that Irs1 null 6 -cells have impaired IRS1 mediated IIS 
inhibition of SERCA, allowing unregulated Ca2+ sequestration and blunting 
increases in intracellular free Ca2+ following GSCI, leading to impaired GSIS 
(Borge and Wolf, 2003; Kulkarni et al., 2004). Neither of these research teams 
report the use of thapsigargin (SERCA inhibitor) on Irs1 null B-cells, which 
would conclusively prove or refute the hypothesis that the failure to elevate 
cytoplasmic free Ca2+ is due to loss of IRS1 inhibition of SERCA. However, Irs1 
overexpression in cell lines has been reported to lead to increased intracellular 
free Ca2+ concentrations following GSCI, leading to enhanced GSIS, the inferred 
mechanism being increased IRS1 inhibition of SERCA Ca2+ sequestration (Borge 
and Wolf, 2003). IRS2 has also been found to colocalise with the same ER cell
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markers as IRS1, suggesting that IRS2 may also interact with SERCA isoforms 
(Borge and Wolf, 2003).
The hypothesis that Plrs2KO B-cells have lost IRS2 mediated IIS inhibition of 
SERCA is a potential explanation for the intracellular free Ca2+ data. The 
addition of 1 1  mmol/l and 2 0  mmol/l glucose to the imaging medium caused a 
small increase in intracellular free Ca2+ levels in the Plrs2KO B-cells which was 
not sustained, in keeping with the theory of an uninhibited SERCA enzyme 
sequestering free Ca2+ into the ER lumen from the cytoplasm. If this were the 
mechanistic explanation for these data, the stabilisation of the cytoplasmic 
free Ca2+ traces near baseline would represent equilibrium of Ca2+ influx via 
VDCC and Ca2* sequestration. Although these data support the hypothesis that 
IRS2 negatively regulates SERCA activity, this requires further rigorous 
investigation before any conclusions can be drawn. Inhibition of SERCA activity 
by thapsigargin during glucose stimulated B-cell cytoplasmic free Ca2+ 
recordings would test this hypothesis.
8 .1.6.2 Calcium oscillations in Plrs2KO B-cells
Another feature of defective calcium signalling seen in Plrs2KO B-cells is an 
impairment of free cytoplasmic Ca2+ oscillations. Loss of Ca2+ oscillations in 
response to glucose is thought to correlate with a loss of pulsatility of insulin 
secretion (Henquin et al., 1998). Interestingly this is another perturbation 
reported in Irs1 null B-cells, although the authors only presented the trace 
from a single cell for each genotype/condition in the manuscript (Kulkarni et 
al., 2004) which does not represent the heterogeneous nature of B-cell 
responses to glucose seen in the control traces presented in this thesis (Fig. 
5.2B). However, as the Plrs2KO Ca2+ traces barely climb above basal levels in 
response to glucose, conclusions cannot be drawn as to the regulation of Ca2+ 
oscillations.
Despite the obvious impairment of Plrs2KO B-cells in sustaining cytoplasmic
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Ca2* concentrations in response to glucose, these cells when part of intact 
islets still show a significant increase in in vitro  GSIS (Fig. 5.1), albeit with a 
fold change over 7 times lower than control islets. This small increase in insulin 
secretion may be triggered by a minority of Plrs2KO B-cells that show a modest 
increase in cytoplasmic Ca2+ levels in reponse to glucose (Fig. 5.2B), which may 
in turn trigger secretion in neighbouring cells. No cre-loxP system provides 
1 0 0 % floxed gene deletion in the tissue targeted, and therefore undeleted B- 
cells in the Plrs2KO islets may trigger low levels of insulin secretion.
8 .1.6.3 Summary
From these studies of B-cell GSIS in Plrs2KO mice, islets and cytoplasmic free 
Ca2+ measurements in single B-cells, it is clear that B-cell loss of Irs2 results in 
a pronounced loss of GSIS. Although a precise mechanism underlying this defect 
cannot be gained from the data presented here, it is clear that B-cell Irs2 
deletion impairs the capacity of Plrs2KO B-cells to elevate and sustain 
cytoplasmic free Ca2+in response to glucose.
These in vitro  results of insulin secretion are surprising in light of the limited 
literature describing enhanced in vitro  GSIS in islets from global Irs2 KO 
(Kubota et al., 2000) and B-cell/hypothalamic Irs2 KO (Kubota et al., 2004) 
mice. The discrepancy between these studies and those presented in this thesis 
are unclear, although the two models published by Kubota et al. have 
peripheral phenotypes complicating the study of Irs2 null B-cells. The global 
Irs2 KO model generated by Kubota et al. showed less severe diabetes 
compared to the previous global Irs2 KO model (Withers et al., 1998), and 
therefore its method of generation or different genetic background on which it 
is bred may affect islet function. The Plrs2KO GSIS defect presented in this 
thesis has been reliably demonstrated in vivo, in vitro  and at the level of B-cell 
GSCI.
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8.1.7 Reduced insulin content and B-cell mass of Plrs2K0 mice
The Plrs2K0 mouse was found to have significantly reduced pancreatic insulin 
content, due to an insufficient B-cell mass when compared to litter mate 
controls animals. Reduced pancreatic insulin content and B-cell mass has 
previously been reported in B-cell Insr KO mice (Kulkarni et al., 1999a; Ueki et 
al., 2006), although these parameters were found to be normal in the B-cell 
Ig f lr  KO mouse (Kulkarni et al., 2002; Ueki et al., 2006). The finding of 
reduced pancreatic insulin in the Plrs2KO mouse consolidates the IIS mouse 
mutant literature and links IRS2 mediated insulin receptor specific signalling in 
sustaining not only B-cell mass but also pancreatic insulin content.
The decreased B-cell mass in the Plrs2KO is a smaller decrease than that 
observed in the global Irs2 KO (Withers et al., 1998), however the global knock 
out is complicated by peripheral insulin resistance with more pronounced 
hyperglycaemia which may cause secondary deleterious B-cell defects due to 
glucose or lipid toxicity (Donath et al., 2005; Kim et al., 2005; Maedler et al.,
2003). Other attempts to conditionally knock out Irs2 in the B-cell were also 
complicated by insulin resistant hypothalamic/obese phenotypes in these mice 
(Choudhury et al., 2005; Kubota et al., 2004; Lin et al., 2004).
8.1.8 Reduced proliferation of Plrs2KO B-celts
Plrs2KO B-cells show significantly reduced numbers of proliferating B-cells in 
the non-GO cell cycle phase, as assessed using KI67 and insulin immunostaining. 
This reduction of B-cell proliferation is the principal cause of the reduced B- 
cell mass in Plrs2KO mice, as the apoptotic rate was not altered between 
Plrs2KO and control B-cells. This suggests that pancreatic IRS2 mediated IIS is 
required to sustain B-cell proliferation and an adequate B-cell mass. Reduced 
B-cell proliferation has been reported in other IIS pathway mutant mice: B- 
cell/hypothalamic Irs2 KO mice show reduced B-cell mass and proliferation 
(Kubota et al., 2004); and the B-cell double knock out of the Insr and I$f1r
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showed reduced proliferation and increased apoptosis in 8 -cells (Ueki et al., 
2006). These other studies are however complicated by obesity (Kubota et al.,
2004) and severe progressive diabetes (Ueki et al., 2006) making it difficult to 
reliably conclude whether the cause of the altered proliferation or apoptosis is 
due to a primary 8 -cell defect or a secondary complication caused by the 
peripheral phenotype. It has been proven that exposure to hyperglycaemia or 
saturated fatty acids can reduce 6 -cell mass in human and rodent islets due to 
reduced proliferation and increased apoptosis (Donath et al., 2005; Kim et al., 
2005; Maedler et al., 2003), therefore Plrs2KO mice provide a more specific 
model with which to study regulation of Irs2 null 8 -cell mass.
Another limitation of the Kubota et al. (2004) and Ueki et al. (2006) studies is 
that they use the mitosis markers bromodeoxy Uridine (BrdU) DNA 
incorporation and phospho-Histone H3 (pHH3) nuclear expression, respectively. 
BrdU only marks cells in the S-phase and is subject to the length of labelling 
period, while pHH3 marks cells in the M-phase (Li and Vaessin, 2000), limiting 
the useful detection window of these reagents. The studies reported in this 
thesis used antibodies directed against KI67, a nuclear antigen expressed 
during all non-GO cell cycle phases (Ohta and Ichimura, 2000), thereby 
capturing all 6 -cells that have entered the cell cycle at time the animal was 
killed.
In summary, loss of 8 -cell IRS2 mediated IIS results in reduced pancreatic 
insulin content due to an insufficient 8 -cell mass. The loss of B-cell mass is due 
to impaired 8 -cell proliferation.
8.1.9 a-cell phenotype of Plrs2KO mice
The data presented in chapter 4 show that as well as the 8 -cell effects of Irs2 
deletion, there is also an effect on a-cell function. Glucagon content of the 
pancreas was significantly reduced, as was the a-cell mass of the pancreas and
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is let glucagon mRNA expression.
A loss of adult a-cell mass or pancreatic glucagon content in vivo has not been 
reported in other models of defective IIS. Studies investigating the global Irs1 
and Irs2 KO models have reported non B-cell islet mass using a cocktail of anti- 
glucagon, anti-somatostatin and anti-pancreatic polypeptide antibodies; this 
non B-cell parameter was not altered with Irs1 or Irs2 global deletion (Kubota 
et al., 2000). Double B-cell Insr and Ig f lr  KO mice show a normal non B-cell 
islet cell mass using the same antibody cocktail approach (Ueki et al., 2006), 
however no conclusions on a-cell mass regulation can be drawn from these 
studies due to the non cell-specific method used. The only mechanistic report 
linking insulin signalling and regulation of a-cell mass was performed using 
transformed a-cell lines, and reported an in vitro  reduction in cell number 
growth when the insulin receptor was knocked down using siRNA (Diao et al.,
2005). However the cell transformation process alters cell cycle regulation, and 
therefore these do not represent a reliable model with which to draw 
conclusions on regulation of in vivo cell growth, and the balance of 
proliferation and apoptosis. Therefore the a-cell mass reduction reported in 
the Plrs2KO mouse is a reliable demonstration that IIS in the a-cell can regulate 
a-cell mass and pancreatic glucagon content in an adult animal.
The effects of pancreatic Irs2 deletion on a-cell mass and glucagon expression 
may hypothetically be due to impaired circulating and intraislet insulin 
secretion from the Irs2 null B-cells, and/or due to an inability of the Irs2 null a- 
cells to respond to the insulin signal. Both of these hypotheses are plausible as 
Plrs2KO mice show severely perturbed GSIS, and it has been demonstrated that 
human a-cells, and therefore presumably rodent a-cells, express the insulin 
receptor isoform A (Muller et al., 2006) and Irs2 (personal communication from 
D. Muller, October 2006). However to objectively disentangle the effects of 
reduced circulating postprandial insulin stimulation of the a-cell, and the 
effect of a-cell loss of IRS2 mediated IIS, in vivo deletion of Irs2 specifically in
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a-ce lls  would be required.
The reduction in glucagon content, a-cell mass, and glucagon expression in the 
Plrs2KO mouse will likely result in insufficient glucagon secretion. Evidence for 
this is provided by the insulin tolerance testing data reported in chapter 3 (Fig 
3.3E), where Plrs2KO mice show a reduced recovery of blood glucose levels 
from the insulin induced hypoglycaemia at the final time point, representing 
either impaired glucagon secretion, reduced clearance of insulin, or increased 
insulin sensitivity. Impaired glucagon secretion is the most likely explanation 
for the ITT data as the Plrs2KO mice do not show any evidence for a peripheral 
muscle/fat/liver phenotype that would be associated with altered insulin 
sensitivity or clearance.
It is plausible that IRS2 mediated insulin signalling in the a-cell may be 
responsible for regulating glucagon secretion in vivo. It has been demonstrated 
that the murine a-cell insulin receptor is required for correct glucose regulated 
glucagon secretion in vitro, in response to low glucose (Diao et al., 2005). It is 
also now accepted that glucagon secreted from a-cells, when forming an intact 
rodent islet, is negatively regulated in the presence of high glucose by insulin 
secreted from islet B-cells (Leung et al., 2006; Ravier and Rutter, 2005) as well 
as other B-cell secretions such as GABA (Franklin and Wollheim, 2004) and 
potentially Zinc ions (Ishihara et al., 2003). Therefore, loss of IRS2 mediated 
insulin receptor signalling in the a-cell, coupled with a reduced a-cell mass and 
islet/pancreatic glucagon content, may result in insufficient glucagon 
secretion.
8.1.10 Potential 6-cell phenotype
Another finding in the Plrs2KO mouse was reduced islet expression of 
somatostatin. This indicates that pancreatic Irs2 deletion influences islet 5- 
cells by either downregulating the number of cells within the islet or impairing
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expression of the somatostatin gene. From the qualitative analysis of islet B- 
cell and 6 -cell organisation (representative images presented in chapter 4, Fig. 
4.2) it is apparent that there are fewer 6 -cells per islet and with a lower level 
of fluorescent immunostaining, which required higher laser power and detector 
gain to detect. Although not formerly measured, this would suggest that loss of 
pancreatic Irs2 may cause reduced numbers of 6 -cells within the islet, and 
reduced somatostatin transcription, due to either impaired insulin stimulation 
of the islet 6 -cell, and/or from an inability of the Irs2 null 6 -cell to respond to 
this insulin signal. Human 6 -cells express the insulin receptor isoforms A and B 
(Muller et al., 2006) and lrs2 (personal communication from D. Muller October
2006), and therefore possess the signalling apparatus to respond to insulin.
The physiological consequences of this reduction of islet somatostatin in the 
Plrs2KO mouse can only be conjectured. 6 -cells secrete short form 
somatostatin, SST-14, and this inhibits secretory function of islet B-cells (Daunt 
et al., 2006) and a-cells (Kendall et al., 1995). Therefore if the reduction in 
somatostatin in Pirs2KO islets reflects impaired SST-14 secretion, then reduced 
action of this inhibitory peptide may be thought to enhance a-cell and B-cell
function; clearly not the case in the Plrs2KO mouse, although it may be that
the defect caused by Irs2 deletion in the B-cell is dominant. However, the main 
source of circulating inhibitory somatostatin is the long form, SST-28, secreted 
from enterocytes in the proximal gut. Levels of SST-28 are increased after 
ingestion of food (Ensinck et al., 1997), and would be expected to override a 
potential 6 -cell impairment of SST-14 secretion in Plrs2KO mice.
8.1.11 Expression of B-cell genes in Plrs2KO islets
The transcription of key B-cell genes assayed in the Plrs2KO islets has revealed 
some consistency and some conflict with existing published data.
PDX1 is an important B-cell transcription factor that determines pancreatic and
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endocrine cell fate during development. Its expression is restricted to the 6 - 
cells in the adult pancreas where it maintains 6 -cell differentiation and 
identity by driving insulin and Glut2 expression (amongst others) and repressing 
glucagon expression (Ahlgren et al., 1998). Several investigators have reported 
the downregulation of Pdx1 in the 6 -cells of global Irs2 null mice (Hennige et 
al., 2003; Kitamura et al., 2002; Kushner et al., 2002), where as the Plrs2KO 
mice showed normal islet levels of Pdx1, indistinguishable from that of 
controls. Downregulation of Pdx1 in global Irs2 null mice has been reported by 
one research group to be strain dependent, and only present in the severely 
diabetic strains of Irs2 null mice (Suzuki et al., 2003). Together with the data 
presented in chapter 4, this would suggest that the downregulation of Pdx1 
previously attributed to irs2 deletion is, in fact, due to either the genetic 
background of the mouse model studied, or due to a secondary effect of the 
severe diabetic pathophysiology. Despite the normal expression levels of Pdx1} 
the PDX1 target genes insulin, Glut2 and Nkx6.1 are downregulated suggesting 
regulation by other IRS2 dependent transcription factors/repressors.
Down regulation of the expression of FoxOI is potentially important as this 
transcription factor is phosphorylated by the IIS pathway, relieving its 
inhibitory effect on the PDX1 promoter (Kitamura et al., 2002). With the 
deletion of Irs2 it would be expected that FoxOI expression would not change, 
but without IRS2 mediated phosphorylation, FOXOI would be active in the 
nucleus. However the normal expression levels of Pdx1 suggest that either: 
FOXOI is phosphorylated by IRS2 independent pathways and excluded from the 
nucleus; FOXOI does not repress Pdx1 expression in lrs2 null 6 -cells; or the 
downregulation of FoxOI in Plrs2KO 6 -cells relieves the inhibition of the Pdx1 
promoter sufficiently to allow normal Pdx1 expression.
6 -cell identity and insulin production is influenced by many genes other than 
Pdx1, although Pdx1 is regarded as the master regulator of these genes. The 
transcription factors NEUROD and NKX6.1 are involved in directly maintaining
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expression of the insulin gene in 8 -cells. NeuroD expression was normal in 
Plrs2KO islets, however the downregulation of its upstream activator FoxOI 
represents the impairment of a key 8 -cell mechanism to respond to 
hyperglycaemia by sustaining insulin expression and halting mitosis. Nkx6.1 is a 
direct PDX1 target and is significantly downregulated in Plrs2KO islets.
8.1.11.1 NKX6.1 regulated GSIS
NKX6.1 has been implicated in positively regulating 6 -cell/islet neogenesis 
during development (Sander et al., 2000) and sustaining B-cell GSIS (Schisler et 
al., 2005). Its downregulation in Plrs2KO islets, which show defective GSIS, 
suggests that NKX6.1 may play a role in the regulation of GSIS. As Plrs2KO mice 
have ablated 8 -cell IRS2 mediated IIS, it is possible that Nkx6.1 expression is 
under the control of the IIS pathway in 8 -cells.
8.1.12 Plrs2KO B-cell glucose sensing
Despite the downregulation of Glut2 in Plrs2KO islets, it is unlikely that glucose 
transport is dysfunctional in these 6 -cells, as the remaining GLUT2 is largely 
membrane localised and therefore likely to be functional, although this cannot 
be ruled out without glucose uptake experiments. The expression levels of 
glucokinase, widely regarded as the rate limiting 6 -cell glucose sensor, are 
normal. The downregulation of Giut2 is interesting as it appears to be PDX1 
independent, yet other reports of Glut2 reduction in Irs2 null models have 
attributed it to loss of PDX1 expression (Kitamura et al., 2002). Also, diabetes 
induced by a high fat diet has been shown to downregulate and impair GLUT2 
glycosylation and membrane localisation, yet this effect is associated with a 
whole body peripheral diabetic phenotype including fasting hyperglycaemia and 
dyslipidaemia (Ohtsubo et al., 2005). The less severe increase in post-prandial 
blood glucose seen in Plrs2KO mice is unlikely to directly cause Glut2 
downregulation, which instead is attributable to impaired IRS2 mediated IIS in 
the Plrs2KO 6 -cell.
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8.1.13 Applicability of Plrs2KO studies to human type 2 diabetes
The Plrs2K0 mouse has revealed that IRS2 is essential in the maintenance of a 
normal 8 -cell, a-cell and potentially 6 -cell mass, as well as being required for 
correct 8 -cell GSIS. So what are the potential implications of the Plrs2KO 
studies reported here for the study of T2DM in humans?
Firstly, human islet cells express the Insr and /rs2, specifically in 8 -cells (Muller 
et al., 2006) a-cells and 6 -cells (personal communication from D. Muller 
October 2006). Evidence of a role for IRS2 in human islets in maintaining 
glucose homeostasis comes from a study which presented the differentially 
expressed genes in islets isolated from humans with normal glucose 
homeostasis or T2DM (Gunton et al., 2005). Gene expression levels of Irs2 and 
the Insr were found to be significantly downregulated in T2DM human islets, 
with expression levels 9% and 23% of controls respectively, implicating IRS2 
mediated insulin signalling in maintaining normal islet function and glucose 
homeostasis.
Increasing the capacity of diabetic 8 -cells and a-cells to utilise IRS2 mediated 
IIS pathways may be a possible path of intervention to restore correct islet 
function in T2DM patients. Indeed, early injection of insulin has been shown to 
preserve 8 -cell function for longer than administration of sulfonylurea drugs 
(Alvarsson et al., 2003) and although there may be many explanations for this 
effect, enhanced 8 -cell insulin signalling is certainly one possibility. Also, 
transgenic overexpression of Irs2 in the B-cells of global lrs2KO mice recovers 
8 -cell mass and insulin secretion in the face of prevailing peripheral insulin 
resistance and hyperglycaemia (Hennige et al., 2003). This suggests that 
strategies to increase Irs2 expression and enhance IRS2 mediated IIS in human 
T2DM islet cells may encourage 8 -cell recovery/compensation to challenge the
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loss o f glucose homeostasis.
8.1.14 Future directions
The studies of the Plrs2KO mouse presented in this thesis have clarified and 
challenged some aspects of the IRS2 literature, as well as raising new insights 
into IRS2 function in the a-cell. Avenues for further research have been 
discussed throughout this chapter, however some specific studies which would 
be interesting if undertaken are listed below.
Impaired in vitro  GSIS had not been previously reported in Irs2 null 6 -cells, and 
therefore to investigate this phenotype further, GSIS and calcium imaging 
experiments could be continued with the use of other non-glucose 
secretagogues such as sulfonylureas, phorbolesters and mitochondrial 
substrates, as well as use of the SERCA inhibitor thapsigargin to probe the 
contribution this ER calcium pump makes to the Plrs2KO 6 -cell phenotype.
The suprising loss of a-cell mass may be coupled with altered glucose or insulin 
regulated glucagon secretion. Defects in either of these mechanisms would 
explain elements of the Plrs2KO in vivo metabolic physiology, and therefore 
warrant further investigation.
Given the value of the Plrs2KO mouse as a tool for studying islet cell function in 
a model uncomplicated by insulin resistance, it would be informative to run 
gene chip arrays using RNA from isolated islets to assay the full gene expression 
profile of these cells.
Although the Plrs2KO mouse is at present the best model with which to study 
Irs2 null 6 -cell function, it could be argued that it suffers from complications 
due to Irs2 deletion in other endocrine cell types. Therefore, a theoretically
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superior model would be using an inducible PDXcre transgenic mouse to delete 
Irs2 during adulthood, when Pdx1 expression is restricted to mature B-cells. 
However, the potential gain in scientific knowledge from this proposed model 
is likely to be negligible over that gained from the Plrs2KO mouse.
8.1.15 Summary of Plrs2KO studies
The Plrs2KO mouse has provided a pure pancreatic model of Irs2 deletion, with 
which to study the function of Irs2 null B-cells other islet endocrine cell types 
in vivo. Previous attempts to study the effect of B-cell Irs2 deletion have been 
complicated by Irs2 deletion in other insulin target tissues and, as such, 
suffered from insulin resistance, dyslipidaemia and/or hyperglycaemia 
(Choudhury et al., 2005; Kubota et al., 2004; Lin et al., 2004; Withers et al., 
1998). The Plrs2KO mouse has demonstrated that IRS2 mediated IIS is required 
in the B-cell for normal maintenance of B-cell proliferation, mass and function, 
correct GSIS and therefore glucose homeostasis. The use of in vitro  calcium 
imaging and secretion techniques to study Plrs2KO B-cells has allowed this 
defective component of stimulus-secretion coupling to be analysed in Irs2 null 
B-cells. The Plrs2KO mouse has also revealed a novel role for IRS2 in sustaining 
a-cell mass as well as a potential role in regulating 5-cell mass.
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8 .2  Discussion o f B-cell Vhl d e le tion /H IF  1a ac tiva tion
8.2.1 Overview of the BVhlKO and PVhlKO mice
The studies of Vhl deletion and HIF1a activation in the BVhlKO and PVhlKO 
models have provided new and interesting insights into an oxygen sensing 
molecular mechanism exerting control over 8 -cell glucose sensing mechanisms. 
These models demonstrated that Vhl deletion/ HIF1 a activation in the 6 -cell 
and pancreas causes impaired glucose tolerance due to insufficient insulin 
secretion. This GSIS defect was found to be due in part to impaired glucose 
uptake caused by an alteration in glucose transporter type: a reduction of the 
high Km non-rate limiting GLUT2 and induction of the low Km rate limiting 
GLUT1. These studies also demonstrated that mitochondrial metabolism and 
distal secretory pathways were functional in BVhlKO and PVhlKO B-cells. 
However, it remains possible that there is also a glycolytic defect in these 6 - 
cells.
8.2.2 Defective glycolytic pathways?
The glucose uptake experiments showed limited uptake of the fluorescent 
glucose analogue 2-NBDG into BVhlKO and PVhlKO B-cells, indicating that a low 
rate of glucose transport is still occurring, via the remaining GLUT2 and/or the 
induced GLUT1. Therefore the question remains, why does this reduced glucose 
transport not trigger mitochondrial metabolism and subsequent insulin 
secretion?
The most obvious answer to this question is that there may be further defects 
in the GSIS pathway prior to mitochondrial metabolism. These are likely to 
include downregulation of the glucose sensor glucokinase as seen in the BVhlKO 
islets. Other possible glycolytic defects include down regulation of glycolytic
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enzymes, or upregulation of lactate dehydrogenase, previously shown to be a 
HIF target (Firth et al., 1995). Upregulation of lactate dehydrogenase has been 
shown to “short circuit” the GSIS pathway by shuttling glucose derivatives away 
from mitochondrial ATP generation, thus impairing GSIS (Ainscow et al., 2000; 
Zhao and Rutter, 1998). Many glycolytic enzymes are HIF targets (Wenger et 
al., 2005) and, as such, this would suggest that if expression of these genes 
were increased by activated HIF1a, this would enhance glycolytic capacity. 
This is unlikely given the impaired mitochondrial metabolism in response to 
glucose in BVhlKO and PVhlKO B-cells. A TCA cycle defect in the mitochondria 
is also possible, although oxidative phosphorylation pathways downstream of 
succinate dehydrogenase (mitochondrial complex II) appear functional.
8.2.3 Comparisons with the 6-cell HIF1B KO mouse
The literature regarding HIF activity and B-cell function is very limited, and the 
only other mouse model with reported B-cell function following HIF pathway 
gene mutation is the B-cell HifIB (ARNT) KO (BHifWKO) mouse (Gunton et al.,
2005), a study which was published during the course of the research for this 
thesis. This mouse showed sexually dimorphic impaired GSIS and glucose 
intolerance; not what would have been predicted from the results presented in 
this thesis which demonstrated that HIF1a activation impairs GSIS. However, 
the genetic manipulation utilised by Gunton et al. is very different to the 
approach presented in this thesis using Vhl deletion to achieve HIF1a 
activation.
Vhl deletion causes HIF1a upregulation in the B-cells or pancreas of a mouse 
with normal oxygen tension, enabling the exploration of HIF1 a/HIF activity in 
the B-cell, normally only present during hypoxia. Gunton and colleagues have 
deleted the constitutively expressed HIF1B binding partner of HIF1a. As this 
mouse will undoubtedly have a normal islet oxygen tension, HIF1a will be 
earmarked for destruction by VHL, regardless of HifIB  expression or deletion.
187
Therefore, the phenotype these authors report, following 8 -cell HifIB  deletion 
in a normoxic model, cannot be due to a loss of HIF1B dimerisation with HIF1a. 
More likely, the phenotype is due to the loss of HIF1B interaction with its non­
oxygen sensitive binding partner, the Aryl hydrocarbon receptor (AHR), known 
to be activated by the environmental toxin dioxin. Indeed, in the Gunton et al. 
study, siRNA knock down of the Ahr transcript significantly blunted GSIS. 
Clearly the HIF pathway impacts on B-cell GSIS mechanisms at multiple levels 
and therefore warrants further investigation.
8.2.4 FIH activity in B-cells
As described in the introduction, HIF activity is not only regulated in an oxygen 
sensitive manner by PHD/VHL mediated HIFa destruction, although this is the 
only fully inactivating mechanism, but also by factor inhibiting HIF (FIH). FIH 
hydroxylates asparagines residues on HIFa, preventing binding of the p300 
transactivator, a potentiater of HIF transcriptional activity. In the BVhlKO and 
PVhlKO B-cells, the oxygen tension is expected to be physiologically normal for 
that tissue compartment, so it would be expected that FIH is active, yet we 
still see strong transcriptional changes, for example the induction of GLUT1. 
There are several possible explanations for this. Firstly, FIH may be active and, 
if inactivated, may augment the transcriptional changes seen in the BVhlKO 
and PVhlKO islets further. Second, FIH may not be active in B-cells. Third, the 
activity of FIH may be negligible in its impact on HIF activity in B-cells, as has 
been reported in other cell types following Vhl deletion (Maxwell, 2004).
8.2.5 HIF independent effects of Vhl deletion
A potential HIFa independent function of VHL is to ubiquitylate Ca2+ 
independent protein kinase C (PKC) isoforms, which have a role in insulin 
secretion. Therefore Vhl deletion may potentially interrupt this mechanism. 
VHL has been demonstrated to interact with atypical PKCA and PKC£ (Okuda et 
al., 1999), ubiquitinate PKCA (Okuda et al., 2001) and novel PKC6  (Iturrioz et
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al., 2006), and although the functional implications of these interactions have 
not been fully established, ubiquitylation by VHL is thought to convey its 
tumour suppressor role by suppressing PKC activity. The diacylglycerol (DAG) 
sensitive PKC isoforms (conventional and novel PKC) have been implicated in 
having a positive role in potentiating insulin secretion due to their activation by 
PMA (DAG substitute), but atypical PKC isoforms (DAG/PMA insensitive) have 
also been implicated in playing a permissive role in GSIS (Harris et al., 1996). 
Therefore loss of VHL ubiquitylation of PKC in BVhlKO and PVhlKO 6 -cells may 
affect GSIS. However, as BVhlKO B-cells are PMA sensitive, this suggests normal 
function of conventional and novel PKC isoforms in potentiating insulin 
secretion.
8.2.6 Altered islet architecture in the BVhlKO pancreas
One striking difference between the pancreatic BVhlKO and PVhlKO mice is the 
mild disruption of islet cellular organisation (islet architecture) in the BVhlKO 
pancreas. As this aspect of the phenotype was absent from PVhlKO mice, this 
suggests that it is a product of either growth hormone/IGF1 deficiency due to 
hypothalamic RIPcre mediated Vhl deletion, or that it is due to an alteration of 
communication/interplay between Vhl null/HIF1a active B-cells and undeleted 
a-cells, which were found scattered throughout the islet. Altered islet 
architecture similar to that seen in the BVhlKO pancreata has been reported in 
two mouse models: one genetically inactivating Hnfla  in the B-cell (Yamagata 
et al., 2002), the other globally deleting one allele of the Hnfla  or Hnf3B genes 
on a Pdx1 haploinsufficient background (Shih et al., 2002). Expression of Hnfla  
and Hnf3B was however found to be unaltered in the BVhlKO islets, suggesting 
this is not the mechanistic link. The Yamagata et al. paper, which targeted a 
dominant negative form of Hnfla  to the B-cell, reported a robust reduction in 
E-cadherin levels around the B-cells: this correlated with loss of islet 
architecture with a-cells scattered throughout the islet, loss of glucose 
stimulated calcium influx into islet cells and loss of B-cell mass. It is possible
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that loss of E-cadherin mediated B-cell to B-cell adherence in this B-cell 
dominant negative Hnfla  model and the BVhlKO model is responsible for the 
loss of islet architecture. The normal islet structure found in the PVhlKO may 
be sustained as all islet cells have reduced E-cadherin levels maintaining a 
structural balance between different islet cell types. Whereas in the BVhlKO, 
the imbalance caused by reduced E-cadherin specifically in B-cells may be 
responsible for the loss of islet organisation. Indeed, it has been reported that 
the expression level and distribution of the E-cadherin protein is uniform across 
the whole of the wild type rodent islet (Cirulli et al., 1994).
8.2.7 Growth hormone deficiency of the BVhlKO mouse
The BVhlKO mice were dwarfed, with reduced somatic growth due to the 
growth hormone and subsequent circulating IGF1 deficiency. BVhlKO mice also 
showed consistently and significantly improved insulin sensitivity compared to 
control animals during the insulin tolerance test, and severe hypoglycaemia 
when fasted for 16 hours. This improvement in insulin sensitivity is highly likely 
to be caused by the pituitary growth hormone deficiency due to hypothalamic 
Vhl deletion, as the growth hormone receptor knock out mouse (GhrKO) 
showed a similar improvement in glucose homeostasis with lower glucose and 
insulin levels compared to controls (Liu et al., 2004). The GhrKO showed a 
significant reduction in liver and pancreatic IGF1 expression, and concomitant 
reduction of B-cell mass proportionally greater than the reduction in body mass 
(Liu et al., 2004). Surprisingly B-cell mass (normalised for body mass) in BVhlKO 
mice was found to be unaltered from that of controls, despite a reduction in 
circulating IGF1 levels. The discordance in B-cell mass phenotypes between 
GhrKO and BVhlKO mice suggests that a hormone or cytokine other than growth 
hormone may act via B-cell growth hormone receptors to sustain B-cell mass in 
the BVhlKO mice.
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The dwarfism and loss of pituitary growth hormone levels observed in the 
BVhlKO suggest impaired growth hormone synthesis. Pituitary growth hormone 
expression, as well as release, is stimulated by growth hormone releasing 
hormone (GHRH) neurons (Barinaga et al., 1983) releasing GHRH into the 
hypothalamic-pituitary portal system. The hypothalamic “RIPcre” neurons 
expressing cre-recombinase in the RIPcre mouse are currently uncharacterised, 
although they have been demonstrated not to be proopiomelanocortin or 
agouti-related polypeptide expressing neurons (Choudhury et al., 2005), and do 
not sense glucose (Withers and Ashford unpublished data). Therefore in light of 
the BVhlKO pituitary growth hormone deficiency it is reasonable to suggest that 
RIPcre neurons interact with GHRH neurons, or RIPcre expression occurs in 
GHRH neurons, potentially disrupting GHRH stimulation of the pituitary.
8.2.8 Insulin sensitivity of the PVhlKO mouse
In comparison to the BVhlKO, the PVhlKO mouse showed a less marked 
improvement in insulin sensitivity, with a slight but significant improvement 
compared to controls at the 30 minute insulin tolerance test time point, a 
significant improvement at the 1 2 0  minute time point, yet unaltered at other 
time points (Fig. 6 .2D). These mice did not suffer from the fasting 
hypoglycaemia seen in the BVhlKO model, are of normal body mass and do not 
present Vhl deletion in the hypothalamus. Therefore, it is unlikely that the 
increased insulin sensitivity in the PVhlKO is due to alterations in growth 
hormone levels. An alternative explanation is that as the PVhlKO mouse has Vhl 
deletion in all pancreatic endocrine cells types, a-cell glucagon secretion may 
be affected by HIFa activation. It is tempting to speculate that glucose sensing 
may be impaired in this cell type, in a similar manner to the impaired B-cell 
glucose sensing, potentially blinding the a-cell to changes in blood glucose 
concentration and impairing glucose regulated glucagon secretion. However 
this has not been investigated during this thesis, and characterisation of a-cell 
function in the PVhlKO model is an interesting project for future investigation.
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8.2.9 Lack of pancreatic tumours in BVhlKO and PVhlKO mice
Neither model of Vhl deletion studied resulted in pancreatic tumour formation, 
despite the high numbers of mice dissected (as presented in chapter 6 ). There 
are several potential explanations for the lack of tumour formation in these 
mice lacking the Vhl tumour suppressor gene in the 8 -cell and pancreas.
Firstly, mouse models show different incidences for Vhl tumour formation with 
different tissue distribution to human patients with the disease. Mice with 
heterozygous deletion of the Vhl gene show spontaneous hepatic tumour 
formation (a relatively uncommon tumour in human VHL patients), where as 
clear cell renal cell tumours (common in human VHL patients) are rare in this 
mouse model of VHL disease (Haase et al., 2001). No pancreatic tumour has 
been reported in mouse models of VHL disease, although mild pancreatic 
angiectasis was reported in a global mosaic model of Vhl deletion (Ma et al., 
2003). Therefore mice may not be predisposed to pancreatic/islet VHL tumour 
formation per se.
Secondly, formation of VHL tumours in mice appears to be highly dependent on 
the genetic background of the animal studied. For example cavernous hepatic 
tumours/hemangiomas show significantly different rates of formation in mice 
bred on different genetic backgrounds (Ma et al., 2003). Therefore, BVhlKO and 
PVhlKO mice bred on the mixed C57BL6/Sv129 background may not create the 
correct conditions for VHL tumour formation.
Thirdly, the type of inactivation of Vhl may determine tumourigenesis. Simply 
deleting both copies of the Vhl gene early in development may not be 
sufficient to promote tumour development, which may require mutational 
inactivation of the Vhl gene later in life.
Whatever the cause, the lack of tumour formation has allowed the
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uncomplicated study of Vhl deletion/HIF1a activation in the BVhlKO and 
PVhlKO mice.
8.2.10 Implications for T2DM in humans
The data presented in this thesis has demonstrated that Vhl deletion and HIF1a 
activation in the rodent 8 -cell impairs glucose sensing, insulin secretion and 
therefore glucose homeostasis. This has potential implications both as a 
potential component of T2DM and also for islet transplantation.
8.2.10.1 Can alterations in glucose transporter types cause diabetes?
A study in mice has demonstrated that impaired glycosylation of GLUT2 due to 
mutation of a glycosyltransferase gene, or high fat feeding, caused reduced 
membrane half-life of the transporter resulting in glucose intolerance due to 
impaired GSIS (Ohtsubo et al., 2005): a phenotype similar to that of the BVhlKO 
and PVhlKO mice. Therefore this would suggest that in rodent 6 -cells, glucose 
sensing can be impaired by alterations in glucose transporter expression and 
type alone.
A recent study reporting the gene expression profile of islets isolated from 
human T2DM patients showed that a non-significant trend for decreased Glut2 
and increased G lutl expression (Gunton et al., 2005) which, together with the 
data presented in this thesis, suggests that this may alter glucose sensing and 
potentially play a role in the pathogenesis of the disease. However, glucose 
transport in human 8 -cells differs from murine 8 -cells, as the human cells 
already predominantly produce GLUT1 with low levels of GLUT2 (De Vos et al., 
1995). Therefore extrapolation of B-cell glucose transport phenotypic data 
from rodents to humans should be validated with functional tests on human 6 - 
cells.
HIFa activity in 6 -cells of the BVhlKO and PVhlKO mice was shown to decrease
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glucokinase expression (chapter 7), although only significantly in BVhlKO islets. 
Potentially this mechanism may impair GSIS by reducing glucose 
phosphorylation and the priming of glycolysis in rodent and human 6 -cells, as 
both species rely on glucokinase as the B-cell glucose sensor (De Vos et al., 
1995). Glucokinase has been shown to be a HIF target gene in hepatocytes, 
where hypoxia induced HIF1a binding to the glucokinase promoter was shown 
to increase glucokinase expression (Roth et al., 2004). Therefore the decrease 
in glucokinase expression seen in the BVhlKO and PVhlKO islets would suggest 
that the glucokinase gene, or gene promoter, is regulated by HIF1a in the 6 - 
cell in a different manner to the liver.
8.2.10.2 Implications for islet transplantation
The finding that HIF1a activation impairs glucose sensing and insulin secretion 
in mouse 6 -cells has potential implications for islet transplantation protocols, 
as hypoxic transplanted islets show HIF1a activation correlating with B-cell 
dysfunction and apoptosis in both humans (Moritz et al., 2002) and mice (Miao 
et al., 2006). The data presented in chapters 6  and 7 of this thesis has 
established that Vhl deletion mediated HIF1a activation in normoxic B-cells 
causes impaired function (GSIS) but not reduced B-cell mass. This clarifies the 
role of HIF1a in the B-cell and suggests that the apoptosis seen in transplanted 
islets may be caused by another hypoxia induced mechanism. The improvement 
in glucose tolerance observed in diabetic mice with transplanted islets in 
response to hyperbaric oxygen therapy (Miao et al., 2006), may be a functional 
consequence of HIF1a inactivation restoring glucose sensing in the transplanted 
islet B-cells.
During the planning of this project, it was predicted that HIF1a activation prior 
to transplant may provide a mechanism to promote islet revascularisation, and 
therefore survival, by upregulation of the classic HIF target gene vascular 
endothelial growth factor (Vegf) and other angiogenic target genes. This still 
may be the possible, however the negative effect of HIF1a activation on
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glucose sensing and insulin secretion may abrogate the usefulness of this 
approach. Possible strategies to circumvent this defective GSIS problem involve 
using protocols to transiently activate HIF1a to upregulate Vegf and enhance 
revascularisation, subsequently allowing HIF activity to repeal and GSIS to be 
restored. For this to be a viable option, confirmation that HIF impaired B-cell 
GSIS is reversible would be needed. Potential methods to transiently 
upregulate HIF1a include hypoxic pre-conditioning of islets, or pharmacological 
treatment of islets with a PHD inhibitor based on iron chelation, cobaltous ion 
exchange or competitive inhibition of 2 -oxoglutarate utilisation using 
dimethyloxalylglycine (Jaakkola et al., 2001).
8.2.11 Induction and reversibility of HIF1a altered glucose uptake
The change in B-cell glucose transporter type in response to chronic HIF1a 
activation in the BVhlKO and PVhlKO mice is marked, although this occurs in 
response to a life time of B-cell HIF1a activation. Acute HIF1a activation by 
hypoxia is likely to rapidly induce G lutl expression/translation following a 
reduction in cellular oxygen tension and subsequent HIF activation, as G lu tl is 
a well documented hypoxia/HIF response gene with a hypoxia response 
element facilitating HIF binding and induction of expression (Ebert et al., 
1995). A reduction in Glut2 expression however, would not immediately affect 
B-cell glucose transport, as the existing GLUT2 protein would be expected to 
have a half-life of 20 hours based on radioactive GLUT2 pulse labelling 
experiments (Gremlich et al., 1997). Therefore a relatively transient hypoxic 
insult may not alter glucose uptake as severely as a longer period of hypoxia or 
HIF1a activation. The effect of HIF1a activation causing reduced Glut2 
expression has not previously been reported.
8.2.12 Future directions for the study of HIF in the 6-cell
The studies of B-cell/pancreatic Vhl deletion, along with those of Gunton et al. 
(Gunton et al., 2005), have clearly demonstrated that different components of
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the HIF pathway can impact on 8 -cell insulin secretion, although surprisingly 
they do not appear to regulate B-cell mass. Therefore there are many more 
potential lines of investigation, at multiple points in the HIF pathway.
With particular reference to 8 -cell HIF1a activation, the next study that should 
be undertaken is to conclusively establish if the phenotype of impaired glucose 
uptake and insulin secretion seen in the BVhlKO and PVhlKO mice is due solely 
to HIF1a activation, as there may possibly be HIF1a independent effects of Vhl 
deletion. This could be done by deleting the H ifla  gene in the 6 -cells of the 
BVhlKO and PVhlKO mice to see if this reverses the glucose intolerant, impaired 
GSIS phenotype, thus testing the hypothesis that chronic HIF1a activation is 
responsible for the phenotype seen.
Another line of investigation would be to acutely activate HIF1a in either 
transformed or primary 8 -cells by transfection/infection with a recombinant 
plasmid/virus containing the H ifla  gene. This approach could also be 
attempted in vivo by perfusion of the pancreas with an adenovirus expressing 
H ifla  under the control of the Insulin 2 promoter. These experiments would 
test if acute 6 -cell HIF1a activation can alter glucose sensing, or if this 
phenotype is purely due to chronic HIF1a activation by stabilisation.
Finally, the relevance of these studies to the treatment of human T2DM with 
islet transplantation could be investigated by making donated human islets 
hypoxic, with or without infection with a H ifla  expressing viral vector, then 
testing the GSIS stimulus-secretion coupling and mRNA expression profile using 
the same methodological ap4proaches as those presented in this thesis.
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8 .3  Regulation o f a functional B-cell mass: roles o f IRS2 and  
HIF
The studies presented in this thesis have confirmed the critical role of IRS2 
mediated IIS in sustaining an adequate 6 -cell mass. IRS2 has been consistently 
demonstrated to be the non-redundant coordinator of 6 -cell growth signals 
downstream of the INSR and IGF1R (Niessen, 2006). This interaction is 
potentiated by increased Irs2 expression by activators of cAMP response 
element binding (CRE8 ) proteins; for example the post-prandial gut secreted 
incretin glucagon-like peptide 1 (Jhala et al., 2003). Therefore, IRS2 
coordinates endocrine signals for energy sufficiency and a requirement for 
insulin, and transduces this signal to increase 6 -cell mass appropriately. It has 
been demonstrated here that deletion of Irs2 in the pancreas alone causes 
decreased 6 -cell mass and also impaired GSIS that leads to glucose intolerance 
and post prandial hyperglycaemia.
It was predicted that activation of HIF in 6 -cells would signal a state of 
insufficient oxygen, and therefore impair 6 -cell mass expansion. However, the 
studies reported here demonstrate that Vhl deletion and constitutive HIF1a 
activation in 8 -cells does not impair the regulation of 6 -cell mass. Rather 6 -cell 
Vhl deletion/HIF1a activation impairs whole body glucose homeostasis by 
altering 6 -cell glucose sensing pathways, significantly blunting GSIS and causing 
glucose intolerance and post prandial hyperglycaemia.
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Appendix 1: Abbreviations
2-NBDG 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy-D-
glucose
4EBP1 Eukaryotic initiation factor 4E binding protein 1
ADP Adenosine di-phosphate
AHT Aryl hydrocarbon receptor
AMP kinase AMP activated protein kinase
ATP Adenosine tri-phosphate
bp Base pair
Ca2+ Calcium ions
Ca2+ Calcium
CAIX Carbonic anydrase IX
CaM kinase Calcium/calmodulin dependent kinase
cAMP cyclic adenosine monophosphate
ere Cre-recombinase
CREB cAMP response element binding protein
DAG Diacylglycerol
E-cadherin Cadnerinl
EGF Epidermal growth factor
EIF-4E Eukaryotic initiation factor 4E
ELISA Enzyme linked immuno sorbant assay
ER Endoplasmic reticulum
ERK Extracellular signal related protein kinase
FADH2 Flavin adenine dinucleotide (reduced form)
FAS Transforming nuclear factor receptor superfamily member6
FCCP Cyanide p-trifluoromethoxyphenylhvdrazone
FGF Fibroblast growth factor
FGFR Fibroblast growth factor receptor
FIH Factor inhibiting HIF
198
Floxed Gene flanked by loxP sites
FOX Forkhead box containing protein
FoxOI Forkhead box 01A
GABA Gamma-aminobutyric acid
GAP GTPase-activating protein
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
GCG Glucagon
GCK Glucokinase
GH Growth hormone
GHRH Growth hormone releasing hormone
GIP Glucose-dependent insulinotropic peptide
GLP1 Glucagon like peptide 1
GLUT Glucose transporter
GSCI Glucose stimulated calcium influx
GSIS Glucose stimulated insulin secretion
GTT Glucose tolerance test
HGF Hepatocyte growth factor
HIF Hypoxia inducible factor
HIFa Hypoxia inducible factor a subunit
HIFB Hypoxia inducible factor B subunit
HNF Hepatic nuclear factor
HPRT1 Hypoxanthine phosphoribosyltransferase 1
HSP Heat shock proteins
i.p. Intra peritoneal
IGF Insulin like growth factor
IGF1R Igf1 receptor
IGFBP IGF bind protein
IIS INSR and IGF1R signalling
IL1B Interleukin-16
INSR Insulin receptor
IRS Insulin receptor substrate
ITT Insulin tolerance test
ITT Insulin tolerance test
JAK Janus kinase
KATP ATP sensitive potassium channel
LDHA Lactate dehydrogenase A
MAP kinase Mitogen activated protein kinase
MAP kinase Mitogen activated protein kinase
MIDD Maternally inherited diabetes and deafness
Min6 Mouse insulinoma B-cell line
mins Minutes
mM mmol/l
MODY Maturity onset diabetes of the young
mSOS Mammalian son of sevenless
mTOR Mammalian target of rapamycin
NADH Nicotinamide adenine dinucleotide (reduced form)
NADPH Nicotinamide adenine dinucleotide phosphate (reduced
form)
NEFA Non esterified fatty acids
NeuroD Neurogenic differentiation 1
NGF Nerve growth factor
Nkx6.1 Nk6, Drosophila, Homolog of, 1
NNT Nicotinamide nucleotide transhydrogenase
NOS Nitric oxide synthase
P70 S6 kinase ribosomal protein S6 kinase 70kd
p90 S6 kinase ribosomal protein S6 kinase 90 kd
PDE3B phosphodiesterase 3B
PDGF Platelet derived growth factor
PDK 3-phosphoinositide dependent protein kinases
PDX1 Pancreatic and duodenal homeobox 1
PDX1 Pancreatic and duodenal homeobox factorl
PDXcre Pdx1 promoter driven ere transgenic mouse
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PH Pleckstrin homology domain
PHD Prolyl hydroxylase
PI3 kinase Phosphatidylinositol-3-kinase
PI3 kinase Phosphatidylinositol-3-kinase
PIP2 phosphoinositide-4,5-biphosphate
PIP3 phosphoinositide-3,4,5-triphosphate
Plrs2K0 Pancreatic Irs2 knock out mouse
PKA Protein kinase A
PKB Protein kinase B
PKC protein kinase C
PPY Pancreatic polypeptide
PS Phosphatidylserine
PTB Phosphotyrosine binding domain
PTEN phosphatase and tensin homologue
PVhlKO Pancreatic Vhl knock out mouse
RCC Clear cell renal cell carcinoma
RIA Radio immuno assay
RIPcre Rat insulin 2 promoter driven ere transgenic mouse
ROS Reactive oxygen species
SEM Standard error of the mean
SERCA Sarco(endo)plasmic reticulum Ca2+ ATPase
SHIP2 SH2 domain containing inositol 5’ phosphatase
SOCS Suppressor of cytokine signaling
SST Somatostatin
STAT Signal transducer and activator of transcription
T1DM Type 1 diabetes mellitus
T2DM Type 2 diabetes mellitus
TCA cycle Tri-carboxylic acid cycle
TSC Tuberous sclerosis complex
VDCC Voltage dependent calcium channel
VEGF Vascular endothelial growth factor
Vhl
WAT
BVhlKO
von Hippel-Lindau 
White adipose tissue 
8-cell Vhl knock out mouse
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